

FILED

James B. Gottstein
Law Project for Psychiatric Rights
406 G St., Ste 206
Anchorage, AK 99501
(907) 274-7686
Attorney for Applicant

SEP - 7 2017
APPELLATE COURTS
OF THE
STATE OF ALASKA

IN THE SUPREME COURT FOR THE STATE OF ALASKA

In the Matter of _____) Supreme Ct. No. S-16812
A Request for Information)
_____) Trial Ct. Case No. 3AN-16-00695DN

ORIGINAL APPLICATION

This Original Application is being filed because Dr. Peter Gøtzsche's June 20, 2016, request to allow access under Administration Rule 37.7 to 30 consecutive court files where a Petition for Court Approval of Administration of Psychotropic Medication under AS 47.30.839 was filed (Information Request) has fallen into a black hole. More particularly, on August 28, 2017, counsel for Dr. Gøtzsche was informed by the Clerk's Office that the "DN" case designation assigned to the Information Request by the Superior Court stands for "Demand for Notice" and that these are not acted upon. Thus, relief is not available from any other court, and cannot be obtained through the process of appeal, petition for review, or petition for hearing.

A. Background and Proceedings

Dr. Gøtzsche is an internationally recognized medical researcher who has published more than 70 papers¹ in "the big five"² and been cited over 15,000 times.³ On

¹ Attachment A, pages 3-54.

June 1, 2016, Dr. Gøtzsche testified in an AS 47.30.839 proceeding held in Anchorage and in connection with that reviewed four petitions for the involuntary administration of medication.⁴ Dr. Gøtzsche found all four petitions strikingly similar and failed to provide the information required in *Bigley v. Alaska Psychiatric Institute*.⁵ Dr. Gøtzsche found this problem similar to his experience in Denmark,⁶ and developed a research protocol, "Forced admission and forced treatment in psychiatry: are patients' rights being respected?" (Research Protocol) to compare 30 consecutive involuntary medication cases in Alaska with 30 such cases in Denmark to evaluate if:

1. The petitions comply with the requirements of *Bigley* in Alaska and Danish requirements in Denmark.
2. Information is provided that documents that the patient cannot provide informed consent.
3. Information about the psychiatric drugs the patient takes or will be forced to take is accurate.
4. A less intrusive alternative is available.
5. The combination of drugs the patient takes is safe.
6. The arguments for using force are reasonable and documented.
7. The patients' rights have been respected.
8. There are striking similarities from case to case considering that patients are different.

Furthermore, the judge's ruling will be noted.⁷

With respect to confidentiality, the Research Protocol provides:

² BMJ (f/k/a British Medical Journal), Lancet, Journal of the American Medical Association, Annals of Internal Medicine, and the New England Journal of Medicine.

³ Attachment A, page 1.

⁴ Attachment A, page 4.

⁵ 208 P.3d 182 (Alaska 2009).

⁶ Attachment A, page 4.

⁷ Attachment A, pages 4-5.

It is not necessary to know the patients' names. To preserve anonymity, these can be redacted before we get access to the documents, or we could sign a legally binding confidentiality agreement. In any case, we will report the results in a way that does not allow identification of any of the patients.⁸

The request was served on the Alaska Psychiatric Institute (API) and the Public Defender Agency. API objected by letter dated June 30, 2016,⁹ and by letter dated July 6, 2016, Dr. Gøtzsche replied.¹⁰ The Public Defender Agency did not respond. On October 19, 2016, the Court issued a Notice stating the Court was still considering the Information Request and all further pleadings be placed under the caption, "In the Matter of a Request for Information and Case No. 3AN-16-00695 DN."¹¹ However, without notice to Dr. Gøtzsche, according to CourtView, just two days later, on October 21, 2016, the case was closed without any action on the Information Request.¹²

On August 7, 2017, due to the length of time since the Information Request had been made and to make the research as timely as possible, Dr. Gøtzsche moved to amend the Information Request to start with files beginning January 1, 2017, rather than January 1, 2016 (Motion to Amend).¹³ Dr. Gøtzsche became aware of the case being marked closed on CourtView shortly before filing the Motion to Amend and the Motion to Amend posited that the closing of the case was a mistake and possibly explained why

⁸ Attachment A, page 5.

⁹ Attachment B.

¹⁰ Attachment C.

¹¹ Attachment D.

¹² Attachment E.

¹³ Attachment F.

nothing further was heard from the Superior Court.¹⁴ No opposition or other response to the Motion to Amend was filed.

It has been a month since the unopposed Motion to Amend was filed and almost 15 months since the Information Request was made and there is no reason to believe the Information Request will be acted upon by the Superior Court without application to this Court.

B. Relief Requested

Dr. Gøtzsche requests that an order be issued by this Court granting his Information Request for access to 30 consecutive court files where a Petition for Court Approval of Administration of Psychotropic Medication under AS 47.30.839 was filed, starting on January 1, 2017, in order to conduct the research set forth in his Research Protocol: "Forced admission and forced treatment in psychiatry: are patients' rights being respected?", including copies of the audio recordings upon request, subject to Dr. Gøtzsche and any co-researchers and staff maintaining the confidentiality of the Respondents, and only reporting the results in a way that does not allow identification of any of the Respondents.

A less desirable alternative is for this Court to order the Superior Court to rule on the Request for Information within 30 days of the Order. It is less desirable because if the Superior Court denies the Request for Information, it will only trigger an appeal back to this Court.

¹⁴ Attachment F, page 1.

C. Discussion

Rule 37.7(a) allows access to non-public court records if the requestor's interest in disclosure outweighs the potential harm to the person whose interests are being protected, including consideration of (1) risk of injury to individuals, (2) individual privacy rights and interests, (3) proprietary business information, 4) the deliberative process, or (5) public safety.

Here, because identifying information will be protected there is no potential harm to the people whose interests are being protected and none of the other considerations listed for denying such a request exist. On the other side of the scale, the requestor's interest is quite compelling. The opportunity to have such an internationally recognized researcher analyze the extent to which petitions under AS 47.30.839 comply with the requirements set forth in *Myers v. Alaska Psychiatric Institute*¹⁵ and *Bigley*, and compare them with Danish analogues will be extremely valuable.

There is a constitutional dimension to the Information Request.¹⁶ In *Nixon v. Warner Communications*,¹⁷ citing to *Sloan Filter Co. v. El Paso Reduction Co.*,¹⁸ *In re Sackett*,¹⁹ *C. v. C.*,²⁰ *State ex rel. Williston Herald, Inc. v. O'Connell*,²¹ *Ex parte*

¹⁵ 138 P.3d 238, 254 (Alaska 2006).

¹⁶ It could be speculated that Administration Rule 37.7 was adopted because of the public's right of access to court records.

¹⁷ 435 U.S. 589, 597, 98 S.Ct. 1306, 1312 (1978).

¹⁸ 117 F. 504 (CC Colo.1902).

¹⁹ 30 C.C.P.A. 1214 (Pat.), 136 F.2d 248 (1943).

²⁰ 320 A.2d 717, 724-727 (Del.1974)

²¹ 151 N.W.2d 758, 762-763 (N.D.1967).

Uppercu;²² *Ex parte Drawbaugh*;²³ and *United States v. Burka*;²⁴ the United States Supreme Court stated.

It is clear that the courts of this country recognize a general right to inspect and copy public records and documents, including judicial records and documents.

This right is not absolute, however, and at that time, the United States Supreme Court said:

It is difficult to distill from the relatively few judicial decisions a comprehensive definition of what is referred to as the common-law right of access or to identify all the factors to be weighed in determining whether access is appropriate.²⁵

One of the cases cited with approval by the United States Supreme Court in *Nixon*, as cited above, is *State ex rel Williston Herald*,²⁶ in which the court made clear that the right to have the "hearing" open to the public necessarily includes access to the court file, subject to reasonable regulation. In rejecting the contention that any information the seeker of the information wanted could be obtained by going to the public hearing, the court held:

We have carefully considered this entire question. We believe that it is the right of the public to inspect the records of judicial proceedings after such proceedings are completed and entered in the docket of the court.²⁷

In *Baby Doe v. Methacton School District*,²⁸ the question was whether documents filed in connection with a child sexual molestation case should be open for public

²² 239 U.S. 435, 36 S.Ct. 140, 60 L.Ed. 368 (1915).

²³ 2 App.D.C. 404 (1894).

²⁴ 289 A.2d 376 (D.C.App.1972).

²⁵ 435 U.S. at 598-9, 98 S.Ct. at 1312.

²⁶ 151 N.W.2d 758, 762-763 (N.D.1967).

²⁷ 151 N.W. 2d at 763.

inspection. The court there first discussed the general principles involved, including recognizing there is a constitutional right of public access:

In the United States, there is a strong tradition of public access to both criminal and civil trials and the resulting judicial records. This tradition is based on both the common law right to access doctrine as well as the First Amendment. *Pansy*, 23 F.3d at 780-81; *Publicker Indus., Inc. v. Cohen*, 733 F.2d 1059, 1066, 1070 (3d Cir.1984). . . .²⁹

Courts should take the least restrictive course when ruling on these matters.

In ordering the file open to the public, the court weighed Baby Doe and her family's interest in keeping the records secret, against the public's right to access as follows:

We turn now to our decision to seal the entire file in the action. PNI asserts that the public has an interest in this action because defendants are two public school districts and its officials, and because it involves the sexual molestation of a child by her school teacher. It alleges that the public has an interest in learning what knowledge the school districts had when they hired and fired the school teacher, whether any other children were molested by the teacher, whether any decision-makers are still in decision-making positions with the schools, and whether any school employees were disciplined as a result of the events. . . .

Plaintiffs argue that, in contrast to the public interest, the interest of the Plaintiffs, especially Baby Doe, is of overwhelming significance. They assert that Baby Doe is still a student at the school where she was molested and where the facts of the case are well known. They argue that:

[w]ere Baby Doe to be identified, or were facts disclosed that might lead to her identification, this minor child could sustain emotional upset, psychological damage, teasing by fellow students, different treatment by her teacher(s), etc. She could become a social outcast among her peers.

* * *

²⁸ 878 F.Supp.40 (E.D.Pa. 1995).

²⁹ 878 F. Supp. At 41.

Given the effective arguments on both sides of this issue, we turn now to the balancing of the Plaintiffs' and the public's interests. Plaintiffs undoubtedly have a compelling interest in maintaining the seal. This Court agrees that Baby Doe was the victim of a heinous crime and should not be put at risk of suffering any additional harm. Potential embarrassment to her and her family is certainly an issue in this situation. *Pansy*, 23 F.3d at 787.

...

However, the case does involve public entities, and other parents have an interest in learning how their school districts address the issue of sexual molestation by teachers and whether the threat of abuse is taken seriously enough.³⁰

It is respectfully suggested the public's interest in learning whether this Court's rulings in *Myers* and *Bigley* protecting respondents' rights to be free from unwanted psychiatric drugs absent a clear and convincing showing that it is in the respondents' best interests and there are no less intrusive alternatives are being followed is as great as in the *Baby Doe* case. It is also respectfully suggested that such information could also be of great interest to this Court.

Most recently, in *Delaware Coalition for Open Government, Inc. v. Strine*,³¹ the United States Court of Appeals for the Third Circuit noted,

"The First Amendment, in conjunction with the Fourteenth, prohibits governments from 'abridging the freedom of speech, or of the press....'" *Richmond Newspapers, Inc. v. Virginia*, 448 U.S. 555, 575, 100 S.Ct. 2814, 65 L.Ed.2d 973 (1980) (quoting U.S. CONST. amend. I). This protection of speech includes a right of public access to trials . . .

We have found a right of public access to civil trials, as has every other federal court of appeals to consider the issue.

³⁰ 878 F.Supp at 42-3.

³¹ 733 F.3d 510, 513-514, (3rd Cir. 2013).

No Alaska cases have been found on this issue, but presumably Alaska's constitutional protections are as great as, if not greater than under the United States Constitution.


D. Conclusion

For the foregoing reasons, Dr. Gøtzsche respectfully requests this Original Application be **GRANTED** and his Information Request be **APPROVED**. In the alternative Dr. Gøtzsche requests that the Superior Court be ordered to rule on the Information Request within 30 days.

DATED September 7, 2017.

Law Project for Psychiatric Rights

By:


James B. Gottstein, ABA # 7811100



June 20, 2016

Presiding Judge William Morse
Nesbett Courthouse
825 W 4th Ave, Rm 601
Anchorage, Alaska

Hand Delivered

Re: Administration Rule 37.7 Research Request

Dear Presiding Judge Morse:

This is a request under Administration Rule 37.7 for access to 30 consecutive court files where a Petition for Court Approval of Administration of Psychotropic Medication, under AS 47.30.839 was filed, starting on January 1, 2016, in order to conduct the research set forth in the attached Research Protocol: "Forced admission and forced treatment in psychiatry: are patients' rights being respected? (Research Protocol)." Also attached is the *Curriculum Vitae* of Peter C. Gøtzsche, MD, the principle investigator under the Research Protocol.

As the Research Protocol specifies, personal identification of the respondents is not necessary or desired:

It is not necessary to know the patients' names. To preserve anonymity, these can be redacted before we get access to the documents, or we could sign a legally binding confidentiality agreement. In any case, we will report the results in a way that does not allow identification of any of the patients.

I understand having court personnel redact the documents might be a burden, especially in the current budgetary climate, and I am willing to redact the documents prior to transmitting them to the researchers if that would help. Otherwise, the commitment of the researchers not to report the results in a way that allows identification of the Respondents should suffice.

As his *Curriculum Vitae* shows, the principle investigator, Dr. Gøtzsche, has quite impressive research credentials, being one of the founders of the Cochrane Collaboration, having had 70 papers published in the big five medical journals (British Medical Journal, Lancet, Journal of the American Medical Association, Annals of Internal Medicine, and the New England Journal of Medicine), being the author of four books, and having his scientific works cited over 15,000 times.

Presiding Judge William Morse


June 20, 2016

Page 2

Rule 37.7(a) provides that access to non-public court records, such as requested here, is allowable if the requestor's interest in disclosure outweighs the potential harm to the person whose interests are being protected, including consideration of (1) risk of injury to individuals, (2) individual privacy rights and interests, (3) proprietary business information, 4) the deliberative process, or 5) public safety.

Here, because identifying information will be protected there is no potential harm to the people whose interests are being protected and none of the other considerations listed for denying such a request exist. On the other side of the scale, the requestor's interest is quite compelling. The opportunity to have such an internationally recognized researcher analyze the extent to which petitions under AS 47.30.839 comply with the requirements set forth in *Myers*¹ and *Bigley*,² and compare them with Danish analogues will be extremely valuable.

Yours truly,



James B. Gottstein, Esq.

cc: Peter C. Gøtzsche, MD

Steve Bookman (via e-mail)

Linda Beecher (via e-mail)

Enc. Forced admission and forced treatment in psychiatry: are patients' rights being respected? Research Protocol

Curriculum Vitae for Peter C. Gøtzsche-last updated in January 2016

¹ *Myers v. Alaska Psychiatric Institute*, 138 P.3d 238 (Alaska 2006).

² *Bigley v. Alaska Psychiatric Institute*, 208 P.3d 168 (Alaska 2009).

Forced admission and forced treatment in psychiatry:
are patients' rights being respected?

research protocol

Peter C Gøtzsche¹ and Anders Sørensen²

¹Professor, DrMedSci, MSc
Nordic Cochrane Centre
Copenhagen
Denmark
pcg@cochrane.dk

²Psychologist
Nordic Cochrane Centre
Copenhagen
Denmark
anders.ks90@gmail.com

17 June 2016

When patients resist forced treatment orders in psychiatry, the legal procedure usually is that the psychiatrists appeal the patients' decision to a local court. The court's ruling can be appealed to a higher court.

In *Myers v. Alaska Psychiatric Institute*,¹ the Alaska Supreme Court held, that in non-emergency cases under AS 47.30.839, a court may not permit a treatment facility to administer psychotropic drugs unless in addition to the statutory requirements, the court expressly finds by clear and convincing evidence the proposed treatment is in the patient's best interests and no less intrusive alternative is available.

In *Bigley v. Alaska Psychiatric Institute*, the Alaska Supreme Court held that a less intrusive alternative is available if it is feasible and, if a less intrusive alternative is feasible, the hospital must provide it or release the person.² *Bigley* also held that when seeking the involuntary administration of psychotropic medication under AS 47.30.839 the petition must provide a plain, concise and definite written statement of the facts underlying the petition, including the nature of and reasons for the proposed treatment and information about the patient's symptoms and diagnosis; the medication to be used; the method of administration; the likely dosage; possible side effects, risks and expected benefits; and the risks and benefits of alternative treatments and nontreatment.³

On June 1, 2016, Peter Gøtzsche testified in an AS 47.30.839 proceeding held in Anchorage, Alaska, and in connection with that reviewed four AS 47.30.839 petitions. All four petitions were strikingly similar and failed to provide the information required in the *Bigley* case.

In Denmark and elsewhere, there are similar problems as in Alaska in relation to court cases of forced drugging of psychiatric patients. This is clear from the many emails we have received from patients and their relatives from all over the world; from contacts we have had to lawyers for the defence; and from a Norwegian superior court case where Peter Gøtzsche provided expert testimony in 2015.

We therefore wish to investigate more formally, in two cohorts of cases, to which extent and how the legal predicates for the involuntary administration of psychotropic medication orders are lacking, comparing and contrasting Anchorage, Alaska and Copenhagen, Denmark.

Methods

We will collect the court files for 30 consecutive AS 47.30.839 petitions, from Anchorage and 30 comparable cases from Copenhagen, with 1 January 2015 as the starting date. Based on the written material available to us, we will evaluate if:

¹ 138 P.3d 238, 254 (Alaska 2006).

² 208 P.3d 168, 182 (Alaska 2009).

³ 208 P.3d at 188.

1. The petitions comply with the requirements of *Bigley* in Alaska and Danish requirements in Denmark.
2. Information is provided that documents that the patient cannot provide informed consent.
3. Information about the psychiatric drugs the patient takes or will be forced to take is accurate.
4. A less intrusive alternative is available.
5. The combination of drugs the patient takes is safe.
6. The arguments for using force are reasonable and documented.
7. The patients' rights have been respected.
8. There are striking similarities from case to case considering that patients are different.

Furthermore, the judge's ruling will be noted.

Data analysis

This is a qualitative study and the statistics being used will mainly be descriptive. We will test whether the legal predicates for the involuntary administration of psychotropic medication orders have been met with a chi-square test and compare the results from Anchorage with those from Copenhagen, also with a chi-square test.

Ethical considerations

It is not necessary to know the patients' names. To preserve anonymity, these can be redacted before we get access to the documents, or we could sign a legally binding confidentiality agreement. In any case, we will report the results in a way that does not allow identification of any of the patients.

Publication

We will publish our results in a peer reviewed journal taking relevant ethical, legal and scientific considerations into account, as described in the literature and summarised on websites and in books.^{4 5 6}

⁴ Gottstein JB. Psychiatry: Force of Law. <http://psychrights.org/>.

⁵ Gøtzsche PC. Deadly psychiatry and organised denial. Copenhagen: People's Press; 2015.

⁶ Breggin P. Brain-disabling treatments in psychiatry: drugs, electroshock and the psychopharmaceutical complex. New York: Springer; 2007

Curriculum vitae
for
Peter C. Gøtzsche

last updated in January 2016

Contents

| | |
|--|----|
| Personal data | 3 |
| Education..... | 3 |
| Appointments | 3 |
| Pregraduate..... | 3 |
| Postgraduate, previous | 3 |
| Postgraduate, current..... | 4 |
| Funding support..... | 4 |
| Awards and other academic honours | 5 |
| Publications | 5 |
| DrMedSci thesis | 5 |
| Textbooks | 5 |
| Travel book | 6 |
| Journal articles, book chapters and similar | 6 |
| Correspondence, book reviews and similar..... | 20 |
| Secondary publications in Danish | 30 |
| Teaching | 30 |
| Pregraduate courses..... | 30 |
| Postgraduate courses | 31 |
| Lectures | 34 |
| Research mentorships..... | 44 |
| Scientific assignments | 45 |
| General | 45 |
| Editorial work..... | 46 |
| Chairman at congresses and meetings..... | 47 |
| Advisory Board member at international congresses..... | 48 |
| Expert witness in court cases | 48 |
| Management experience..... | 48 |

Personal data

Name: Peter Christian Gøtzsche
Address: Kløvervang 39, 2970 Hørsholm
Telephone: 45 86 88 66
Date of birth: 26 November 1949
Family relation: Married, 2 children
Citizenship: Danish

Title: Director, Chief Physician
Academic titles: MD, DrMedSci, MSc (biology and chemistry), fil. mag.
Address: The Nordic Cochrane Centre, Rigshospitalet, Dept. 7811, DK-2100 Copenhagen
Work phone: 35 45 70 04
Fax: 35 45 70 07
Email: pcg@cochrane.dk

Education

1968 Student exam, Næstved Gymnasium. Marks: 9.0.
1970 First part of biology, University of Copenhagen. Marks: ug-.
1970-73 Studies at the universities of Uppsala and Lund.
1973 Fil. mag. in biology, University of Lund.
1974 MSc (cand. scient.), University of Copenhagen, zoology and chemistry.
Special subject in entomology. Marks only in this: 10.
1984 MD, University of Copenhagen. Marks: 10.0.
1990 Thesis, University of Copenhagen.
1995 Specialist in internal medicine.

Appointments

Pregraduate

01.04.75 - 31.03.77 Drug representative and product manager, Astra Group A/S.
01.04.77 - 31.08.83 Chief of medical department, Astra-Syntex A/S.

Postgraduate, previous

| | | months |
|---------------------|---|--------|
| 01.06.84 - 30.09.84 | Registrar, Bispebjerg Hospital, Med Dept C | 4 |
| 01.10.84 - 31.12.85 | Registrar, Herlev Hospital, Surgical Dept | 12 |
| 01.06.85 - 31.08.85 | Registrar, Herlev Hospital, Med Dept F | 3 |
| 01.01.86 - 31.08.86 | Registrar, Rigshospitalet, Dept of Infect Dis | 8 |
| 01.09.86 - 30.09.87 | Registrar, Hvidovre Hospital, Dept of Hepatology | 13 |
| 01.09.87 - 31.05.95 | Chief, Nordic coordination office for AIDS trials, Rigshospitalet | 93 |
| 01.09.88 - 31.01.90 | Junior Lecturer, Theory of Medicine, University of Copenhagen | 17 |
| 01.02.89 - 28.02.90 | Registrar, Herlev Hospital, Med Dept C | 11 |
| 01.03.90 - 28.02.91 | Registrar, Rigshospitalet, Med Dept A | 12 |
| 01.03.91 - 31.08.91 | Registrar, Rigshospitalet, Med Dept L | 6 |
| 01.09.91 - 29.02.92 | Registrar, Rigshospitalet, Dept of Infect Dis | 6 |
| 01.03.92 - 30.06.93 | Senior registrar, Hvidovre Hospital, Dept of Rheumatology | 16 |
| 01.09.92 - 30.06.93 | Lecturer, internal medicine, Hvidovre Hospital | 10 |
| 01.07.93 - 31.08.95 | Senior registrar, Rigshospitalet, Dept of Infect Dis | 12 |
| 01.10.93 - 31.05.97 | Senior House Medical Officer, Rigshospitalet | 45 |
| 01.03.92 - 31.12.98 | Editor, Bibliotek for Læger | 82 |
| 01.02.90 - 31.03.10 | Lecturer, Theory of Medicine, University of Copenhagen | 242 |

Postgraduate, current

- 01.10.93 - Director, The Nordic Cochrane Centre
01.06.97 - Chief physician, Rigshospitalet
01.04.10 - Professor, Clinical Research Design and Analysis, University of Copenhagen

Funding support

- 1987 Danish Medical Research Council
1988 Danish Medical Research Council
1989 Danish Medical Research Council
1990 Danish Medical Research Council
1990 Danish Arthritis Foundation
1992 Medical Society in Copenhagen
1992 Fund for progress in Medical Science
1992 Danish Arthritis Foundation
1993 Research Foundation for Greater Copenhagen, Faroe Islands and Greenland.
1993 Ministry of Health
1994 Rigshospitalet
1994 European Union, BIOMED I
1995 European Union, BIOMED II
1995 Nordic Council of Ministers
1995 Rigshospitalet
1995 Copenhagen Hospital Foundation
1996 Danish Medical Research Council
1996 Nordic Council of Ministers
1996 Apothecary Foundation
1997 Nordic Council of Ministers
1997 Sygekassernes Helsefond
1997 Research Fund, Leo Pharmaceuticals
1998 European Union, BIOMED 2
1998 Nordic Council of Ministers
1998 Danish Medical Research Council
1999 Nordic Council of Ministers
1999 State Institute for Medical Health Technology Assessment
2000 Nordic Council of Ministers
2000 Ministry of Health
2001 Nordic Council of Ministers
2002 Nordic Council of Ministers
2003 Danish Medical Research Council
2003 Danish Ministry of Health
2003 Rigshospitalet
2003 Nordic Council of Ministers
2004 Nordic Council of Ministers
2005 Nordic Council of Ministers
2006 Nordic Council of Ministers
2006 IMK Charitable Fund
2007 Danish Medical Research Council
2007 The Cancer Foundation
2008 Nordic Council of Ministers
2008 Sygekassernes Helsefond
2008 Rigshospitalet
2008 Danish Medical Research Council
2009 Rigshospitalet
2009 Capital Region of Denmark
2009 Agnes and Poul Friis' Foundation
2010 Augustinus Foundation
2010 Oticon Foundation

| | |
|------|---|
| 2010 | Rigshospitalet |
| 2010 | Lundbeck Foundation |
| 2010 | Kontorchef Gerhard Brønsted's Travel Grant |
| 2010 | Tryg Foundation |
| 2010 | University of Copenhagen |
| 2010 | Sygekassernes Helsefond |
| 2010 | Julie von Müllen's Foundation |
| 2010 | The Free Research Councils |
| 2011 | The Cochrane Collaboration |
| 2011 | Rigshospitalet |
| 2012 | Rigshospitalet |
| 2012 | Tryg Foundation |
| 2012 | Sygekassernes Helsefond |
| 2012 | The Cochrane Collaboration |
| 2014 | Laura and John Arnold Foundation, Houston, Texas, PhD stipend |
| 2015 | University of Copenhagen, PhD stipend |
| 2014 | Laura and John Arnold Foundation, Houston, Texas, , PhD stipend |

In addition, we have received support from The Cochrane Collaboration 2003-2015 that comes from royalties through sales of licences to The Cochrane Library (The Cochrane Collaboration is registered as a charity).

Awards and other academic honours

| | |
|------|---|
| 1992 | Farmer from Stenløse, Peder Laurids Pedersen's donation. |
| 1997 | Award of the year from the foundation "A good start in life". |
| 1999 | Henrik R. Wulff's prize from Danish Society for Theory in Medicine |
| 2001 | Skrabaneck Foundation Prize, Trinity College, Dublin. |
| 2001 | Niels A. Lassen's prize. |
| 2003 | Queen Ingrid's Lecture, Åbenrå Hospital. |
| 2004 | Harry Boström Lecture, Swedish Society for Internal Medicine, Annual Meeting. |
| 2006 | Top-ten peer reviewer for British Medical Journal for the year 2006. |
| 2007 | Winner of the 2007 Society of Medical Writers' Academic Writing Award (for: Jørgensen KJ, Gøtzsche PC. Content of invitations to publicly funded screening mammography. BMJ 2006;332:538-41). |
| 2009 | Michael Berger award, Düsseldorf. |
| 2012 | Winner of the annual Prescrire Prize for medical and pharmaceutical books (for: Gøtzsche PC. mammography screening: truth, lies and controversy. London: Radcliffe Publishing; 2012:1-388). |
| 2014 | Winner of the Annual LAP Award (psychiatry award), Denmark. |
| 2014 | Winner of the British Medical Association's Annual Book Award in the category Basis of Medicine for Deadly Medicines and Organised Crime: How big pharma has corrupted health care. |
| 2014 | Award from the International Society of Ethical Psychology and Psychiatry for "intellectual honesty and bravery in tackling the biomedical-industrial complex." |
| 2015 | Honourable Award, Consul General Ernst Carlsen's Foundation. |
| 2015 | Book of the Year, US Tributaries Radio, for Deadly Psychiatry and Organised Denial. |

Publications

DrMedSci thesis

Bias in double-blind trials. Dan Med Bull 1990;37:329-36. Review that refers to references 12 and 23-27.
Defended 10 May 1990 at the University of Copenhagen, Faculty for Health Sciences. Examiners: Professor, DrMedSci Ib Lorenzen and chief physician, DrMedSci Henrik R. Wulff.

Textbooks

Wulff HR, Gøtzsche PC. Rationel klinik. Evidensbaserede diagnostiske og terapeutiske beslutninger, 4. udgave. København: Munksgaard, 1997:1-278.

- Wulff HR, Gøtzsche PC. Rational Diagnosis and Treatment. Evidence-Based Clinical Decision-Making, 3rd edition. Oxford: Blackwell Scientific, 2000:1-221.
 Translated into Swedish, Spanish and Polish.,
- Wulff HR, Gøtzsche PC. Rationel klinik. Evidensbaserede diagnostiske og terapeutiske beslutninger, 5. udgave. København: Munksgaard Danmark, 2006:1-304.
- Gøtzsche PC. Rational Diagnosis and Treatment. Evidence-Based Clinical Decision-Making, 4th edition. Chichester: Wiley, 2007:1-229.
- Gøtzsche PC. Mammography screening: truth, lies and controversy. London: Radcliffe Publishing; 2012:1-388.
- Gøtzsche PC. Deadly medicines and organised crime: How big pharma has corrupted health care. London: Radcliffe Publishing; 2013.
 Translated into many languages.
- Gøtzsche PC. Dødelig medicin og organiseret kriminalitet: Hvordan medicinalindustrien har korrumperet sundhedsvæsenet. København: People's Press, 2013.
- Gøtzsche PC. Deadly psychiatry and organised denial. Copenhagen: People's Press; 2015.
 Will be translated into many languages.
- Gøtzsche PC. Dødelig psykiatri og organiseret fornægtelse. København: People's Press; 2015.

Travel book

Gøtzsche PC. På safari i Kenya. København: Samlerens forlag, 1985:128 sider.

Journal articles, book chapters and similar

Total number of citations: more than 14,000; H-index: 51 (Web of Science).

1. Gøtzsche PC. Vandtægers respirationsforhold (Heteroptera, Hydrocorisae). Special subject, University of Copenhagen, Faculty for Natural Sciences, 1974, 83 pp.
2. Gøtzsche PC, Marinelli K, Gylding-Sabroe JP, Larsen N-E, Sørensen K. Bioavailability of naproxen tablets and suppositories in steady state. Scand J Rheumatol 1983;suppl 50:1-9.
3. Gøtzsche PC, Gjørup IE. Virkninger af moderat lakridsindtagelse. Ugeskr Læger 1983;145:3902-4.
4. Andersen LA, Gøtzsche PC. Naproxen and aspirin in acute musculoskeletal disorders: a double-blind, parallel study in sportsmen. Pharmatherapeutica 1984;3:535-41.
5. Sindet-Pedersen S, Petersen JK, Gøtzsche PC. Incidence of pain conditions in dental practice in a Danish county. Community Dent Oral Epidemiol 1985;13:244-6.
6. Geisler C, Gøtzsche PC, Hansen SS, Juul K, Plesner AM, Nissen NI. Naproxen has greater antipyretic effect on fever related to Hodgkin's disease than to other tumours or to infection. Scand J Haematol 1985;35:325-8.
7. Sindet-Pedersen S, Petersen JK, Gøtzsche PC, Christensen H. A double-blind, randomized study of naproxen and acetylsalicylic acid after surgical removal of impacted lower third molars. Int J Oral Maxillofac Surg 1986;15:389-94.
8. Gøtzsche PC, Karlsen FØ, Andersen B. Dosis-respons bias. Nord Med 1986;101:24-5.
9. Jørgensen FR, Gøtzsche PC, Hein P, Jensen CM, Nielsen BM, Nielsen FM, Rønholz EB, Tranberg FH. Naproxen (Naprosyn) og mobilisering ved behandling af akut ankeldistorsion. Ugeskr Læger 1986;148:1266-8.
10. Gøtzsche PC. Vurdering af kliniske lægemiddelundersøgelser. Ugeskr Læger 1986;148:2417-20.
11. Gøtzsche PC, Hvidberg EF, Juul P. Rational choice of dose: insufficient background knowledge? Ration Drug Ther 1986;20:1-7.
12. Gøtzsche PC. Reference bias in reports of drug trials. BMJ 1987;295:654-6.
13. Fogh S, Schapira A, Bygbjerg IC, Jepsen S, Mordhorst CH, Kuijlen K, Ravn P, Rønn A, Gøtzsche PC. Malaria chemoprophylaxis in travellers to east Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine/pyrimethamine. BMJ 1988;296:820-2.
14. Ørnskov F, Gøtzsche PC. Lodtrækningsprincippet. Et forsøg på en medicinsk-etisk analyse. Ugeskr Læger 1988;150:897-900.
15. Gøtzsche PC, Hørding M. Condoms to prevent HIV transmission do not imply truly safe sex. Scand J Infect Dis 1988;20:233-4.

16. Gøtzsche PC, Andreasen F, Egsmose C, Lund B. Steady state pharmacokinetics of naproxen in elderly rheumatics compared with young volunteers. *Scand J Rheumatol* 1988;17:11-6.
17. Gøtzsche PC. Oversigtsartikler og meta-analyser (leder). *Ugeskr Læger* 1988;150:1765-6.
18. Gøtzsche PC, Bygbjerg IC, Olesen B, Møller LH, Salim YS, Faber V. Yield of diagnostic tests of opportunistic infections in AIDS: a survey of 33 patients. *Scand J Infect Dis* 1988;20:395-402.
19. Olesen B, Gøtzsche PC, Bygbjerg IC, Møller LH, Faber V. Hospitalsomkostninger ved diagnostik og behandling af AIDS-patienter. De første 33 patienter på Rigshospitalet. *Ugeskr Læger* 1988;150:2250-2.
20. Jørgensen PE, Forrest M, Hermann GG, Gøtzsche PC, Andersen B. Videnskabelige artikler i Ugeskrift for Læger gennem 25 år. Artikletype og forsøgsdesign. *Ugeskr Læger* 1989;151:218-20.
21. Gøtzsche PC, Forrest M, Hermann GG, Jørgensen PE, Andersen B. Videnskabelige artikler i Ugeskrift for Læger gennem 25 år. Analyse og tolkning af forsøgsresultater. *Ugeskr Læger* 1989;151:220-2.
22. Andersson PG, Hinge HH, Johansen O, Andersen CU, Lademann A, Gøtzsche PC. Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks. *Cephalgia* 1989;9:29-32.
23. Gøtzsche PC. Patients' preference in indomethacin trials: an overview. *Lancet* 1989;i:88-91.
24. Gøtzsche PC. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal, antiinflammatory drugs in rheumatoid arthritis. *Controlled Clin Trials* 1989;10:31-56 (amendment:356).
25. Gøtzsche PC. Multiple publication in reports of drug trials. *Eur J Clin Pharmacol* 1989;36:429-32.
26. Gøtzsche PC. Review of dose-response studies of NSAIDs in rheumatoid arthritis. *Dan Med Bull* 1989;36:395-9.
27. Gøtzsche PC. Meta-analysis of grip strength: most common, but superfluous variable in comparative NSAID trials. *Dan Med Bull* 1989;36:493-5.
28. Gøtzsche PC. Medicinske studenters holdning til lodtrækning og selvvalg ved brystkræftkirurgi og forslag om et nyt design. *Ugeskr Læger* 1989;151:2719-21.
29. Hørding M, Gøtzsche PC, Bygbjerg I, Pedersen M, Faber V, Berg K. Lack of immunomodulating effect of disulfiram in HIV positive patients. *Internat J Immunopharmacol* 1990;12:145-7.
30. Pedersen C, Gerstoft J, Tauris P, Lundgren JD, Gøtzsche PC, Buhl M, Salim Y, Schmidt K. Opportunistic infections and malignancies in 231 Danish AIDS patients. *AIDS* 1990;4:233-8.
31. Jørgensen A, Shao J, Maselle S, Yangi E, Thomsen A, Matunda S, Bygbjerg I, Gøtzsche P, Svendsen J, Skinhøj P, Faber V. Evaluation of simple tests for detection of HIV antibodies: analysis of interobserver variation in Tanzania. *Scand J Infect Dis* 1990;22:283-5.
32. Jørgensen AF, Mwakyusa D, Cegielski P, Gøtzsche P, Hørding M, Lallinger G, Mbaga I, Pallangyo K, Richter C, Shao J, Bygbjerg I, Skinhøj P, Faber V. The effect of fusidic acid on Tanzanian patients with AIDS. *AIDS* 1990;4:1037-8.
33. Jørgensen AF, Jensen VG, Shao JF, Maselle S, Mbaga IM, Mwakyusa DH, Gøtzsche PC, Richter C, Pallangyo K, Cegielsky P, Lallinger G, Bygbjerg I, Skinhøj P, Faber V. Beta-2-microglobulin as a prognostic marker for patients with AIDS in Dar es Salaam, Tanzania. *AIDS* 1990;4:1168-9.
34. Gøtzsche PC. Sensitivity of effect variables in rheumatoid arthritis: a meta-analysis of 130 placebo controlled NSAID trials. *J Clin Epidemiol* 1990;43:1313-8.
35. Hørding M, Gøtzsche PC, Christensen LD, Bygbjerg IC, Faber V. Double-blind trial of bestatin in HIV-positive patients. *Biomed Pharmacother* 1990;44:475-8.
36. Pedersen C, Gerstoft J, Tauris P, Lundgren JD, Gøtzsche PC, Buhl M, Salim Y, Schmidt K, Nielsen JO. Trends in survival of Danish AIDS patients from 1981 to 1989. *AIDS* 1990;4:1111-6.
37. Mandrup-Poulsen T, Gøtzsche PC, Ott P, Pedersen BK, Sørensen JB. Dansk intern medicin i en brydningstid på tærsken til det 21. århundrede. *Bibliotek for Læger* 1991;183:69-82.
38. Gøtzsche PC, Kelbæk H, Vissing SF, Nielsen SL, Munck O, Christensen NJ, Lyngsøe J, Mathiesen ER. Acute cardiovascular effects of insulin in hyperglycaemic type I diabetics. *Scand J Clin Lab Invest* 1991;51:93-7.
39. Gøtzsche PC. Patients' views on the least acceptable increase in survival with zidovudine treatment. *Scand J Infect Dis* 1991;23:509-10.
40. Gjørup IE, Gøtzsche PC, Baden H, Andersen B. Surgical treatment of morbid obesity: a survey of overall outcome 1968-89. *Dan Med Bull* 1991;38:405-7.
41. Nielsen C, Nielsen CM, Petersen JL, Gøtzsche PC, Pedersen C, Arendrup M, Vestergaard BF. Isolation of HIV from cultures of purified CD4+ lymphocytes. *J Virol Methods* 1991;35:15-25.

42. Gøtzsche PC, Lange B. Comparison of search strategies for recalling double-blind trials from MEDLINE. *Dan Med Bull* 1991;38:476-8.
43. Nordic Medical Research Councils' HIV Therapy Group. Double-blind dose-response study of zidovudine in AIDS and advanced HIV infection. *BMJ* 1992;304:13-7 (manuscript and scientific coordinator: PC Gøtzsche).
44. Gøtzsche PC. Biasproblemer i kort- og langtidsdobbeltblindforsøg og forslag til forbedringer. *Månedsskr Prakt Lægegern* 1992;70:159-64.
45. Gøtzsche PC. Problemer og muligheder ved lægemiddelundersøgelser ved reumatoid artrit. I: Jarner D, Friis J, eds. *Dansk Reumatologisk Selskab: postgraduat kursus om arthritis rheumatoïdes*. København: Astra, 1992:18-30.
46. Gøtzsche PC, Pødenphant J, Olesen M, Halberg P. Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit. *J Clin Epidemiol* 1992;45:587-94.
47. Nielsen C, Gøtzsche PC, Nielsen CM, Gerstoft J, Vestergaard BF. Development of resistance to zidovudine in HIV strains isolated from CD4+ lymphocytes and plasma during therapy. *Antiviral Res* 1992;18:303-16.
48. Gøtzsche PC, Nielsen C, Gerstoft J, Nielsen CM, Vestergaard BF. Trend towards decreased survival in patients infected with HIV resistant to zidovudine. *Scand J Infect Dis* 1992;24:563-5.
49. Gøtzsche PC. Metaanalyser: metodologiske og forskningsetiske overvejelser. *Bibliotek for Læger* 1993;185:17-29.
50. Gøtzsche PC, Pødenphant J, Olesen M, Halberg P. Critique of meta-analysis of second-line antirheumatic drugs. *J Clin Epidemiol* 1993;46:319-21.
51. Rasmussen MH, Andersen T, Breum L, Gøtzsche PC, Hilsted J. Cimetidine suspension as adjuvant to energy restricted diet in treating obesity. *BMJ* 1993;306:1093-6.
52. Gøtzsche PC. Zidovudine in HIV infection. *Ann Med* 1993;25:213-4.
53. Rasmussen MH, Andersen T, Breum L, Hilsted J, Gøtzsche PC. Observer variation in measurements of waist-hip ratio and the abdominal sagittal diameter. *Int J Obes* 1993;17:323-7.
54. Gøtzsche PC. Meta-analysis of NSAIDs: contribution of drugs, doses, trial designs, and meta-analytic techniques. *Scand J Rheumatol* 1993;22:255-60.
55. Gøtzsche PC. Det Nordiske Cochrane Center: samarbejde om systematiske oversigter over behandlings effekter. *Nord Med* 1994;109:244-5.
56. The Cochrane Collaboration Handbook. Sackett D, Chalmers I, Silagy C, Gøtzsche PC, Dickersin K, Oxman A, eds. 1994.
57. Gøtzsche PC. Meta-analyser og kvalitetssikring. *Journal* 1994;2:16-7.
58. Gøtzsche PC. Is there logic in the placebo? *Lancet* 1994;344:925-6.
59. Gøtzsche PC. Er placebobegrebet logisk? *Bibl Læger* 1995;187:71-8.
60. Rigshospitalets Forskningspolitik, 1994, 16 pp.
61. Gøtzsche PC. Supplement til Rigshospitalets Forskningspolitik, 1994, 40 pp.
62. Gøtzsche PC. Steroids and peptic ulcer: an end to the controversy? *J Intern Med* 1994;236:599-601.
63. The Standards of Reporting Trials Group. A proposal for structured reporting of randomized controlled trials. *JAMA* 1994;272:1926-31 (member of writing committee).
64. Gøtzsche PC. Kontrollerede kliniske forsøgs troværdighed - randomiseringsproblemet. *Ugeskr Læger* 1995;157:597-8.
65. Gøtzsche PC, Gjørup I, Bonnén H, Brahe NEB, Becker U, Burcharth F. Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. *BMJ* 1995;310:1495-8.
66. Gøtzsche PC, Krog JW, Moustgaard R. Bibliometrisk analyse af dansk sundhedsvidenskabelig forskning 1988-1992. *Ugeskr Læger* 1995;157:5075-81.
67. Gøtzsche PC. Clinical practice should reflect clinical science. In: Gordon C, Christensen JP, eds. *Health Telematics for Clinical Guidelines and Protocols*. Amsterdam: IOS Press, 1995:17-25.
68. Ullum H, Gøtzsche PC, Victor J, Dickmeiss E, Skinhøj P, Pedersen BK. Defective natural immunity: an early manifestation of human immunodeficiency virus infection. *J Exp Med* 1995;182:789-99.
69. Gøtzsche PC. Patientbehandling og sikkerhed - Cochrane-databasernes betydning. *Ugeskr Læger* 1995;157:6247.

70. Mulward S, Gøtzsche PC. Sample size of randomized double-blind trials 1976-1991. *Dan Med Bull* 1996;43:96-8.
71. Gøtzsche PC, Liberati A, Luca P, Torri V. Beware of surrogate outcome measures. *Int J Technol Ass Health Care* 1996;12:238-46.
72. Gøtzsche PC. Det sundhedsvidenskabelige grundlag for medicinsk teknologivurdering. København: Det Etiske Råd; 1996:1-32.
73. Gøtzsche PC. Det Nordiske Cochrane Center og Netværk: Nordisk samarbejde om systematiske oversigter over behandlingers effekter. *Social- og Helsevårdsnytt i Norden* 1996;13:10-11.
74. Gøtzsche PC, Hansen M, Stoltenberg M, Svendsen A, Beier J, Faarvang KL, et al. Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. *Scand J Rheumatol* 1996;25:194-9.
75. Gøtzsche PC. Blinding during data analysis and writing of manuscripts. *Controlled Clin Trials* 1996;17:285-90.
76. Gøtzsche PC. Anvendte procedurer skal være videnskabeligt dokumenterede. *Lægen* 1996;14:10-2.
77. Ullum H, Diamant M, Victor J, Gøtzsche PC, Bendtzen K, Skinhøj P, Pedersen BK. Increased circulating levels of interleukin-6 in HIV seropositive subjects. *J AIDS* 1996;13:93-9.
78. Gøtzsche PC. Meta-analyses: assets and limitations. In: Rose C, Larsen S, Hansen O, Bergh J, Andersen J, eds. *Recent advances in breast cancer. Colloquium, Scandinavian Breast Group, Hindsgavl, Oct 11-14. Bristol-Myers Squibb*, 1996:139-45.
79. Hallas J, Gøtzsche PC. Det Nordiske Cochrane Center og Netværk - et samarbejde om systematiske oversigter over behandlingseffekter. *Farmakopei-Nyt* 1996;nov:4-5.
80. Gøtzsche PC, Johansen HK. Antifungal prophylactic or empiric therapy vs placebo or no treatment in cancer patients with neutropenia (Cochrane Review). In: *The Cochrane Library, Issue 2*. Oxford: Update Software; 1997. Updated quarterly.
81. Gøtzsche PC. Somatostatin or octreotide vs placebo in bleeding oesophageal varices (Cochrane Review). In: *The Cochrane Library, Issue 3*. Oxford: Update Software; 1997. Updated quarterly.
82. Gøtzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis (Cochrane Review). In: *The Cochrane Library, Issue 3*. Oxford: Update Software; 1997. Updated quarterly.
83. Christensen PM, Gøtzsche PC, Brøsen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. *Eur J Clin Pharmacol* 1997;51:389-93.
84. Olsen O, Gøtzsche PC. Nødvendigheden af elektronisk opdaterede metaanalyser: Doppler-ultralyd i obstetrikken som eksempel. *Ugeskr Læger* 1997;159:27-8.
85. Kleijnen J, Gøtzsche PC, Kunz RH, Oxman A, Chalmers I. So what's so special about randomisation? In: Maynard A, Chalmers I, eds. *Non-random reflections on health services research: on the 25 anniversary of Archie Cochrane's Effectiveness and Efficiency*. London: BMJ Books, 1997:231-49.
86. Gøtzsche PC, Johansen HK. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. *BMJ* 1997;314:1238-44.
87. Gerstoft J, Melander H, Bruun JN, Pedersen C, Gøtzsche PC, Berglund O, et al. Alternating treatment with didanosine and zidovudine versus either drug alone for the treatment of advanced HIV infection: the ALTER study. *Scand J Infect Dis* 1997;29:121-8.
88. Gøtzsche PC. Fibigers forsøg om serumbehandling af difteri. *Bibl Læger* 1997;189:143-6.
89. Ullum H, Victor J, Katzenstein TL, Gerstoft J, Gøtzsche PC, Bendtzen K, Skinhøj P, Pedersen BK. Decreased short-term production of tumor necrosis factor- α and interleukin-1 β in human immunodeficiency virus-seropositive subjects. *J Infect Dis* 1997;175:1507-10.
90. Gøtzsche PC, Jensen KL, Hammarquist C. Randomiserede kliniske forsøg i Ugeskrift for Læger 1948-1995. *Ugeskr Læger* 1997;159:4762-5.
91. Gøtzsche PC. Cochrane-samarbejdets betydning for evidensbaseret medicin. *Ugeskr Læger* 1997;159:6721-4.
92. Ullum H, Cozzi-Lepri A, Bendtzen K, Victor J, Gøtzsche PC, Phillips AN, Skinhøj P, Klarlund Pedersen B. Low production of interferon gamma is related to disease progression in HIV infection: evidence from a cohort of 347 HIV-infected individuals. *AIDS Res Hum Retroviruses* 1997;13:1039-46.

93. Hammarquist C, Burr ML, Gøtzsche PC. House dust mites and control measures in the management of asthma (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 1998. Updated quarterly.
94. Gøtzsche PC. Somatostatin or octreotide vs placebo in bleeding oesophageal varices (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 1998. Updated quarterly.
95. Gøtzsche PC, Johansen HK. Meta-analysis of short term low dose prednisolone versus placebo and non-steroidal, anti-inflammatory drugs in rheumatoid arthritis. BMJ 1998;316:811-8.
96. Rønn AM, Ronne-Rasmussen J, Gøtzsche PC, Bygbjerg IC. Neuropsychiatric manifestations after mefloquine therapy for *Plasmodium falciparum* malaria: comparing a retrospective and a prospective study. Trop Med Int Health 1998; 3:83-8.
97. Gøtzsche PC. Hjælp til et evidensbaseret sundhedsvæsen. Social- & Hälsovårdsnytt i Norden 1998;2:12-13 og www.shn.dk/2-98/cochrane.htm.
98. Gøtzsche PC, Hammarquist C, Burr M. House dust mite control measures in the management of asthma: meta-analysis. BMJ 1998;317:1105-10.
99. Hróbjartsson A, Gøtzsche PC, Gluud C. The controlled trial turns 100 years: Fibiger's trial of serum treatment of diphtheria. BMJ 1998;317:1243-5.
100. Gøtzsche PC. Hjælp til selvhjælp: Hvad kan Cochrane-samarbejdet tilbyde sundhedsvæsenet, og hvad kan sundhedsvæsenet tilbyde Cochrane-samarbejdet? I: Evidensbaseret sundhedsvæsen. Rapport fra II symposium om evidensbaseret sundhedsvæsen. København: Institut for Sundhedsvæsen, DSI rapport 98.04, 1998:119-25.
101. Gøtzsche PC. Randomisering og blinding i sundhedsvidenskabelig forskning. Bibl Læger 1998;190:369-80.
102. Gøtzsche PC. Lus i skindpelsen. Ugeskr Læger 1998;160:7610-1.
103. Christensen PM, Gøtzsche PC, Brøsen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. Pharmacogenetics 1998;8:473-9.
104. Astrup A, Gøtzsche PC, van de Werken K, Ranneries C, Toubro S, Raben A, Buemann B. Meta-analysis of resting metabolic rate in formerly obese subjects. Am J Clin Nutr 1999;69:1117-22.
105. Gøtzsche PC. Det Nordiske Cochrane Center: Status efter 5 år og fremtidsperspektiver. Ugeskr Læger 1999;161:932-4.
106. Gøtzsche PC. Metaanalyse - begreber og metoder. I: Andersen D, Almind G, Bock E, Havsteen B, Hørder M, Riis P. Sundhedsvidenskabelig forskning, 5. udg. København: FADL's Forlag, 1999:303-14.
107. Johansen HK, Gøtzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 1999;282:1752-9.
108. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 1999;2:430-6.
109. Gøtzsche PC. Eettisiä näkökulmia systemaattisiin kirjallisuuskatsauksiin. Helsinki: Stakes, FinOHTAn raportti 11, 1999:19-24.
110. Gøtzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000;355:129-34.
111. Olsen O, Gøtzsche PC. Der er noget galt i mammografistudierne! Ingen støtte til konklusionen at brystkræftscreening har gavnlig effekt. Lækartidningen 2000;97:286-7.
112. Gøtzsche PC, red. Introduktion til forskning. http://www.dadlnet.dk/dok/?2videnskab/bibliotekforlaeger/frz_forskning.htm, april 2000.
113. Gøtzsche PC. Det Nordiske Cochrane Center og dets samarbejde med klinisk praksis. I: MTV, sundhedstjenesteforskning og klinisk praksis. Rapport fra et symposium om evidensbaseret sundhedsvæsen. København: Statens Institut for Medicinsk Teknologivurdering, 2000. p. 38-44.
114. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. BMJ 2000;320:1058-61.
115. Gøtzsche PC. Do patients with osteoarthritis get the clinical research they need? Ann Rheum Dis 2000;59:407-8.
116. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2000;3:521-8 (updated).
117. Gøtzsche PC. Cochrane-samarbetets betydelse för evidensbaserad medicin. Lækartidningen 2000;97:3180-2.
118. Gøtzsche PC. Why we need a broad perspective on meta-analysis: It may be crucially important for patients. BMJ 2000;321:585-6.

119. Johansen HK, Gøtzsche PC. Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2000.
120. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2000.
121. Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2000.
122. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer (Cochrane Review). In: The Cochrane Library, Issue 2. Oxford: Update Software; 2000. (updated).
123. Olesen V, Engell L, Jensen KL, Gøtzsche PC. Randomised clinical trials in the Scandinavian Journal of Rheumatology. Scand J Rheumatol 2000;29:349-51.
124. Gøtzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 2001. (updated).
125. Wille-Jørgensen PA, Gøtzsche PC. Evidensbaseret kirurgi. Ugeskr Læger 2001;163:737-40.
126. Gøtzsche PC. Reporting of outcomes in arthritis trials measured on ordinal and interval scales is inadequate in relation to meta-analysis. Ann Rheum Dis 2001;60:349-52.
127. Olsen O, Gøtzsche PC. Mister flere kvinder brystet efter screening - og hvornår må vi diskutere det? Ugeskr Læger 2001;163:1576.
128. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T, for the CONSORT Group. The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med 2001;134:663-94.
129. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001;344:1594-602.
130. Gøtzsche PC, Johansen HK, Burr ML, Hammarquist C. House dust mite control measures for asthma (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 2001. (updated).
131. Pedersen T, Gluud CN, Gøtzsche PC, Matzen P, Wille-Jørgensen P. Hvad er evidensbaseret medicin? Ugeskr Læger 2001;163:3769-72.
132. Olsen O, Middleton P, Ezzo J, Gøtzsche PC, Hadhazy V, Herxheimer A, et al. Quality of Cochrane reviews: assessment of sample from 1998. BMJ 2001;323:829-32.
133. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2001;5:800-7 (updated).
134. Hróbjartsson A, Gøtzsche PC. Core belief in powerful effects of placebo interventions is in conflict with no evidence of important effects in a large systematic review. Adv Mind-Body Med 2001;17:312-8.
135. Olsen O, Gøtzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet 2001;358:1340-2.
136. Olsen O, Gøtzsche PC. Systematic review of screening for breast cancer with mammography. Lancet 2001 (<http://image.thelancet.com/extras/fullreport.pdf>).
137. Olsen O, Gøtzsche PC. Screening for breast cancer with mammography (Cochrane Review). In: The Cochrane Library, Issue 4. Oxford: Update Software, 2001.
138. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2001;6:894-901 (updated).
139. Gøtzsche PC. Somatostatin analogues for acute bleeding oesophageal varices (Cochrane Review). In: The Cochrane Library, Issue 1, 2002. Oxford: Update Software (updated).
140. Johansen HK, Gøtzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software. (updated).
141. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software. (updated).
142. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software. (updated).

143. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2002;7:1063-70.
144. Mowatt G, Shirran L, Grimshaw JM, Rennie D, Flanagin A, Yank V, MacLennan G, Gøtzsche PC, Bero LA. Prevalence of honorary and ghost authorship in Cochrane reviews. *JAMA* 2002;287:2769-71.
145. Gøtzsche PC. Medicalisation of risk factors. *BMJ* 2002;324:890-1.
146. McDonald S, Lefebvre C, Antes G, Galandi D, Gøtzsche P, Hammarquist C, Haugh M, Jensen KL, Kleijnen J, Loep M, Pistotti V, Rüther A. The contribution of handsearching European general health care journals to the Cochrane Controlled Trials Register. *Evaluation & The Health Profession* 2002;25:65-76.
147. Gøtzsche PC, Olsen O. Screening for mammacancer - to år efter. *Ugeskr Læger* 2002;164:204-6.
148. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2002;8:1203-11 (updated).
149. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2003;9:1292-300.
150. Hróbjartsson A, Gøtzsche PC. Placebo treatment versus no treatment (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.
151. Kösters JP, Gøtzsche PC. Regular self-examination or clinical examination for early detection of breast cancer (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
152. Gøtzsche PC. The debate on breast cancer screening with mammography is important. *J Am Coll Radiol* 2004;1:8-14.
153. Wienecke T, Gøtzsche PC. Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 1, 2004. Chichester: John Wiley & Sons, Ltd.
154. Jørgensen KJ, Gøtzsche PC. Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study. *BMJ* 2004;328:148-51.
155. Gøtzsche PC. On the benefits and harms of screening for breast cancer. *Int J Epidemiol* 2004;33:56-64.
156. Johansen HK, Nørregaard L, Gøtzsche PC, Pressler T, Koch C, Høiby N. Antibody response to *Pseudomonas aeruginosa* in cystic fibrosis patients: A marker of therapeutic success?-A 30-year Cohort study of survival in Danish CF patients after onset of chronic *P. aeruginosa* lung infection. *Pediatr Pulmonol* 2004;37:427-32.
157. Chan A-W, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. *JAMA* 2004;291:2457-65.
158. Pildal J, Gøtzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. *Clin Infect Dis* 2004;39:38-46.
159. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2004;11:1551-9 (updated).
160. Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd (updated).
161. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. *J Intern Med* 2004;256:91-100.
162. Gøtzsche PC, Johansen HK, Schmidt LM, Burr ML. House dust mite control measures for asthma. The Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD001187.
163. Ioannidis JPA, Evans SJW, Gøtzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D, for the CONSORT Group. Better reporting of harms in randomized trials: An extension of the CONSORT statement. *Ann Intern Med* 2004;141:781-8.
164. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2004;12:1702-10 (updated).
165. Johansen HK, Gøtzsche PC Lægemiddelindustrien og ytringsfriheden. I: Høiby (red): Råb op og sig stop. http://www.laegersytringsfrihed.dk/pdf/Yderligere_indlaeg.pdf. 2005.
166. Gøtzsche PC. Screeningsindustrien og ytringsfriheden. I: Høiby (red): Råb op og sig stop. http://www.laegersytringsfrihed.dk/pdf/Yderligere_indlaeg.pdf. 2005.
167. Gøtzsche PC, Jørgensen KJ. Screening for brystkræft - et tveægget sværd. *Ugeskr Læger* 2005;167:1312-4.
168. Gøtzsche PC. Uafhængig klinisk interventionsforskning er meget påkrævet. *Ugeskr Læger* 2005;167:1491-4.

169. Schmidt LM, Gøtzsche PC. Of mites and men: reference bias in narrative review articles: a systematic review. *J Fam Pract* 2005;54:334-8.
170. Pildal J, Chan A-W, Hróbjartsson A, Forfang E, Altman DG, Gøtzsche PC. Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. *BMJ* 2005;330:1049-52.
171. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2005;13:1525-32 (updated).
172. Karmisholt K, Gyntelberg F, Gøtzsche PC. Physical activity for primary prevention of disease: systematic reviews of randomised clinical trials. *Dan Med Bull* 2005;52:86-9.
173. Karmisholt K, Gøtzsche PC. Physical activity for secondary prevention of disease: systematic reviews of randomised clinical trials. *Dan Med Bull* 2005;52:90-4.
174. Gøtzsche PC. Research integrity and pharmaceutical industry sponsorship: trial registration, transparency and less reliance on industry trials are essential. *Med J Aust* 2005;182:549-50.
175. Gluud LL, Sørensen TIA, Gøtzsche PC, Gluud C. The journal impact factor as a predictor of trial quality and outcomes: cohort study of hepato-biliary randomized clinical trials. *Am J Gastroenterol* 2005;100:2431-5.
176. Haug C, Gøtzsche PC, Schroeder TV. Registries and registration of clinical trials. *N Engl J Med* 2005;353:2811-2.
177. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2005;14:1498-1505 (updated).
178. Gøtzsche PC. Assessment bias. In: Kotz S, Balakrishnan N, Read CB, Vidakovic B, eds. Encyclopedia of statistical sciences, 2nd ed. Hoboken, New Jersey: John Wiley & Sons, 2006;vol 1:237-40.
Also published in: Wiley Encyclopedia of Clinical Trials, 2007. DOI: 10.1002/9780471462422.eoct062.
179. Jørgensen KJ, Johansen HK, Gøtzsche PC. Voriconazole versus amphotericin B in cancer patients with neutropenia. The Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD004707.
180. Jørgensen KJ, Johansen HK, Gøtzsche PC. Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations. *Trials* 2006;7:3.
181. Jørgensen KJ, Gøtzsche PC. Content of invitations to publicly funded screening mammography. *BMJ* 2006;332:538-41.
182. Gøtzsche PC. Lessons from and cautions about noninferiority and equivalence randomized trials. *JAMA* 2006;295:1171-3.
183. Hróbjartsson A, Gøtzsche PC. Unsubstantiated claims of large effects of placebo on pain: serious errors in meta-analysis of placebo analgesia mechanism studies. *J Clin Epidemiol* 2006;59:336-8.
184. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan A-W. Constraints on publication rights in industry-initiated clinical trials. *JAMA* 2006;295:1645-6.
185. Johansen HK, Gøtzsche PC, Keegan MT. Vaccines for preventing infection with *Pseudomonas aeruginosa* in people with cystic fibrosis. The Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD001399 (updated).
186. Gøtzsche PC. COX-2-hæmmere og andre nonsteroide antiinflammatoriske stoffer - hvad er fremtiden? *Ugeskr Læger* 2006;168:1972-3.
187. Gøtzsche PC. Paracetamol har samme effekt som nonsteroide antiinflammatoriske stoffer ved akutte skader i bevægeapparatet. *Ugeskr Læger* 2006;168:1981-2.
188. Gøtzsche PC. Believability of relative risks and odds ratios in abstracts: cross-sectional study. *BMJ* 2006;333:231-4.
189. Due AK, Johansen HK, Gøtzsche PC. Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents. *BMC Medical Research Methodology* 2006;6:40.
190. Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. *BMJ* 2006;333:782-5.
191. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD001877.
192. Haedersdal M, Gøtzsche PC. Laser and photoepilation for unwanted hair growth. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD004684.
193. Zahl P-H, Gøtzsche PC, Andersen JM, Mæhlen J. Results of the Two-County trial of mammography screening are not compatible with contemporaneous official Swedish breast cancer statistics. *Dan Med Bull* 2006;53:438-40.

194. Gøtzsche PC, Mæhlen J, Zahl P-H. What is publication? *Lancet* 2006;368:1854-5.
195. Gøtzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Ghost authorship in industry-initiated randomised trials. *PLoS Med* 2007; 4(1):e19.
196. Gøtzsche PC, Hrobjartsson A, Maric K, Tendal B. Data extraction errors in meta-analyses that use standardized mean differences. *JAMA* 2007; 298(4):430-7.
197. Hrobjartsson A, Gøtzsche PC. Powerful spin in the conclusion of Wampold et al.'s re-analysis of placebo versus no-treatment trials despite similar results as in original review. *J Clin Psychol* 2007; 63(4):373-7.
198. Jørgensen KJ, Klahn A, Gøtzsche PC. Are benefits and harms in mammography screening given equal attention in scientific articles? A cross-sectional study. *BMC Med* 2007; 5:12.
199. Pildal J, Hrobjartsson A, Jørgensen KJ, Hilden J, Altman DG, Gøtzsche PC. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. *Int J Epidemiol* 2007; 36(4):847-57.
200. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Epidemiology* 2007; 18(6):805-35.
- Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *PLoS Med* 2007; 4(10):e297.
- Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Ann Intern Med* 2007; 147(8):W163-94.
201. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007; 370(9596):1453-7.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Epidemiology* 2007; 18(6):800-4.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Bull World Health Organ* 2007; 85(11):867-72.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Prev Med* 2007; 45(4):247-51.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ* 2007; 335(7624):806-8.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *PLoS Med* 2007; 4(10):e296.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med* 2007; 147(8):573-7.
202. Welch HG, Woloshin S, Schwartz LM, Gordis L, Gøtzsche PC, Harris R, Kramer BS, Ransohoff DF. Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. *Arch Intern Med* 2007; 167(21):2289-95.
203. Gøtzsche PC, Johansen HK. House dust mite control measures for asthma: systematic review. *Allergy* 2008 Jun;63(6):646-59.
204. Gøtzsche PC. [Freedom of expression and editorial independence: Four firings and a Kafkaian process]. *Ugeskr Laeger* 2008 Apr 28;170(18):1537-8.
205. Lundh A, Gøtzsche PC. Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. *BMC Med Res Methodol* 2008 Apr 21;8:22.
206. Gøtzsche PC, Johansen HK. House dust mite control measures for asthma. *Cochrane Database Syst Rev* 2008; (2):CD001187.
207. Gøtzsche PC, Hrobjartsson A. Somatostatin analogues for acute bleeding oesophageal varices. *Cochrane Database Syst Rev* 2008; (3):CD000193.

208. Johansen HK, Gøtzsche PC. Vaccines for preventing infection with *Pseudomonas aeruginosa* in cystic fibrosis. *Cochrane Database Syst Rev* 2008; (4):CD001399.
209. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandebroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol* 2008 Apr; 61(4):344-9.
 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandebroucke JP; Iniciativa STROBE. [The Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] statement: guidelines for reporting observational studies]. *Gac Sanit* 2008 Mar-Apr; 22(2):144-50.
 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandebroucke JP. [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies]. *Rev Esp Salud Publica* 2008; 82(3):251-9.
 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandebroucke JP. [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies]. *Internist (Berl)* 2008; 49(6):688-93.
210. Zahl PH, Jørgensen KJ, Maehlen J, Gøtzsche PC. Biases in estimates of overdetection due to mammography screening. *Lancet Oncol* 2008 Mar; 9(3):199-201.
211. Brodersen J, Hartling O, Nielsen M, Gøtzsche P. Det informerede samtykke ved screening for brystkræft. *Månedsskr Prakt Lægegern* 2008; 86 (maj):551-7.
212. Jørgensen AW, Maric KL, Tendal B, Faurschou A, Gøtzsche PC. Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions. *BMC Med Res Methodol* 2008; 8:60.
213. Gøtzsche PC. Commercial interests versus common goods. In: Lötjönen S, von Troil H, eds. *Bioethics, Politics and Business*. Copenhagen: Nordic Council of Ministers, TemaNord 2008:119-26. ISBN 978-92-893-1728-3.
214. Chan A-W, Hróbjartsson A, Jørgensen KJ, Gøtzsche PC, Altman DG. Reporting of sample size calculations and data analysis methods in randomized trials: comparison of publications with protocols. *BMJ* 2008; 337:1404-7.
215. Madsen MV, Gøtzsche PC, Hróbjartsson A. Acupuncture treatment for pain: systematic review of randomised clinical trials with acupuncture, placebo acupuncture, and no acupuncture groups. *BMJ* 2008; 338:330-3.
216. Gøtzsche PC. Readers as research detectives. *Trials* 2009; 10:2.
217. Gøtzsche P, Hartling OJ, Nielsen M, Brodersen J, Jørgensen KJ. Breast screening: the facts - or maybe not. *BMJ* 2009; 338:446-8.
218. Gøtzsche PC. Alternativ behandling. I: Ove B. Schaffalitzky de Muckadell, Stig Haunso og Hendrik Vilstrup, red. *Medicinsk Kompendium*, 17. udg. København: Nyt Nordisk Forlag, 2009, kap. 75. ISBN 978-87-17-03933-9.
219. Gøtzsche PC. Kasuistiske meddelelser: fortsat en hovedkilde til forvirring, men nu på patientgruppeniveau. *Bibl Læger* 2009; 201:87-91.
220. Gøtzsche PC, Johansen HK, Haahr MT, Altman DG, Chan A-W. Videnskabelig uredelighed. *Ugeskr Læger* 2009; 171:1206-9.
221. Gøtzsche PC. Atter fri adgang til Cochrane-biblioteket for alle danskere. *Ugeskr Læger* 2009; 171:932-3.
222. Brodersen J, Hartling O, Nielsen M, Gøtzsche P. Informerat samtycke vid mammografiscreening. I: Brodersen J, Hovelius B, Hvas L, eds. *Skapar vården ohälsa? Allmänmedicinske reflektioner*. Lund: Studentlitteratur AB, 2009:167-75.
 Brodersen J, Hartling O, Nielsen M, Gøtzsche P. Det informerede samtykke ved screening for brystkræft. I: Brodersen J, Hovelius B, Hvas L, eds. *Kan sundhedsvæsenet skabe usundhed? Reflekstioner fra almen praksis*. København: Månedsskrift for Praktisk Lægegerning, 2009:153-162.
223. Krogsbøll LT, Hróbjartsson A, Gøtzsche PC. Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention. *BMC Medical Research Methodology* 2009, 9:1.
224. Gøtzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, Gertel A, Hamilton C. What should be done to tackle ghostwriting in the medical literature? *PLoS Med* 2009; 6(2):e23.
225. Jørgensen KJ, Brodersen J, Hartling OJ, Nielsen M, Gøtzsche PC. Informed choice requires information about both benefits and harms. *J Med Ethics* 2009; 35(4):268-9.

226. Vandenbroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; Iniciativa STROBE. [Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration]. *Gac Sanit*. 2009 Mar-Apr;23(2):158.
227. Gøtzsche PC, Hartling O, Nielsen M, Jørgensen KJ, Brodersen J. Invitation til brystkræftscreening: propaganda eller information? *Ugeskr Læger* 2009;171:1963.
228. Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. *BMJ* 2009;339:b2587.
229. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Ann Intern Med* 2009 Aug 18;151(4):W65-94.
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med* 2009 Jul 21;6(7):e1000100.
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol* 2009;62(10):e1-34.
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009 Jul 21;339:b2700.
230. Tendal B, Higgins JP, Jüni P, Hróbjartsson A, Trelle S, Nüesch E, Wandel S, Jørgensen AW, Gesser K, IIsøe-Kristensen S, Gøtzsche PC. Disagreements in meta-analyses using outcomes measured on continuous or rating scales: observer agreement study. *BMJ* 2009 Aug 13;339:b3128.
231. Gøtzsche PC, Lundh A. Industrisponsoreret esteruddannelse hører ikke hjemme i et evidensbaseret sundhedsvæsen. *Ugeskr Læger* 2009;171:2228-9.
232. Hróbjartsson A, Pildal J, Chan AW, Haahr MT, Altman DG, Gøtzsche PC. Reporting on blinding in trial protocols and corresponding publications was often inadequate but rarely contradictory. *J Clin Epidemiol*. 2009 Sep;62(9):967-73.
233. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. *Cochrane Database of Systematic Reviews* 2009, Issue 4. Art. No.: CD001877.
234. Gøtzsche PC, Jørgensen KJ. [Honest information about mammography screening, please!]. *Lakartidningen*. 2009;106(44):2860-1.
235. Gøtzsche PC. Evidensbaseret medicin: Ankestyrelsen mod Sundhedsstyrelsen om husstøvmider. *Ugeskr Læger* 2009;171:3727.
236. Jørgensen KJ, Hróbjartsson A, Gøtzsche PC. Divine intervention? A Cochrane review on intercessory prayer gone beyond science and reason. *J Negat Results Biomed* 2009 Jun 10;8:7.
237. Gøtzsche PC. Evidensbaseret medicin: Ankestyrelsen mod Sundhedsstyrelsen om husstøvmider. *Ugeskr Læger* 2009;171:3727.
238. Jørgensen KJ, Zahl P-H, Gøtzsche PC. Overdiagnosis in organised mammography screening in Denmark: a comparative study. *BMC Women's Health* 2009;9:36.
239. Jørgensen KJ, Gøtzsche PC. Who evaluates public health programmes? A review of the NHS Breast Screening Programme. *J R Soc Med* 2010;103:14-20.
240. Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. *Cochrane Database of Systematic Reviews* 2010, Issue 1. Art. No.: CD003974.
241. Jørgensen KJ, Zahl P-H, Gøtzsche PC. Breast cancer mortality in organised mammography screening in Denmark: comparative study. *BMJ* 2010;340:e1241.
242. Brodersen J, Jørgensen KJ, Gøtzsche PC. The benefits and harms of screening for cancer with a focus on breast screening. *Pol Arch Med Wewn* 2010;120:89-94.
243. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. *Obstet Gynecol* 2010 May;115(5):1063-70.
- Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *PLoS Med* 2010 Mar 24;7(3):e1000251.

- Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. *J Clin Epidemiol* 2010 Aug;63(8):834-40.
- Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. *Ann Intern Med* 2010 Jun 1;152(11):726-32.
- Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMC Med* 2010 Mar 24;8:18.
- Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *Trials* 2010 Mar 24;11:32.
- Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010 Mar 23;340:c332.
244. Gøtzsche PC, Berg S. Sleep apnoea: from person to patient, and back again. *BMJ* 2010 Mar 30;340:c360.
245. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010 Mar 23;340:c869.
- Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG; Consolidated Standards of Reporting Trials Group. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. *J Clin Epidemiol* 2010 Aug;63(8):e1-37.
- Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. [CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials (Chinese version)]. *Zhong Xi Yi Jie He Xue Bao* 2010;8(8):701-41.
246. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg* 2010;8(5):336-41.
247. Jørgensen AW, Jørgensen KJ, Gøtzsche PC. Unbalanced reporting of benefits and harms in abstracts on rofecoxib. *Eur J Clin Pharmacol* 2010 Apr;66(4):341-7.
248. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. *Cochrane Database Syst Rev* 2010;(7):CD007851.
249. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy: systematic review. *Dan Med Bull* 2010;57(9):A4175.
250. Lundh A, Barbateskovic M, Hrobjartsson A, Gøtzsche PC. Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort study. *PLoS Med* 2010;7(10):e1000354.
251. Jørgensen AW, Gøtzsche PC. [Insufficient access to research data not acceptable]. *Ugeskr Laeger* 2010 May 24;172(21):1585.
252. Gøtzsche PC, Delamothe T, Godlee F, Lundh A. Adequacy of authors' replies to criticism raised in electronic letters to the editor: cohort study. *BMJ* 2010 Aug 10;341:c3926.
253. Cordoba G, Schwartz L, Woloshin S, Bae H, Gøtzsche PC. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. *BMJ* 2010;341:c3920.
254. la Cour JL, Brok J, Gøtzsche PC. Inconsistent reporting of surrogate outcomes in randomised clinical trials: cohort study. *BMJ* 2010;341:c3653.
255. Lundh A, Gøtzsche PC. Sponsorship of medical textbooks by drug or device companies. *CMEJ* 2011;1:e10-7.
256. Gøtzsche PC. Lovforslaget om kliniske forsøg viger uden om de allerstørste problemer. *Ugeskr Laeger* 2011;173(11):840.
257. Gøtzsche PC. Re: Time to stop mammography screening? *CMAJ* 2011;(183):1957-8.
258. Gøtzsche PC. Hvorfor fejlinformerer Sundhedsstyrelsen om mammografiscreening? *Videnskab.dk* 2011; <http://videnskab.dk/krop-sundhed/hvorfor-fejlinformerer-sundhedsstyrelsen-om-mammografiscreening>.
259. Gøtzsche PC. Medicinalindustriens forskningsfusk og de købte læger. 2011; <http://videnskab.dk/kultursamfund/medicinalindustriens-forskingsfusk-og-de-kobte-laeger>.
260. Gøtzsche PC. Åbent brev til Lundbeck om antidepressiva og selvmord. *Videnskab dk* 2011; <http://videnskab.dk/krop-sundhed/abent-brev-til-lundbeck-om-antidepressiva-og-selvmord>.
261. Gøtzsche PC, Jørgensen AW. Opening up data at the European Medicines Agency. *BMJ* 2011;342:d2686.
262. Gøtzsche PC, Jørgensen KJ. The Breast Screening Programme and misinforming the public. *J R Soc Med* 2011;104(9):361-9.

263. Gøtzsche PC, Tendal B, Clarke M. Review production in The Cochrane Collaboration - where is it happening and why? *Cochrane Database Syst Rev* 2011;Suppl 1:16-9.
264. Gøtzsche PC. We need access to all data from all clinical trials. *Cochrane Database Syst Rev* 2011;12:ED000035.
265. Gøtzsche PC. Niels Finsen's treatment for lupus vulgaris. *J R Soc Med* 2011;104(1):41-2.
266. Gøtzsche PC. Relation between breast cancer mortality and screening effectiveness: systematic review of the mammography trials. *Dan Med Bull* 2011;58(3):A4246.
267. Higgins JP, Altman DG, Gøtzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.
268. Jørgensen KJ, Keen JD, Gøtzsche PC. Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality? *Radiology* 2011;260(3):621-7.
269. Lundh A, Krogsbøll LT, Gøtzsche PC. Access to data in industry-sponsored trials. *Lancet* 2011;378(9808):1995-6.
270. Nielsen M, Gøtzsche P. An analysis of psychotropic drug sales. Increasing sales of selective serotonin reuptake inhibitors are closely related to number of products. *Int J Risk Saf Med* 2011;23(2):125-32.
271. Schroll JB, Moustgaard R, Gøtzsche PC. Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study. *BMC Med Res Methodol* 2011;11:22.
272. Suhrke P, Machlen J, Schlichting E, Jørgensen KJ, Gøtzsche PC, Zahl PH. Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. *BMJ* 2011;343:d4692.
273. Tendal B, Nuesch E, Higgins JP, Juni P, Gøtzsche PC. Multiplicity of data in trial reports and the reliability of meta-analyses: empirical study. *BMJ* 2011;343:d4829.
274. Zahl PH, Gøtzsche PC, Maehlen J. Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. *Lancet Oncol* 2011;12(12):1118-24.
275. Gøtzsche PC. Why we need easy access to all data from all clinical trials and how to accomplish it. *Trials* 2011;12(1):249.
276. Gøtzsche PC, Jørgensen KJ, Zahl PH, Maehlen J. Why mammography screening has not lived up to expectations from the randomised trials. *Cancer Causes Control* 2012;23(1):15-21.
277. Gøtzsche PC. Hvorfor så snævre grænser for omfang i Ugeskriftet? *Ugeskr Læger* 2012;174:297.
278. Gøtzsche PC, Hartling OJ, Nielsen M, Brodersen J. Screening for breast cancer with mammography. The Nordic Cochrane Centre 2012. www.cochrane.dk.
279. Gøtzsche PC, Hartling OJ, Nielsen M, Brodersen J. Screening for brystkræft med mammografi. The Nordic Cochrane Centre 2012. www.cochrane.dk.
280. Gøtzsche PC. Strengthening and opening up health research by sharing our raw data. *Circ Cardiovasc Qual Outcomes* 2012 Mar 1;5(2):236-7.
281. Jørgensen KJ, Gøtzsche PC. [Mortality in breast cancer is decreasing - but not because of screening. Time to abolish the mammography screening]. *Läkartidningen* 2012;109:690-2.
282. Jørgensen KJ, Gøtzsche PC. Rintasyöpäkuolleisuus vähenee, muttei seulonnan ansiosta. *Suomen Lääkärilehti* 2012;11:856-8.
283. Grønhoj Larsen C, Jørgensen KJ, Gøtzsche PC. Regular health checks: cross-sectional survey. *PLoS One*. 2012;7(3):e33694.
284. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG; CONSORT. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *Int J Surg* 2012;10(1):28-55.
285. Nielsen M, Hansen EH, Gøtzsche PC. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. *Addiction*. 2012;107(5):900-8.
286. Gøtzsche PC. Mammografiscreening gør raske kvinder syge. *Fokus på Kræft og sygepleje* 2012;2:18-20.
287. Lundh A, Krogsbøll LT, Gøtzsche PC. Sponsor's participation in conduct and reporting of industry trials: a descriptive study. *Trials* 2012;13:146.
288. Schroll JB, Maund E, Gøtzsche PC. Challenges in coding adverse events in clinical trials: a systematic review. *PLoS One* 2012;7:e41174.
289. Gøtzsche PC. Lægers råd om medicin er ikke sunde. *Politikens kronik* 2012 Nov 29.

290. Gøtzsche PC. Vores lykkepille-epidemi er dybt skadelig. Berlingskes kronik 2012 Dec 16.
291. Gøtzsche PC. Deficiencies in proposed new EU regulation of clinical trials. BMJ 2012;345:e8522.
292. Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database of Systematic Reviews. 2012;10:CD009009.
293. Gøtzsche PC, Ioannidis JPA. Content area experts as authors: helpful or harmful for systematic reviews and meta-analyses? BMJ (Online). 2012;345:e7031.
294. Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease: Cochrane systematic review and meta-analysis. BMJ (Online). 2012;345:e7191.
295. Gøtzsche PC. Big pharma often commits corporate crime, and this must be stopped. BMJ 2012;345:e8462.
296. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K et al. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Annals of Internal Medicine. 2013;158(3):200-7.
297. Beller EM, Glasziou PP, Altman DG, Hopewell S, Bastian H, Chalmers I et al. PRISMA for Abstracts: reporting systematic reviews in journal and conference abstracts. PLoS medicine. 2013;10(4):e1001419.
298. Bindslev JBB, Schroll J, Gøtzsche PC, Lundh A. Underreporting of conflicts of interest in clinical practice guidelines: cross sectional study. B M C Medical Ethics. 2013;14:19.
299. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ (Online). 2013;346:e7586.
300. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews. 2013;6:CD001877.
301. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. JAMA 2013 jun 19;309(23):2489-90.
302. Nielsen M, Hansen EH, Gøtzsche PC. Dependence and withdrawal reactions to benzodiazepines and selective serotonin reuptake inhibitors. How did the health authorities react? International Journal of Risk and Safety in Medicine. 2013;25(3):155-68.
303. Rasmussen K, Jørgensen KJ, Gøtzsche PC. Citations of scientific results and conflicts of interest: the case of mammography screening. Evidence - Based Medicine (English Edition). 2013 jun;18(3):83-9.
304. Schroll JB, Bero L, Gøtzsche PC. Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ (Online). 2013;346:f2231.
305. Wolfe N, Gøtzsche PC, Bero LA. Strategies for obtaining unpublished drug trial data: a qualitative interview study. Systematic Reviews. 2013;2:31.
306. Zahl P-H, Juhl Jørgensen K, Gøtzsche PC. Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. B J C. 2013 okt 1;109(7):2014-9.
307. Gøtzsche PC. Overdiagnostik og overmedicinering i børnepsykiatrien. Pædagogisk Psykologisk Tidsskrift 2013;50:95-100.
308. Gøtzsche PC. Bør bekendtgørelsen om videnskabelig uredelighed revideres endnu en gang? Ugeskr Læger 2013;175:2512-3.
309. Gøtzsche PC. Alternativ behandling. I: Ove B. Schaffalitzky de Muckadell, Stig Haunsø og Hendrik Vilstrup, red. Medicinsk Kompendium, 18. udg. København: Nyt Nordisk Forlag, 2013, kap. 73.
310. Chan AW, Song F, Vickers A, Jefferson T, Dickersin K, Gøtzsche PC, Krumholz HM, Ghersi D, van der Worp HB. Increasing value and reducing waste: addressing inaccessible research. Lancet. 2014;383(9913):257-66.
311. Smith R, Gøtzsche PC, Groves T. Should journals stop publishing research funded by the drug industry? BMJ. 2014 Jan 14;348:g171.
312. Maund E, Tendal B, Hróbjartsson A, Lundh A, Gøtzsche PC. Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study. BMJ. 2014 Jun 4;348:g3555.
313. Maund E, Tendal B, Hróbjartsson A, Jørgensen KJ, Lundh A, Schroll J, Gøtzsche PC. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. BMJ. 2014 Jun 4;348:g3510.
314. Gøtzsche PC. Questionable research and marketing of a combination drug for smoker's lungs. J R Soc Med 2014;107:256-7.
315. Gøtzsche PC. Why I think antidepressants cause more harm than good. Lancet Psychiatry 2014;1:104-6.
316. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database of Systematic Reviews. 2014;9:CD002033.

317. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database of Systematic Reviews. 2014;9:CD000026.
318. Gøtzsche PC. "Human guinea pig" asks for animal studies. BMJ (Online). 2014;349:g6714.
319. Gøtzsche PC. Our prescription drugs kill us in large numbers. Polskie Archiwum Medycyny Wewnętrznej. 2014;124(11):628-34.
320. Johansen HK, Gøtzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. Cochrane Database of Systematic Reviews. 2014;9:CD000239.
321. Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia. Cochrane Database of Systematic Reviews. 2014;9:CD000969.
322. Jørgensen KJ, Gøtzsche PC, Dalbøge CS, Johansen HK. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. Cochrane Database of Systematic Reviews. 2014;2:CD004707.
323. Jørgensen AW, Lundstrøm LH, Wetterslev J, Astrup A, Gøtzsche PC. Comparison of results from different imputation techniques for missing data from an anti-obesity drug trial. PLoS One. 2014;9(11):e111964.
324. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. International journal of surgery (London, England). 2014 dec;12(12):1500-24.
325. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. International journal of surgery (London, England). 2014 dec;12(12):1495-1499.
326. Zahl P-H, Jørgensen KJ, Gøtzsche PC. Lead-time models should not be used to estimate overdiagnosis in cancer screening. Journal of General Internal Medicine. 2014 sep;29(9):1283-6.
327. Gøtzsche PC. Overdiagnostik og overbehandling i psykiatrien. I: Brinkmann S and Petersen, eds. Diagnoser. Aarhus: Klim; 2015.
328. Gøtzsche PC. Does long term use of psychiatric drugs cause more harm than good? BMJ 2015;350:h2435.
329. Gøtzsche PC. Mammography screening is harmful and should be abandoned. J Royal Soc Med 2015;108(9):341-5.
330. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162(11):777-84.
331. Johansen HK, Gøtzsche PC. Vaccines for preventing infection with *Pseudomonas aeruginosa* in cystic fibrosis. Cochrane Database Syst Rev 2015;8:CD001399.
332. Jørgensen KJ, Gøtzsche PC. Breast cancer: Updated screening guidelines - much ado about small improvements. Nature Reviews Clin Oncol 2015; Dec 31.
333. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. Screening with urinary dipsticks for reducing morbidity and mortality. Cochrane Database Syst Rev 2015;1:CD010007.
334. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
335. Rasmussen KM, Schroll J, Gøtzsche PC, Lundh A. Under-reporting of conflicts of interest among trialists: a cross-sectional study. J Royal Soc Med 2015;108:101-7.
- 336.

Correspondence, book reviews and similar

1. Gøtzsche PC, Gjørup IE. Virkninger af moderat lakridsindtagelse. Ugeskr Læger 1984;146:207.
2. Gøtzsche PC. Turnusordningen - eller hvordan tre måneder bliver til ingenting. Ugeskr Læger 1984;146:2765.
3. Gøtzsche PC, Karlsen FØ. Buprenorfín og morfin. Ugeskr Læger 1985;147:1786.
4. Gøtzsche PC, Bygbjerg IC. Leverbiopsi ved AIDS? Ugeskr Læger 1988;150:173-4.
5. Gøtzsche PC. Enalapril, atenolol, and hydrochlorothiazide in hypertension. Lancet 1986;iii:38-9.
6. Gøtzsche PC, Karlsen FØ. Lodtrækningsprincippet. Ugeskr Læger 1988;150:1899-1990.
7. Gøtzsche PC, Hørding M. Kondomers sikkerhed. Ugeskr Læger 1988;150:1000.
8. Gøtzsche PC, Hørding M. Kondomers sikkerhed. Ugeskr Læger 1988;150:1697.
9. Gøtzsche PC. Ditiocarb in HIV infection. Lancet 1988;Oct 29:1024.
10. Jørgensen PE, Forrest M, Hermann GG, Gøtzsche PC, Andersen B. (U)videnskabeligt bogholderi. Ugeskr Læger 1989;151:901.

11. Gøtzsche PC. Forskningsmetodologisk lærestykke 2. Ugeskr Læger 1989;151:319.
12. Gøtzsche PC. Forskningsmetodologiske lærestykker 4. Vurdering af korrelationer. Ugeskr Læger 1989;151:456-7.
13. Gøtzsche PC (book review). Duodenal ulcer. Analyses of 293 randomized trials. Stat Med 1990;9:1225-6.
14. Rosenberg R, Gøtzsche PC. Urigtig påstand om naturmedicin. Ugeskr Læger 1991;153:3027.
15. Gøtzsche PC (bogameldelse). Schou I, ed. Good clinical practice. Kvalitetskrav til klinisk undersøgelse. Ugeskr Læger 1991;153:3636.
16. Gøtzsche PC. P-piller giver ikke brystkraeft. Ugeskr Læger 1992;154:1437.
17. Gøtzsche PC. Kommentar (til artikel om placebo). Ugeskr Læger 1992;154:2452.
18. Gøtzsche PC. Placeboeffekt? Ugeskr Læger 1992;154:3006.
19. Rasmussen MH, Andersen T, Breum L, Gøtzsche PC, Hilsted J. Cimetidine and weight loss. BMJ 1993;307:446-7.
20. Gøtzsche PC. Trials of homeopathy. Lancet 1993;June 12:1533.
21. Gøtzsche PC. Zidovudine dosage. BMJ 1993;307:682-3.
22. Gøtzsche PC. Randomiseret undersøgelse af oxytocin? Ugeskr Læger 1994;156:201.
23. Gøtzsche PC (bogameldelse). Skrabanek P, McCormick J. Follies and fallacies in medicine, anden udgave. Ugeskr Læger 1994;156:7386.
24. Gøtzsche PC. Metaanalyse af magnesiumbehandling af myokardieinfarkt. Ugeskr Læger 1995;157:2727-8.
25. Gøtzsche PC (book review). Xenotransplantation. J Med Ethics 1995;190-1.
26. Gøtzsche PC (bogameldelse). Chalmers I, Altman DG, eds. Systematic reviews. Ugeskr Læger 1995;157:4364-5.
27. Gøtzsche PC. Ekspertviden eller medicinsk teknologivurdering? Ugeskr Læger 1996;158:6291-2.
28. Gøtzsche PC. Det sundhedsvidenkabelige grundlag for medicinsk teknologivurdering. Ugeskr Læger 1997;159:68-9.
29. Gøtzsche PC. Ekspertviden eller medicinsk teknologivurdering II. Ugeskr Læger 1997;159:70-1.
30. Gøtzsche PC, Johansen HK. Prophylactic and empirical antifungal treatment in cancer complicated by neutropenia. BMJ 1997;315:489.
31. Johansen HK, Gøtzsche PC. Meta-analysis of prophylactic or empirical antifungal therapy in cancer with neutropenia. Topics Supp Care Oncol 1997;26:9-10.
32. Johansen HK, Gøtzsche PC. Use of odds ratio in calculation of number needed to treat was inappropriate. BMJ 1997;315:879.
33. Gøtzsche PC. Screening for colorectal cancer. Lancet 1997;349:356.
34. Gøtzsche PC. Greenhalgh T: How to read a paper: the basics of evidence based medicine (bogameldelse). Ugeskr Læger 1998;160:305-6.
35. Gøtzsche PC. Løgn, forbandet løgn og ... metaanalyse (svar). Ugeskr Læger 1998;160:896-7.
36. Gøtzsche PC. Somatostatin for acute oesophageal variceal bleeding. Lancet 1998;351:911.
37. Gøtzsche PC, Johansen HK. Intermittent low dose prednisolone is safe in rheumatoid arthritis. BMJ 1998;316:1606-7.
38. Gøtzsche PC. Statusartikel om antibiotikas effekt ved halsbetændelse. Ugeskr Læger 1998;160:5376.
39. Gøtzsche PC. Hvad er relationen mellem randomiserede forsøg og evidensbaseret medicin? Ugeskr Læger 1999;161:624.
40. Gøtzsche PC. Probability without equations (book review). Stat Med 1999;18:622-3.
41. Gøtzsche PC, Hammarquist C, Burr M. Control of house dust mite in managing asthma. BMJ 1999;318:871.
42. Gøtzsche PC. Var zoneterapiforsøget randomiseret? Ugeskr Læger 1999;161:2224.
43. Gøtzsche PC. Cochranologiens vokseværk. Ugeskr Læger 1999;161:2690-1.
44. Gøtzsche PC. Om Cochrane og brugen af albumin. Ugeskr Læger 1999;161:5552-4.
45. Gøtzsche PC. Skal radikal prostatektomi indføres? Ugeskr Læger 1999;161:3472-3.
46. Gøtzsche PC. Radikal prostatektomi er udokumenteret. Ugeskr Læger 1999;161:5691-2.
47. Gøtzsche PC, Olsen O. Screening mammography re-evaluated. Lancet 2000;355:752.
48. Johansen HK, Gøtzsche PC. Improving the conduct and reporting of clinical trials. JAMA 2000;283:2789.

49. Gøtzsche PC. "Skarp kritik af mammografiscreening"(svar). Ugeskr Læger 2000;162:817.
50. Gøtzsche PC. Openness about the Swedish breast cancer screening trials is needed. Läkartidningen 2000;97:3105-6.
51. Gøtzsche PC, Olsen O. God begrundelse for mammografiscreening. Ugeskr Læger 2000;162:4166-7.
52. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. BMJ 2000;321:568-9.
53. Gøtzsche PC. Openness about the Swedish breast cancer screening trials is needed (author's reply). Läkartidningen 2000;97:3105.
54. Gøtzsche PC, Olsen O. More on mammography. Lancet 2000;356:1276.
55. Gøtzsche PC. Albumin: et vigtigt princip i behandlingen af dekompenseret leversygdom (svar). Ugeskr Læger 2001;163:63-4.
56. Olsen O, Gøtzsche PC. Mister flere kvinder brystet efter screening - og hvornår må vi diskutere det? Ugeskr Læger 2001;163:1576.
57. Gøtzsche PC. Er evidensbaseret medicin evidensbaseret? (svar). Ugeskr Læger 2001;163:182.
58. Gøtzsche PC, Olsen O. Postoperativ strålebehandling øger mortaliteten hos kvinder, der får diagnosticeret brystkræft ved screening. Läkartidningen 2001;98:347.
59. Wille-Jørgensen PA, Gøtzsche PC. Angående evidensbaseret kirurgi (svar). Ugeskr Læger 2001;163:1450.
60. Pedersen T, Møller AM, Gøtzsche PC. Albumin, evidens og metaanalyse: kan dommen appelleres (svar)? Ugeskr Læger 2001;163:1719-20.
61. Gøtzsche PC. Mortalitet efter human albumin. Ugeskr Læger 2001;163:2260-1.
62. Gøtzsche PC. Debate on screening for breast cancer is not over. BMJ 2001;323:693.
63. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? N Engl J Med 2001;345:1278-9.
64. Gøtzsche PC. Office of NHS cancer screening programme misrepresents Nordic work in breast screening row. BMJ 2001;323:1131.
65. Gøtzsche PC. Cochrane-rapport om mammografiscreening. Ugeskr Læger 2001;163:6768.
66. Pildal, Gøtzsche PC. Kritikken er berettiget. Läkartidningen 2001;98:5625.
67. Gøtzsche PC. Screening for breast cancer with mammography. Lancet 2001;358:2167-8.
68. Gøtzsche PC. Kritik af Cochrane-oversigt om screening med mammografi er überettiget. Ugeskr Læger 2002;164:653-4.
69. Gøtzsche PC. Trends in breast-conserving surgery in the Southeast Netherlands: Comment on article by Ernst and colleagues Eur J Cancer 2001, 37, 2435-2440. Eur J Cancer 2002;38:1288.
70. Gøtzsche PC. Update on effects of screening mammography. Lancet 2002;360:338-9.
71. Gøtzsche PC. Terlipressin for acute esophageal variceal hemorrhage. Comment on Cochrane Review. In: The Cochrane Library, Issue 3. Oxford: Update Software; 2002.
72. Gøtzsche PC. Beyond randomized controlled trials. Cancer 2002;94:578.
73. Gøtzsche PC. Mammographic screening: no reliable supporting evidence? Lancet 2002;359:706.
74. Gøtzsche PC. Alarmerande att screeningsförsöken inte ger minskad cancerdödlighet. Läkartidningen 2002;99:945.
75. Hróbjartsson A, Gøtzsche PC. Placebo og bevisbyrde. Ugeskr Læger 2002;164:1525-6.
76. Gøtzsche PC. Misvisende fremstilling af vort arbejde om screening med mammografi. Läkartidningen 2002;99:75-6.
77. Gøtzsche PC. Albumin ved dekompenseret levercirrose. Ugeskr Læger 2002;164:1203-4.
78. Gøtzsche PC. Screening mammography: setting the record straight. Lancet 2002;359:440-1.
79. Gøtzsche PC. Misleading paper on mastectomy rates in a screening programme.
<http://bmj.com/cgi/eletters/325/7361/418#24972>, 26 Aug 2002.
80. Gøtzsche PC. How to swallow one's words with a standard deviation.
<http://bmj.com/cgi/eletters/325/7366/682#26186>, 11 Oct 2002.
81. Gøtzsche PC. Grønt lys for udokumenteret behandling. Ugeskr Læger 2002;164:3568-9.
82. Gøtzsche PC. WHO og The Lancet: ja til mammografiscreening (svar). Ugeskr Laeger 2002;164:3082-3.
83. Gøtzsche PC. Invited reponse to "The mammographic screening trials: commentary on the recent work by Olsen and Gøtzsche". J Surg Oncol 2002;81:162-3.

84. Gøtzsche PC. Placebokirurgi: artroskopisk lavage og débridement ved slidgigt. Ugeskr Læger 2002;164:5151.
85. Gøtzsche PC. Kræftens Bekæmpelse, screening og troværdigheden. Ugeskr Læger 2003;165:611-2.
86. Gøtzsche PC. Screening mammography and mortality. Med J Aust 2003;178:189-90.
87. Gøtzsche PC, Hartling O. Er oplysninger om brystkræftscreening troværdige? Ugeskr Læger 2003;165:1068-70.
88. Gøtzsche PC. Uærighed i lægemiddelafsprøvninger koster samfundet dyrt. Ugeskr Læger 2003;165:1691-2.
89. Gøtzsche PC. Breast cancer screening. International Agency for Research on Cancer (IARC) Handbooks of Cancer Prevention (book review). Int J Epidemiol 2003;32:472.
90. Gøtzsche PC. Screening for breast cancer. Ann Intern Med 2003;138:769-70.
91. Gøtzsche PC, Hartling O. Svar på debatindlæg "Mister kvinder unødigt brystet, hvor der screenes for brystkræft?". Ugeskr Læger 2003;165:2586-7.
92. Gøtzsche PC. Uærighed i lægemiddelafsprøvninger koster samfundet dyrt (svar). Ugeskr Læger 2003;165:2673-4.
93. Gøtzsche PC, Hartling O. Svar på "Ingen evidens for at mammografiscreening fører til overbehandling". Ugeskr Læger 2003;165:3026-7.
94. Gøtzsche PC. Uærighed i lægemiddelforskning og Cochrane Centeret (svar). Ugeskr Læger 2003;165:3098-9.
95. Gøtzsche PC. Skadelig screening for kræft. Politiken 2003; 1. juni, 3. sektion, s. 9.
96. Gøtzsche PC. Mammographic screening for breast cancer. N Engl J Med 2003;349:611.
97. Gøtzsche PC. Mortality reduction by breast-cancer screening. Lancet 2003;362:246.
98. Gøtzsche PC. Mammographic service screening and mortality. Lancet 2003;362:329-30.
99. Gøtzsche PC. Hvornår er noget skadeligt? Politiken 2003; 31. august, 3. sektion, s. 9.
100. Hróbjartsson A, Gøtzsche PC. Unreliable analysis of placebo analgesia in trials of placebo pain mechanisms. Pain 2003;104:714-5.
101. Gøtzsche PC. "Behandlingen er veldokumenteret". Politiken 2003; 5. oktober, 3. sektion, s. 9.
102. Gøtzsche PC. Medicinalindustrien har alt for let spil. Politiken 2003; 23. november, 3. sektion, s. 9.
103. Gøtzsche PC. Ikke-evidensbaseret kommentar om nytten af madrasbetræk ved astma med husstøvmideallergi. Ugeskr Læger 2003;165:4234-5.
104. Gøtzsche PC, Johansen HK, Burr M. Are encasings effective in asthma caused by house dust mite allergens (letter)? J Allergy Clin Immunol 2003;112:220.
105. Gøtzsche PC, Martin Bland and Janet Peacock, Statistical questions in evidence-based medicine (book review). Stat Med 2003;22:2817-20.
106. Gøtzsche PC. Hendes Majestæt Dronning Ingrids XI Festforelæsning, 2003. SØLK 2003;27(9):16-20.
107. Gøtzsche PC. Ondt i ryggen og muskelrelaksantia (reply). Ugeskr Læger 2004;166:1034.
108. Jørgensen KJ, Gøtzsche PC. Websites on screening for breast cancer (authors' reply). BMJ 2004;328:769-70.
109. Gøtzsche PC. Vær forsiktig med videnskabelig uredelighed. Politiken 2004; 25. januar, 3. sektion, s. 9.
110. Gøtzsche PC, Vestergård B. Åbent bibliotek om virkninger og bivirkninger. Politiken 2004; 9. maj, 3. sektion, s. 9.
111. Gøtzsche PC. What to conclude when treatments are harmful. CoRect News, Newsletter, The Cochrane Colorectal Cancer Group 2004;8:2-4.
112. Hróbjartsson A, Gøtzsche PC. Tesen om the powerless placebo. Ugeskr Læger 2004;166:2693-4.
113. Jørgensen KJ, Gøtzsche PC. Overfortolkning af inkonklusivt populationsstudie om brystkræft. Ugeskr Læger 2004;166:2822.
114. Gøtzsche PC. Kreativ markedsføring af margarine og medicin. Politiken 2004; 15. aug., 3. sektion, s. 9.
115. Gøtzsche P. Niels Finsen's treatment for lupus vulgaris. James Lind Library (www.jameslindlibrary.org). © Peter Gøtzsche, 2004.
116. Gøtzsche PC. Re: Trends in the treatment of ductal carcinoma *in situ* of the breast. J Natl Cancer Inst 2004;96:1257.
117. Gøtzsche PC, Jørgensen KJ. Mammografiscreening uden overdiagnostik (reply). Ugeskr Læger 2004;166:3737-8.

118. Gøtzsche PC, Møller A, Pedersen T. Albumin eller fysiologisk saltvand til volumendepleterede intensivpatienter? Ugeskr Læger 2004;166:3835.
119. Gøtzsche PC, Hróbjartsson A. Undocumented editorial on placebos. <http://bmj.bmjjournals.com/cgi/eletters/329/7472/927>, 2004.
120. Gøtzsche PC. Reply: What to conclude when treatments are harmful (reply). CoRect News, Newsletter, The Cochrane Colorectal Cancer Group 2004;8(2):4.
121. Gøtzsche PC. Misleading quotations and other errors persist in rejoinder on breast cancer screening. Int J Epidemiol 2004;33:1404.
122. Gøtzsche PC. Does exercise training lower mortality in patients with chronic heart failure? <http://bmj.bmjjournals.com/cgi/eletters/328/7433/189>, 2005.
123. Gøtzsche PC, Jørgensen KJ, Thornton H. Benefits and harms of breast cancer screening. <http://bmj.bmjjournals.com/cgi/eletters/330/7485/220>, 2005.
124. Gøtzsche PC, Jørgensen KJ, Hartling O. Mammografiscreening - igen. Ugeskr Læger 2005;167:783-4.
125. Gøtzsche PC, Wille-Jørgensen P. Ghost authorship in evidence-based medicine. <http://bmj.bmjjournals.com/cgi/eletters/330/7484/163>, 2005.
126. Gøtzsche PC, Jørgensen KJ. Outcomes of screening mammography: information to support informed choices. <http://bmj.bmjjournals.com/cgi/eletters/bmj.38398.469479.8Fv1>, 2005.
127. Gøtzsche PC. Reporting bias: any consequences for Methods and Results sections in Cochrane Reviews? Cochrane News 2005;33:1+8. Also published in: The Cochrane Collaboration Methods Groups Newsletter 2005;9:5.
128. Gøtzsche PC. Screening for brystkræft. Ugeskr Læger 2005;167:1871.
129. Gøtzsche PC, Jørgensen KJ, Thornton H. Presentation of benefits and harms needs to be balanced. BMJ 2005;330:1024.
130. Pedersen T, Møller AM, Gøtzsche PC. Human albumin in critically ill patients. Crit Care Med 2005;33:1183.
131. Gøtzsche PC. Klinisk interventionsforskning: to ledere og et indlæg. Ugeskr Læger 2005;167:2308-9.
132. Gøtzsche PC, Jørgensen KJ. Information needs to support informed choices. BMJ 2005;331:350-1.
133. Gøtzsche PC. Uafhængig klinisk interventionsforskning - eller evidence biased medicine? Ugeskr Læger 2005;167:2916-7.
134. Gøtzsche PC. ALLHAT - epokegørende? Ugeskr Læger 2005;167:3422-3.
135. Gøtzsche PC. The mammography controversy (book review). Lancet 2005;366:1519-20.
136. Gøtzsche PC, Johansen HK. Misleading statements in industry-sponsored meta-analysis of itraconazole. J Clin Oncol 2005;23:9428-9.
137. Gøtzsche PC. Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. Int J Cancer 2005; 15 Oct: DOI 10.1002/ijc.21632 (and 2006;118:2648).
138. Gøtzsche PC. Screening and breast cancer. N Engl J Med 2006;354:768.
139. Gøtzsche PC. Ramifications of screening for breast cancer: overdiagnosis in the Malmö trial was considerably underestimated. BMJ 2006;332:727.
140. Haug C, Gøtzsche PC, Schroeder TV. Clinical trials report card (reply). N Engl J Med 2006;354:1429.
141. Gøtzsche PC, Jørgensen KJ. Estimate of harm/benefit ratio of mammography screening was five times too optimistic. <http://bmj.bmjjournals.com/cgi/eletters/332/7543/691>, 2006.
142. Hróbjartsson A, Gøtzsche PC. Follow-up commentary. J Clin Epidemiol 2006;59:340-1.
143. Gøtzsche PC. Disclosures should not be delayed. WHO International Clinical Trials Registry Platform (ICTRP) 2006, March 31 (http://www.who.int/ictrp/006-Peter_Gøtzsche_31March06.pdf)
144. Gøtzsche PC. No double standards in research, please. <http://bmj.bmjjournals.com/cgi/eletters/333/7564/374>, 2006.
145. Gøtzsche PC, Jørgensen KJ. Mammografiscreening - ideologi kontra videnskab (svar). Ugeskr Læger 2006;168:2263-5.
146. Gøtzsche PC. Tvivilsom dokumentation for effekten af akupunktur. Ugeskr Læger 2006;168:3635.
147. Gøtzsche PC. Tvivilsom dokumentation for effekten af akupunktur 2. Ugeskr Læger 2006;168:4331-2.
148. Hróbjartsson A, Gøtzsche PC. Were patients with unfavorable outcomes deleted in a covert duplicate publication reporting effect of placebo on hypertension? Am J Hypertens 2006;19:655.

149. Gøtzsche PC, Hróbjartsson, Marić K, Tendal B. Comment on Cochrane review CD004878. Cochrane Database of Systematic Reviews 2007.
150. Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews and other meta-analyses, authors' reply. <http://bmj.bmjjournals.com/cgi/eletters/333/7572/782>, 2006.
151. Gøtzsche PC. Mammography screening leads to an increase in mastectomies, not a decrease. <http://www.annals.org/cgi/eletters/146/7/511>, 2007.
152. Gøtzsche PC. Comment on: A Martí-Carvajal, G Salanti, AF Cardona. Human recombinant activated protein C for severe sepsis. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD004388.
153. Gøtzsche P, Hróbjartsson A, Johansen HK, Altman DG, Chan AW. Criticism is unwarranted: Please read our paper again. September 12, 2007. <http://medicine.plosjournals.org/perlServ/?request=read-response&doi=10.1371/journal.pmed.0040019#r1759>, 2007.
154. Gøtzsche PC. Asthma guidelines on house dust mites are not evidence-based. Lancet 2008; 370(9605):2100-1.
155. Gøtzsche PC. Mammographic screening from age 40 years. Lancet 2007; 369(9563):737-8.
156. Gøtzsche PC, Bjarnason NH. COX-2 inhibitor. Rheumatology (Oxford) 2007; 46(10):1623-4.
157. Gøtzsche PC, Maehlen J, Zahl PH. Undeclared motives in withdrawing a publication. Lancet 2007; 369(9574):1690.
158. Gøtzsche PC. Covert duplicate publication and misleading sample size calculation: commentary on Lee et al. (2008). Int J Nurs Stud 2008; 45(9):1398.
159. Gøtzsche PC. [Non-useful cancer survival statistics following the Danish Cancer Control Plan]. Ugeskr Laeger 2008; 170(43):3442.
160. Gøtzsche PC. Osteoarthritis of the knee: Topical NSAIDs have unknown effectiveness. BMJ 2008; 336(7640):344.
161. Jørgensen KJ, Hróbjartsson A, Gøtzsche PC. Comment on review of intercessory prayer for the alleviation of ill health (Roberts L, Ahmed I, Hall S. Intercessory prayer for the alleviation of ill health). Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD000368.
162. Gøtzsche PC, Hartling OJ, Nielsen M, Brodersen J, Jørgensen KJ. Estimate of breast screening benefit was 6 times too large. http://www.bmjjournals.com/cgi/eletters/338/jan27_2/b86. 2009.
163. Gøtzsche PC, Jørgensen KJ. Stephen Duffy's claims on the benefits and harms of breast screening are seriously wrong. http://www.bmjjournals.com/cgi/eletters/338/jan27_2/b86#212985. 2009.
164. Gøtzsche P. Are new drugs for schizophrenia better than old ones? Lancet 2009;373:1248.
165. Gøtzsche PC, Jørgensen KJ, Maehlen J, Zahl PH. Estimation of lead time and overdiagnosis in breast cancer screening. Br J Cancer 2009;100(1):219.
166. Berry DA, Baines CJ, Baum M, Dickersin K, Fletcher SW, Gøtzsche PC, Jørgensen KJ, Junod B, Maehlen J, Schwartz LM, Welch HG, Woloshin S, Thornton H, Zahl PH. Flawed inferences about screening mammography's benefit based on observational data. J Clin Oncol 2009;27(4):639-40.
167. Gøtzsche PC. Quackery, chiropractic and alternative medicine. BMJ 2009: http://www.bmjjournals.com/cgi/eletters/339/jul08_4/b2766.
168. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Svar til Lif. Ugeskr Læger 2009;171:1308.
169. Hróbjartsson A, Gøtzsche PC. Acupuncture for pain: our result is robust to trial selection, and our threshold for minimal clinically effect is low. BMJ rapid responses (17 March); 2009.
170. Hróbjartsson A, Gøtzsche PC. Authors' reply: The quality of the acupuncture interventions was considered in our systematic review. BMJ rapid responses (5 October); 2009.
171. Hróbjartsson A, Gøtzsche PC. Effect of acupuncture and placebo acupuncture. BMJ rapid responses (3 March); 2009.
172. Hróbjartsson A, Gøtzsche PC. Reply to Linde. FACT 2009;14:105.
173. Gøtzsche PC, Johansen HK. Authors' reply on 'House dust mite control measures for asthma'. Allergy 2009;64:190.
174. Jørgensen KJ, Brodersen J, Nielsen M, Hartling OJ, Gøtzsche PC. Fall in breast cancer deaths. A cause for celebration, and caution. BMJ. 2009 May 27;338:b2126.
175. Jørgensen KJ, Gøtzsche PC. Fundamental mistakes in estimate of lives saved by breast screening. BMJ 2009: http://www.bmjjournals.com/cgi/eletters/339/jul21_2/b2922.

176. Jørgensen KJ, Gøtzsche PC. Fundamental errors in estimate of lives saved by screening. *BMJ* 2009 Aug 25;339:b3359.
177. Jørgensen KJ, Gøtzsche PC. It is time for a new paradigm for overdiagnosis with screening mammography. http://www.bmjjournals.org/cgi/eletters/339/jul09_1/b2587.
178. Jørgensen KJ, Gøtzsche PC. Wald et al.'s estimate of the effect of breast screening is about 10 times higher than the most reliable evidence shows. http://www.bmjjournals.org/cgi/eletters/339/aug25_1/b3359#220390.
179. Jørgensen KJ, Gøtzsche PC. Overdiagnosis with breast screening was seriously underestimated. http://www.annals.org/content/151/10/727.full/reply#annintmed_el_120127. 2009, 20 Nov.
180. Gøtzsche PC, Johansen HK. Alpha1-antitrypsin deficiency. *N Engl J Med*. 2009;361(21):2101-2.
181. Gøtzsche PC, Jørgensen KJ. [Overdiagnosis with mammography screening is a serious problem]. *Lakartidningen*. 2009;106(47):3180.
182. Jørgensen KJ, Gøtzsche PC. No visible effect of mammography screening in Denmark. http://www.bmjjournals.org/cgi/eletters/340/mar23_1/c1241.
183. Jørgensen KJ, Gøtzsche PC. Mammography screening hasn't lived up to expectations. http://www.bmjjournals.org/cgi/eletters/340/mar23_1/c1241.
184. Gøtzsche PC. Overdiagnosis with mammography screening is around 25-50%, not 10%. http://www.bmjjournals.org/cgi/eletters/340/jun24_1/c3106.
185. Gøtzsche P. Depression severity and effect of antidepressant medications. *JAMA* 2010 Apr 28;303(16):1597.
186. Gøtzsche PC. [When one doesn't WANT to see the evidence?]. *Ugeskr Laeger* 2010 Mar 1;172(9):733.
187. Jørgensen KJ, Gøtzsche PC. The background review for the USPSTF recommendation on screening for breast cancer. *Ann Intern Med* 2010 Apr 20;152(8):538-9.
188. Jørgensen KJ, Gøtzsche PC. Where is the effect of mammography screening? *BMJ* 2010. http://www.bmjjournals.org/cgi/eletters/341/aug11_1/c3620.
189. Baum M, Thornton H, Gøtzsche PC, Bewley S, Jørgensen KJ, Barratt A, et al. Breast cancer awareness month. Still awaiting screening facts. *BMJ* 2010;341:c6152.
190. Gøtzsche P. Depression severity and effect of antidepressant medications. *JAMA* 2010;303(16):1597.
191. Gøtzsche PC. [When one doesn't WANT to see the evidence?]. *Ugeskr Laeger* 2010;172(9):733.
192. Gøtzsche PC, Lundh A. [The rheumatologists' conflict of interest and biological medicines]. *Ugeskr Laeger* 2010;172(45):3126.
193. Gøtzsche PC, Jørgensen KJ, Zahl PH. Breast screening: why estimates differ by a factor of 20-25. *J Med Screen* 2010;17(3):158-9.
194. Gøtzsche PC. Lessons from the mammography wars. *N Engl J Med* 2010;363(26):2569.
195. Gøtzsche PC, Jørgensen KJ. Kopans, Smith and Duffy Misrepresent Facts about Mammographic Screening. *Radiology* 2011; http://pubs.rsna.org/doi/suppl/10.1148/radiol.11110716/suppl_file/110716supp.pdf.
196. Gøtzsche PC, Lundh A. Vigtig deklarering af interessekonflikter. *Dagens Medicin* 2011;13:27.
197. Gøtzsche PC. [Control should be counteracted]. *Ugeskr Laeger* 2011;173(33):1991.
198. Gøtzsche PC. Mammography screening ten years on: reflections on a decade since the 2001 review. The Cochrane Collaboration 2011; <http://www.cochrane.org/news/blog/mammography-screening-ten-years-reflections-decade-2001-review>.
199. Gøtzsche PC. Stop medicinudgifternes himmelflugt. *Politiken* 5 marts 2011. <http://politiken.dk/debat/kroniker/ECE1214179/stop-medicinudgifternes-himmelflugt/>
200. Gøtzsche PC. UK drug regulator destroys all evidence after 15 years. *BMJ* 2011;343:d4203.
201. Gøtzsche PC. Unreliable studies are quoted instead of reliable ones. *CMAJ* 2011;183:1957-8.
202. Jørgensen KJ, Gøtzsche PC. Elementary flaws in the FH01 study. *Lancet Oncol* 2011;12(3):215-6.
203. Jørgensen KJ, Gøtzsche PC. The proposed review will not be independent without NICE. *BMJ* 2011;343:d7533.
204. Jørgensen KJ, Hrobjartsson A, Gøtzsche PC. Leibovici's non-study must be excluded from the Cochrane review. <http://www.cochranefeedback.com/cf/cda/citation.do?id=10133#10133> 2011;
205. Jørgensen KJ, Zahl PH, Gøtzsche PC. More on screening mammography. *N Engl J Med* 2011;364(3):284-6.

206. Krogsgaard LT, Jørgensen KJ, Gøtzsche PC. [Should the population be offered general health screenings?]. Ugeskr Laeger 2011;173(23):1671.
207. Lunde IM, Gøtzsche PC. [Transparency, reliability and conflict of interest]. Ugeskr Laeger 2011;173(33):1989.
208. Gøtzsche PC. Psykiaterne har ukritisk accepteret ssri-præparaterne. Dagens Medicin 2011;<http://www.dagensmedicin.dk/opinion/debat/psykiaterne-har-ukritisk-accepteret-ssri-praparaterne/>.
209. Gøtzsche PC. RE: Peter Gøtzsche burde anerkende det vigtige forskningssamarbejde, der foregår mellem læger og medicinalindustrien. Ugeskr Laeger 2011;173(8):599-600.
210. Gøtzsche PC. Selektiv rapportering er et stort problem. Ugeskr Laeger 2011;173(15):1154.
211. Gøtzsche PC. Vigtig debat om gavnlige og skadelige virkninger. Dagens Medicin 2011;14:29.
212. Gøtzsche PC, Jørgensen KJ. RE: Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. BMJ 2011;343:d7017.
213. Gøtzsche PC, Jørgensen KJ. RE: Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. BMJ 2011;343:d7017.
214. Gøtzsche PC. Cancer specific mortality is biased in breast screening trials. BMJ 2011;343:d6395.
215. Gøtzsche PC. Total mortality should be the primary outcome in cancer screening trials. BMJ 2011;(343):d6397.
216. Suhrke P, Maehlen J, Schlichting E, Jørgensen KJ, Gøtzsche PC, Zahl PH. RE: Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. BMJ 2011;343:d4692.
217. Gøtzsche PC. Kopans' arguments are untruthful. 2011 Aug 18. Available at: www.auntminnie.com/index.aspx?sec=log&URL=http%3a%2f%2fwww.auntminnie.com%2findex.aspx%3fsec%3dsup%26sub%3dwom%26pag%3ddis%26ItemID%3d96204 (accessed 1 Sept).
218. Gøtzsche PCRE: Etisk analyse på automatpilot. Dagens Medicin 2012;<http://www.dagensmedicin.dk/blog/kristians-blog/blog-etisk-analyse-pa-automatpilot/>.
219. Jørgensen KJ, Gøtzsche PG. Breast Cancer Screening. An independent review is under way. BMJ 2012; 24 April. <http://www.bmjjournals.org/content/343/bmj.d6843?tab=responses>.
220. Jørgensen KJ, Keen JD, Zahl PH, Gøtzsche PC. The Two-County breast screening trial cannot provide a reliable estimate of the effect of breast cancer screening. Radiology 2012;262(2):729-30.
221. Gøtzsche PC. Why does the BMJ support donations of pulse oximeters when they have no effect? BMJ 2012;344:e409.
222. Gøtzsche PC, Jørgensen KJ. Effect of population-based screening on breast cancer mortality. Lancet 2012;379(9823):1297.
223. Jørgensen KJ, Gøtzsche PC. Mammografiscreening redder ikke liv. Dagens Medicin 2012;28 Sept.
224. Gøtzsche PC. Screening for tvangstanker, depression og ADHD?. Ugeskrift for Laeger. 2013;175(1-2):77.
225. Gøtzsche PC. Developing a new drug costs less than \$100m, not \$900m. BMJ. 2013;346:f398.
226. Jørgensen KJ, Gøtzsche PC. Effect of screening mammography on breast cancer incidence. New England Journal of Medicine. 2013;368(7):677-8.
227. Gøtzsche PC. The EMA should continue its new openness policy despite current lawsuits. <http://www.bmjjournals.org/content/346/bmj.f2961?tab=responses> (21 June 2013).
228. Gøtzsche PC, Maund E. Re: Restoring invisible and abandoned trials: a call for people to publish the findings. <http://www.bmjjournals.org/content/346/bmj.f2865/rr/650915> (21 June 2013)
229. Gøtzsche PC. AbbVie considers harms to be commercially confidential information: sign a petition. B M J (Online). 2013;347:f7569.
230. Gøtzsche PC. Developing a new drug costs less than \$100m, not \$900m. B M J. 2013;346:f398.
231. Gøtzsche PC. Roche continues to drag its feet on access to Tamiflu data. B M J (Online). 2013;346:f3001.
232. Jørgensen KJ, Gøtzsche PC. Effect of screening mammography on breast cancer incidence. New England Journal of Medicine. 2013;368(7):677-8.
233. Jørgensen KJ, Brodersen J, Gøtzsche PC. Thirteen years of breast screening had no measurable effect on breast cancer mortality in Norway. International Journal of Cancer. 2013;132(7):1725-1726.

234. Krogsbøll L, Juhl Jørgensen K, Gøtzsche PC. Social ulighed i sundhed. Ugeskrift for Læger. 2013;175(1):74-75.
235. Zahl P-H, Suhrke P, Jørgensen KJ. Overdiagnosis of breast cancer in Norway: what have the authors adjusted for? IntJ Cancer 2013 dec 1;133(11):2754-5.
236. Gøtzsche PC. Nye cancermidler er ikke bedre end gamle. Ugeskrift for Laeger. 2013 sep 9;175(37):2138.
237. Gøtzsche PC. Screening for tvangstanker, depression og ADHD? Ugeskrift for Laeger. 2013;175(1-2):77.
238. Gøtzsche PC. Tivilsomt om lokalt appliceret NSAID har nogen effekt. Ugeskrift for laeger. 2013 feb 4;175(6):377-8.
239. Gøtzsche PC. Vildledning fra Kræftens Bekæmpelse om mammografiscreening. Ugeskrift for Laeger. 2013 apr 8;175(15):1056.
240. Gøtzsche PC. Vores forskning om lægemiddelindustrien er veldokumenteret. Ugeskrift for Læger. 2013;175(49):3048.
241. Gøtzsche PC. Der er ikke effekt af drotrecogin alfa ved svær sepsis. Ugeskrift for Laeger 2013;175(13):903-4.
242. Gøtzsche PC, Jørgensen KJ. The benefits and harms of breast cancer screening. Lancet. 2013 mar 9;381(9869):799.
243. Krogsbøll LT, Jørgensen KJ. Helbredstjek - igen. Ugeskrift for Laeger. 2013 feb 18;175(8):532.
244. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. Universal health checks should be abandoned. BMJ 2013;347:f5227.
245. Gøtzsche PC. Mammography screening increases non-breast cancer mortality. Trials 2013;14:368.
246. Gøtzsche PC. The drug industry is similary harmful as the tobacco industry. BMJ 2013;347:f5193.
247. Gøtzsche PC. Treatment of urinary incontinence with antimuscarinic drugs is pointless. BMJ 2013;347:f5170.
248. Gøtzsche PC. "I don't want the truth, I want something I can tell Parliament!" BMJ 2013;347:f5222.
249. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. Health check check. The Times 2013;Aug 20:25.
250. Gøtzsche PC. Incorrect statements by Novo Nordisk. BMJ 2013;347:f4386.
251. Gøtzsche PC. SSRI kan føre til selvmord. Dagens Medicin 2013; Maj 3.
252. Gøtzsche PC. Whistleblowere skal beskyttes. Berlingske 2013;Aug 5:21.
253. Gøtzsche PC. GlaxoSmithKline and Roche won't disclose their results. BMJ 2013;346:f819.
254. Gøtzsche PC. Comment on risk of bias tool. www.thecochanelibrary.com/details/editorial/5655441. 10 Jan 2014.
255. Gøtzsche PC. Medicinalindustriens mange løgne. Jyllands-Posten, kronik, 4 Jan 2014.
256. Gøtzsche PC. Psykiatri på afveje. Politiken, kronik, 6 Jan 2014.
257. Gøtzsche PC. Lykkepille-epidemien: skyd ikke budbringeren, men se budskabet. www.epracticus.dk/flx/debat/?FID=2&MID=30. 13 Jan 2014.
258. Gøtzsche PC. Toneangivende psykiatere er fortsat på afveje. Politiken, kronik, 21 Jan 2014.
259. Gøtzsche PC. Brug psykofarmaka mindre og bedre. Weekendavisen 2014; 31 Jan.
260. Gøtzsche PC. Vi skal bruge mindre psykofarmaka. ugeskriftet.dk, 6 Feb 2014.
261. Gøtzsche PC. Om statistik og bias. Ugeskr Læger 2014;176:273.
262. Gøtzsche PC. Unwarranted criticism of "Psychiatry Gone Astray". davidhealy.org/get-real-peter-gotsche-responds/ 17 Feb 2014.
263. Gøtzsche PC. Vildledende forskning og markedsføring. Ugeskr Læger 2014;176:373.
264. Gøtzsche PC. Fejlciteringer om psykiatri. Berlingske 2014;23 Feb.
265. Gøtzsche PC. Fup eller fakta om dødelig medicin. Dagens Medicin, 28 Feb 2014.
266. Gøtzsche PC. Screening virker ikke. Jyllands-Posten, 8 Mar 2014.
267. Gøtzsche PC. Screening af gravide for depression. Månedsskr Almen Praksis 2014;326-8.
268. Auken M, Gøtzsche PC. Kun via EU sikrer vi åbenhed i medicinalindustrien. Information 2014; 5 April.
269. Auken M, Gøtzsche PC. Hyklerisk medicinalindustri. Information 2014; 9 April.
270. Gøtzsche PC. Misvisende oplysninger om Cochrane. Altinget 2014; 8 April.
271. Gøtzsche PC. Lægger ikke luft til mig. Politiken 2014; 9 April.

272. Gøtzsche PC. Cochrane-fjeren, der blev til fem høns. Dagens Medicin 2014; 11 April.
273. Gøtzsche PC. Antidepressiv medicin bør undgås til børn og unge. OCD-nyt 2014;1-14:7.
274. Gøtzsche PC. Nyhed om Cochrane var misvisende. <http://ugeskriftet.dk/nyhed/cochrane-laegger-afstand-til-goetzsche#comment-354>. 2014;8 Apr.
275. Gøtzsche PC. Adverse effects of statins are very common. 21 May 2014. www.bmjjournals.org/content/348/bmj.g3306/rr/698864.
276. Gøtzsche PC. Sundhedstjek: Den politiserende Sundhedsstyrelse. Dagens Medicin 2014; 10 Oct.
277. Bewley S, Rose L, Gøtzsche P, Blennnerhassett M, Colquhoun D, Pryke M et al. Time to halt an out of control trial with ineffective oversight. B M J (Online). 2014;349:g5601.
278. Gøtzsche PC, Jørgensen KJ, Krogsbøll LT. Authors' reply to Lauritzen and colleagues, Newton and colleagues, and Mangin. B M J (Online). 2014;349:g4790.
279. Gøtzsche PC. Muscular adverse effects are common with statins. B M J (Online). 2014;348:g3724.
280. Gøtzsche PC, Jørgensen KJ, Krogsbøll LT. General health checks don't work. B M J (Online). 2014;348:g3680.
281. Gøtzsche PC. Questionable research and marketing of a combination drug for smoker's lungs. Royal Society of Medicine. Journal. 2014 jul 10;107(7):256-257
282. Gøtzsche PC. Study of study of changes in antidepressant use after FDA warnings is not reliable. B M J (Online). 2014;349:g5623.
283. Gøtzsche PC, Jørgensen KJ, Zahl P-H. Lead-Time Models Produce Far Too Low Estimates of Overdiagnosis With Mammographic Screening. JACR. 2014 okt 6;11(11):1098.
284. Gøtzsche PC. Przepisywane leki przyczyną zgonu rzeszy pacjentów. Polskie Archiwum Medycyny Wewnętrznej. 2014 dec 23;124(12):750-6.
285. Gøtzsche PC. Antidepressiva bør ikke bruges til børn og unge. Ugeskr Læger 2015;May 18.
286. Gøtzsche PC. Atomoxetin til ADHD er værre end sit rygte. Ugeskr Læger 2015;177(13):1301-2.
287. Gøtzsche PC. Author's reply to Tovey and colleagues. BMJ 2015;350:h2955.
288. Gøtzsche PC. Comment on "Our prescription drugs kill us in large numbers". Author's reply. Polskie Archiwum Medycyny Wewnętrznej 2015;125(1-2):106-7.
289. Gøtzsche PC. Correction to "Author's reply to Tovey and colleagues". BMJ 2015;350:h3138.
290. Gøtzsche PC. Days tomme postulater om psykiatrien. Berlingske Tidende. 2015;Sep 12;16.
291. Gøtzsche PC. Gøtzsche melder psykiater til Lægeetisk Nævn. Dagens Medicin 2015;Oct 9;16:1.
292. Gøtzsche PC. Hvor stor en rolle spiller antipsykotika i overdødeligheden ved skizofreni? Ugeskr Læger 2015;177(18):895-6.
293. Gøtzsche PC. Psychiatric drugs should not be used in demented people. BMJ 2015;350:h369.
294. Gøtzsche PC. Psykiateren prøver at skyde budbringeren. Dagens Medicin 2015;Oct 9;16:1.
295. Gøtzsche PC. RE: Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ 2015;351:h6019.
296. Gøtzsche PC. Re: Suicide risk assessment and intervention in people with mental illness. BMJ 2015;351:h4978.
297. Gøtzsche PC. Re: Does long term use of psychiatric drugs cause more harm than good?: Maudsley debate and guild interests. BMJ 2015;351:h2435.
298. Gøtzsche PC. Screening doesn't reduce the occurrence of advanced cancers. BMJ 2015;350:h867.
299. Gøtzsche PC. Svar: Børn behandlet med stimulanser udvikler ofte hjerneatrofi. Ugeskr Læger 2015;Nov 4.
300. Gøtzsche PC. Svar: Dokumentationen for, at antidepressiva forårsager selvmord. Ugeskr Læger 2015;177(34):1649.
301. Gøtzsche PC. Svar: Selvmord forårsaget af antidepressiva skal frem i lyset. Ugeskr Læger 2015;177(26):1303.
302. Gøtzsche PC. Svar: Tavshedspligt, akademisk dannelse, lægelig pli. Ugeskrift for Læger 2015;Jun 18.
303. Gøtzsche PC. Tre psykiatrisprofessorer på afveje. Politiken 2015;Sep 4.
304. Gøtzsche PC. Tvang i psykiatrien bør forbydes. Politiken 2015;Aug 5.
305. Gøtzsche PC. Usandheder i psykiaterformands bogenmeldelse. Ugeskr Læger 2015;Oct 7.
306. Jørgensen KL, Gøtzsche PC. Helbredstjek til lavtuddannede er skadeligt. Ugeskr Læger 2015;Feb 11.

307. Jørgensen KJ, Zahl P-H, Gøtzsche PC. Influence of mammography screening on use of mastectomies in Denmark. *Acta oncologica* (Stockholm, Sweden). 2015;133:54.

Secondary publications in Danish

1. Gøtzsche PC. Reference-bias. *Ugeskr Læger* 1988;150:228-9.
2. Nordic Medical Research Councils' HIV Therapy Group. Dobbeltblind dosis-responsundersøgelse af zidovudin ved AIDS og fremskreden HIV-infektion. *Ugeskr Læger* 1993;155:104-7.
3. Gøtzsche PC, Nielsen C, Gerstoft J, Nielsen CM, Vestergaard BF. Patientoverlevelse ved zidovudinresistant HIV. *Ugeskr Læger* 1994;156:185-6.
4. Gøtzsche PC, Gjørup I, Bonnén H, Brahe NEB, Becker U, Burcharth F. Randomiseret undersøgelse og metaanalyse af somatostatin overfor placebo ved blødende øsofagusvaricer. *Ugeskr Læger* 1996;158:2393-6.
5. Gøtzsche PC. Vigtigheden af et bredt perspektiv på metaanalyse: kan have afgørende betydning for patienterne. *Ugeskr Læger* 2000;162:5601.
6. Gøtzsche PC. Bredt perspektiv på metaanalyse af afgørende betydning for patienten. *Läkartidningen* 2000;97:5882-3.
7. Gøtzsche PC. Bredt perspektiv på metaanalyse - kan have afgørende betydning for patienterne. *Tidsskr Nor Lægeforen* 2000;120:2810-1.
8. Hróbjartsson A, Gøtzsche PC. Hvad er effekten af placebobehandling? *Ugeskr Læger* 2002;164:329-33.
9. Jørgensen KJ, Gøtzsche PC. Information om brystkræftscreening på internetsider er ensidig og mangelfuld - sekundærpublikation. *Ugeskr Læger* 2005;167:174-8.
10. Gøtzsche PC. Forbedret rapportering af skadevirkninger i randomiserede forsøg: udvidelse af CONSORT-vejledningen. *Ugeskr Læger* 2005;167:1520-2.
11. Hróbjartsson A, Chan A-W, Haahr MT, Gøtzsche PC, Altman DG. Selektiv rapportering af effektmål i randomiserede forsøg. Sekundærpublikation. *Ugeskr Læger* 2005;167:3189-91.
12. Haug C, Gøtzsche PC, Schroeder T. Registre og registrering af kliniske forsøg. Sekundærpublikation. *Ugeskr Læger* 2006;168:457-8.
13. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Begrænsninger i publikationsrettighederne i industriinitierede kliniske forsøg - sekundærpublikation. *Ugeskr Læger* 2006;168:2467-9.
14. Jørgensen KJ, Gøtzsche PC. Er invitationer til mammografiscreening et rimeligt udgangspunkt for det informerede samtykke? Sekundærpublikation. *Ugeskr Læger* 2006;168:1658-60.
15. Gøtzsche PC. Er relative risici og oddsratioer i resumeer troværdige? Sekundærpublikation. *Ugeskr Læger* 2006;168:2678-80.

Teaching

Pregraduate courses

1988-89 Junior lecturer, Theory of Science, University of Copenhagen.

1990-2012 Lecturer, Theory of Science, University of Copenhagen.

1992-93 Lecturer, internal medicine, Hvidovre Hospital.

Course in research methodology, human biology, University of Copenhagen, 13 May 1993 and 2-3 Feb 1994.

When is one drug better than another? Denmark's Pharmaceutical University, 2 Sept 2003.

Meta-analyses and their role in systematic reviews. Course in advanced and specialised epidemiology for students in Public Health, Copenhagen, 20 Oct 2003.

See also Lectures below, which include many for students.

2015, 15 April Lectures on Theory of Science for pharmacy students.

Postgraduate courses

CM: course manager; more recent titles have been translated into English, for convenience.

1. Controlled clinical trials of drugs, Rigshospitalet, 3-5 Nov 1986.
2. CM Statistics and epidemiology. Scandinavian Diploma Course in Tropical Medicine, University of Copenhagen, 28 Oct 1987.
3. A-course in research methodology. National Board of Health, 15 Nov 1988.
4. A-course in clinical decision theory. National Board of Health, 17 Apr 1989.
5. CM Statistics and epidemiology. Scandinavian Diploma Course in Tropical Medicine, University of Copenhagen, 2 Nov 1989.
6. CM Transdisciplinary course in medical ethics. Danish Society for Theory in Medicine, Copenhagen, 29 Apr 1989.
7. CM Transdisciplinary course in medical ethics. Danish Society for Theory in Medicine, Copenhagen, 29 Apr 1990.
8. Course on meta-analyses. Medicom, Copenhagen, 21 May 1990.
9. CM Transdisciplinary course in medical ethics. Danish Society for Theory in Medicine, Copenhagen, 10 Nov 1990.
10. PhD course in medical ethics. University of Southern Denmark, 17 May 1991.
11. Course on rheumatoid arthritis. Danish Rheumatological Society, 27 Okt 1991.
12. Course in clinical trials. Apothecary Society, Hillerød, 5 Nov 1991.
13. CM Litterature evaluation for pharmacists, Hillerød, 2-4 Dec 1991.
14. Bias. Course in pharmacodynamics. Danish Society for Clinical Pharmacology, 6 Dec 1991.
15. CM Rigshospitalet's course in clinical trials. Hillerød, 2-6 Mar 1992.
16. A-course in clinical pharmacology. National Board of Health, 3 Mar 1992.
17. Research methodology for back diseases. Back research group, Copenhagen, 2 Apr 1992.
18. A-course in clinical pharmacology. National Board of Health, 5 May 1992.
19. PhD course in medical ethics. University of Southern Denmark, 8 May 1992.
20. A-course in clinical pharmacology. National Board of Health, 6 Oct 1992.
21. CM Rigshospitalet's course in clinical trials. Hillerød, 19-23 Oct 1992.
22. A-course in rheumatology. National Board of Health, 24 Nov 1992.
23. A-course in clinical pharmacology. National Board of Health, 8 Dec 1992.
24. A-course in rheumatology. National Board of Health, 9 Feb 1993.
25. A-course in clinical pharmacology. National Board of Health, 2 Mar 1993.
26. PhD course in medical ethics. University of Southern Denmark, 26 Mar 1993.
27. CM Rigshospitalet's course in clinical trials. Hillerød, 31 Mar-2 Apr 1993.
28. Course on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 19-20 Oct 1993.
29. A-course in clinical pharmacology. National Board of Health, 1 Mar 1994.
30. CM PhD course in systematic reviews. Panum Institute, 11-12 Apr 1994.
31. CM PhD course in systematic reviews. Panum Institute, 13-14 Apr 1994.
32. CM Rigshospitalet's course in clinical trials. Hillerød, 18-22 Apr 1994.
33. Rigshospitalet's research policy. Rigshospitalet, 18 Aug 1994.
34. Course in biological psychiatric research. Bispebjerg Hospital, 17 Jan 1995.
35. Scientific dishonesty. University hospitals' Centre for Nursing Research. Rigshospitalet, 23 Feb 1995.
36. Course on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Copenhagen, 27-29 Mar 1995.
37. Post Conference Course in Evidence-based Health Care: critical appraisal of evidence. International Society for Technology Assessment in Health Care, Dalarna, Sweden, 7-10 June 1995.
38. Use of research results. Rigshospitalet's course in quality development, 15 June 1995.

39. Course on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 29-31 Oct 1995.
40. Course in quality development. Rigshospitalet, 13 Dec 1995.
41. CM Course on systematic reviews. Panum Institute, 14-15 Dec 1995.
42. Meta-analyses and evaluation of the quality of research. Danish Society for Internal Medicine. Sundby Hospital, 27 Mar 1996.
43. CM Workshop on Handsearching. Nordic Cochrane Centre, 16 Apr 1996.
44. CM Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 17 Apr 1996.
45. CM Workshop on Systematic Reviews for Cochrane Reviewers. Getting a review into Review Manager. Nordic Cochrane Centre, 18 Apr 1996.
46. Workshop on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 12-14 May 1996.
47. CM Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 12 Sept 1996.
48. CM Workshop on Systematic Reviews for Cochrane Reviewers. Getting a review into Review Manager. Nordic Cochrane Centre, 13 Sept 1996.
49. Course on systematic reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 4-6 Dec 1996.
50. CM Course on systematic reviews. Swedish Council for Technology Assessment in Health Care, Göteborg, 17 Dec 1996.
51. The controlled clinical trial and meta-analysis. Danish Society for Internal Medicine. Sundby Hospital, 10 Mar 1997.
52. Meta-analyses and the international Cochrane Collaboration. PhD course in clinical intervention research. MEDIF/MEFA, 13 Mar 1997.
53. Second Nordic Course in Evidence-based Medicine. Oslo, 1-5 June 1997.
54. Minicourse in evidence-based medicine and the Cochrane Library. Rigshospitalet, 5 Nov 1997.
55. CM Workshop on Handsearching. Nordic Cochrane Centre, 12 Nov 1997.
56. CM Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 13 Nov 1997.
57. Course in evidence-based medicine. Rigshospitalet, 30 Apr-2 May 1998.
58. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 27 May 1998.
59. CM Workshop on Handsearching. Nordic Cochrane Centre, 9 July 1998.
60. CM Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Helsinki, 21 Sept 1998.
61. Course in evidence-based medicine. Rigshospitalet, 9-12 Nov 1998.
62. CM Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 1 Mar 1999.
63. CM Workshop on Handsearching. Nordic Cochrane Centre, 3 Mar 1999.
64. Course in evidence-based medicine. Panum, 14-17 June 1999.
65. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 21 Mar 2000.
66. Workshop on Handsearching. Nordic Cochrane Centre, 22 Mar 2000.
67. CM Evidence-based medicine. Ringe Back Centre, 14 Apr 2000.
68. CM Evidence-based cardiology. Society for Younger Cardiologists, 15 Apr 2000.
69. Workshop on controversial issues related to clinical trials and systematic reviews. Barcelona, 30 June 2000.
70. Workshop on Handsearching. Nordic Cochrane Centre, 11 Sept 2000.
71. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, 31 Jan 2001.

72. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 27 Mar 2001.
73. Meta-analyses - use and misuse. Danish Drug Industry Association, 30 May 2001.
74. CM Workshop on Cochrane editing. Hotel Marina, 6-8 Sept 2001.
75. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, Karrebæksminde, 6 Feb 2002.
76. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 23 Apr 2002.
77. Course in evidence-based medicine. Rigshospitalet, 3-4 og 17-18 June 2002.
78. CM Workshop on Cochrane editing. Hotel Marina, 12-14 Sept 2002.
79. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 7 Oct 2002.
80. Meta-analysis and potential and limitations of evidence-based medicine. 6. Lübecker course, Lübeck, 9-10 Oct 2002.
81. PhD course, Panum Institute, 12 Dec 2002.
82. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, Tune Landbrugsskole, 29 Jan 2003.
83. Prioritisation and evidence-based medicine. Nordjyllands Amtsråd, Ålborg, 13 Feb 2003.
84. CM Workshop on Cochrane editing. Nordic Cochrane Centre, 18-19 Sept 2003.
85. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 6 Oct 2003.
86. CM Quality of allocation concealment. 11th Cochrane Colloquium, Barcelona, 28 Oct 2003.
87. PhD course, Panum Institute, 24 Nov 2003.
88. Workshop on research in alternative medicine, Rigshospitalet, 30-31 Mar 2004.
89. Course in evidence-based medicine. Panum Institute, 1-2 og 14-15 June 2004.
90. CM PhD course in systematic reviews and meta-analyses. Rolighed, 8-11 Nov 2004.
91. PhD course, Panum Institute, 1 Dec 2004.
92. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, KVL, 24 Aug 2005.
93. Course in infection pathogenesis. Rigshospitalet, 5 Sept 2005.
94. Doctors' Annual Gathering (Lægedage). Copenhagen, 18 Nov 2005.
95. PhD course in planning clinical research. Panum Institute, 21 Feb 2006.
96. PhD course in epidemiology. Køge, 30 Mar 2006.
97. Reporting of harms. GCP units in Denmark, Nyborg, 31 Mar 2006.
98. PhD course. Pharmaceutical University, 13 June 2006.
99. Doctors' Annual Gathering (Lægedage). Copenhagen, 11 Nov 2006.
100. Systematic reviews. Advanced seminar, Madrid, 16-17 Nov 2006.
101. Seminar on peer review and scientific misconduct. Karolinska Institute, Stockholm, 30 Nov 2006.
102. PhD course, Research ethics. Copenhagen Business School, 19 Mar 2007.
103. Course in clinical decision theory. National Board of Health, Copenhagen, 8 May 2007.
104. PhD course, Ethics in science. Faculty of life sciences, Copenhagen, 13 Aug 2007.
105. Evidence-based medicine. WHO, delegation from Uzbekistan, Hillerød, 21 Sept 2007.
106. Course for clinical microbiologists. National Board of Health, Copenhagen, 24 Sept 2007.
107. PhD course, Research ethics. Copenhagen Business School, 31 Oct 2007.
108. PhD course, Research ethics. Copenhagen Business School, 31 Mar 2008.
109. Course in Clinical Pharmacology, National Board of Health, 17 April 2008.
110. PhD course in planning clinical research. University of Copenhagen, 31 May 2008.
111. Workshop: Clinical trials registration & results reporting: The CONSORT guidelines and beyond. 2nd South Asian Regional Symposium on Evidence Informed Health Care. Vellore, India, 9 April 2008.
112. Course in clinical decision theory. National Board of Health, Copenhagen, 7 and 20 May 2007.

- 113. PhD course in clinical epidemiology. Køge, 9 Oct 2008.
- 114. Course in clinical decision theory. National Board of Health, Copenhagen, 19 Nov 2008.
- 115. Course in clinical decision theory. National Board of Health, Copenhagen, 24 Nov 2009.
- 116. PhD course in planning clinical research. University of Copenhagen, 21 Jan 2010.
- 117. Course in clinical decision theory. National Board of Health, Copenhagen, 18 May 2010.
- 118. Course in clinical pharmacology. National Board of Health, Copenhagen, 1 Apr 2011.
- 119. Forskeruddannelsesnetværket. Korsør, 17 May 2011.
- 120. PhD course. Herlev, 16 June 2011.
- 121. Highlights i reumatologien. Korsør, 1 Sept 2011.
- 122. PhD course, systematic reviews. University of Copenhagen, 26-29 Sept 2011.
- 123. Lægemiddelinformation – fup eller fakta? DULM-kursus, 20 April 2012.
- 124. PhD course, Good scientific practice and reporting, University of Copenhagen, 26-28 Sept 2012.

Lectures

IS: invited speaker; more recent titles have been translated into English, for convenience.

- 1. IS Steady state pharmacokinetics of naproxen in rheumatoid arthritis. XV congrès international de rheumatologie, Paris, 21-27 June 1981.
- 2. Dosis-respons forhold ved rheumatoid artrit. Ribe amts lægekredsforening, 5 nov 1982.
- 3. Klinisk farmakologi af naproxen (Naprosyn). Aftenmøder den 7, 11, 12, 19, 25 og 26 april 1983 på hhv. Store Kro, Fredensborg, Hotel H. C. Andersen, Odense, Hotel Impala, Silkeborg, Mogenstrup kro, Hotel Sheraton, København og Rold Storkro.
- 4. Månedens forskningsproblem: bedre end sig selv. Staff-meeting, amtssygehuset i Herlev, 24 okt 1985.
- 5. IS Reference bias. En undersøgelse af litteraturreferencemønstret i offentliggjorte lægemiddelundersøgelser. Dansk Selskab for Klinisk Farmakologi, 27 jan 1987.
- 6. IS Værdien af mikrobiologiske undersøgelser hos HIV-inficerede patienter. Dansk Selskab for Klinisk Mikrobiologi, 7 dec 1987.
- 7. Yield of diagnostic investigations of opportunistic infections in 33 AIDS patients. European Conference on Clinical Aspects of HIV Infection, Bruxelles, 10-11 Dec 1987.
- 8. IS Bias i dobbeltblinde undersøgelser af NSAID's med perspektiver for meta-analyser. Dansk Selskab for Medicinsk Reumatologi, 17 feb 1989.
- 9. IS Meta-analyse af antirheumatica behandling. Møde om den kontrollerede kliniske undersøgelses metodologi: status og perspektiver. Rigshospitalet, 28 apr 1989.
- 10. IS Meta-analyse af non-steroide antiinflammatoriske stoffer. Dansk Selskab for Intern Medicin, amtssygehuset i Herlev, 13 okt 1989.
- 11. IS Hvordan stiller man forsøg op, og hvordan analyserer man resultaterne? Årsmøde i Den Danske Klub for Centralsterilisering og Sygehushygiejne, Hotel Frederik II, Slagelse, 10 nov 1989.
- 12. IS Valg af NSAID ud fra kliniske studier. Specialistmøde for reumatologer, Novo Nordisk, København, 3 maj 1990.
- 13. IS Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit. 23rd Nordic Congress of Rheumatology, Tampere, 15 June 1990.
- 14. IS Bias. Fællesundervisning for den medicinske blok, Hvidovre Hospital, 19 sept 1990.
- 15. IS Bias in NSAID trials. Italian Meeting on Meta-analysis within Hepatology. Erice, Sicilien, 3-5 Dec 1990.
- 16. IS Meta-analysis of multiple clinical trials: biases revealed by analysis of trials on first- and secondline antirheumatic drugs. 75th Anniversary of the Danish Association for Internal Medicine, København, 24 Jan 1991.
- 17. IS Muligheder og farer ved meta-analyser. Dansk Selskab for Medicinsk Filosofi, Etik og Metode, København, 13 feb 1991.
- 18. IS Hvilket NSAID er bedst? Møde arrangeret af medicinsk afdeling C med de praktiserende læger, amtssygehuset i Herlev, 9 apr 1991.

19. IS Præliminære resultater fra AIDSDOSE studiet. Dansk Selskab for Infektionsmedicin, Rigshospitalet, 30 apr 1991.
20. IS Detection of bias problems through the use of meta-analysis with examples from drug trials in rheumatology. Society for Clinical Drug Trials and Society for Medical Statistics, Stockholm, 22 May 1991.
21. IS Meta-analysis of DMARD's: are they effective? DAK's Rheuma Meeting in Tivoli, 23 Aug 1991.
22. IS Dobbelt-blind dosis responsundersøgelse af zidovudin ved AIDS og fremskreden HIV infektion, Statens Sundhedsvidenskabelige Forskningsråd, 12 nov 1991.
23. IS Internationella och nordiska erfarenheter av zidovudinbehandling. XLVIII Läkaresällskapets Riksstämma, Stockholm, 27 nov 1991.
24. Clinimetric problems in arthritis. Seminar on Bias and Controversies in Clinical Research, Rigshospitalet, 28 Feb 1992.
25. IS Problems and opportunities in drug trials with DMARDs. 24th Scandinavian Congress of Rheumatology, Malmö, 1 June 1992.
26. Meta-analysis is more than a combination of odds ratios. 13th International Meeting of International Society for Clinical Biostatistics, København, 18 Aug 1992.
27. IS Faldgruber i den klinisk kontrollerede undersøgelse. Medicinsk Selskab for Fyns Stift, Odense, 2 nov 1992.
28. IS Statistiske og filosofiske aspekter ved score systemer. Reumatologisk symposium, Nyborg, 12 mar 1993.
29. IS Good Clinical Practice. Ph.d.-studerende på Hvidovre Hospital, 30 sept 1993.
30. The Scandinavian Cochrane Centre. Dansk Selskab for Medicinsk Filosofi, Etik og Metode og Dansk Selskab for Medicinsk Prioritering, København, 13 okt 1993.
31. Det etiske grundlag for det danske sundhedsvæsen. Folkeuniversitetet, 9 november 1993.
32. IS NSAID og gastrointestinal tractus. Metodologiske problemer: er der forskelle mellem midlerne af klinisk relevans? Dansk Gastroenterologisk Selskabs E-kursus, København, 11 jan 1994.
33. IS Clinical practice should reflect clinical science. EU meeting, AIMCOM, Bruxelles, 24 Apr 1994.
34. IS Systematic reviews of clinical trials in policy making and health planning. Nordisk konference om kritiske valg i sundhedssektoren, Dansk Sygehus Institut, 26 Apr 1994.
35. IS Bias in statistical reporting: should the data analyst be blinded? Society for Clinical Trials, 15th annual meeting, Houston, Texas, 9 May 1994.
36. IS Meta-analyses in rheumatology. 25th Scandinavian Congress of Rheumatology, Lillehammer, 2 June 1994.
37. IS Cochrane Center på Rigshospitalet - meta-analyser i klinikken. Dansk Medicinsk Selskabs 75-års jubilæumsmøde, København, 26 aug 1994.
38. IS Orientering om Det Nordiske Cochrane Center. GCP-selskabet, Gentofte, 2 feb 1995.
39. IS Forskningen som prioriteringsgrundlag. Dansk Selskab for Medicinsk Prioritering, Svendborg, 28 apr 1995.
40. IS Meta-analysis of continuous data - NSAIDs as an example. Dansk Epidemiologisk Selskab, København, 2 June 1995.
41. IS Philosophy of sciences - in meta-analysis. 4th Nordic Conference for Medical Libraries, København, 24 Aug 1995.
42. IS Det internationale Cochrane-samarbejde. Nordisk medicinaldirektormøde, Hornbæk, 1 sept 1995.
43. IS Cochrane Collaboration: implementering i *evidence based medicine*. Prioritering i sundhedsvæsenet, Ringkøbing amtskommune, 27 sept 1995.
44. Cochrane centres. 3rd Annual Cochrane Colloquium, Oslo, 6 Oct 1995.
45. IS Meta-analyses: assets and limitations. Recent Advances in Breast Cancer, Scandinavian Breast Cancer Group, Hindsgavl, 13 Oct 1995.
46. IS A randomized trial of withdrawal of slow acting antirheumatic drugs. Dansk Reumatologisk Selskab, København, 20 okt 1995.
47. IS Forskning som grundlag for indførelse af nye behandlingsmetoder. Temadag om prioritering i sundhedsvæsenet. Nordjyllands amt, Rebild, 1 nov 1995.

48. IS What is sound evidence for decision making? Medicine 96, Finnish Medical Association (Duodecim), Helsinki, 10 Jan 1996.
49. IS Cochrane Collaboration and the health care technology assessment. Medicine 96, Finnish Office for Health Care Technology Assessment, Helsinki, 11 Jan 1996.
50. IS Metaanalyse og kvalitetssikring. Dansk Selskab for Medicinsk Onkologi, Helsingør, 19 jan 1996.
51. Cochrane Centret, Rigshospitalet. Staff-meeting, Sundby Hospital, 23 jan 1996.
52. IS Nordic Cochrane Centre. H:S Forskningsråd, København, 12 mar 1996.
53. Cochrane-samarbejdet. Staff-meeting, Sankt Elisabeths Hospital, 9 apr 1996.
54. IS Bibliometrisk analyse af publikationer udgået fra danske intern medicinske afdelinger 1988-92. Dansk Selskab for Intern Medicins konference om forskningens vilkår i intern medicin, Hillerød, 12 apr 1996.
55. IS Hvad ved vi, og hvad gør vi? Temadag om tværfaglige specialeråd, Rigshospitalet, 2 maj 1996.
56. IS The Cochrane Collaboration. Cochrane Hepato-Biliary Group Meeting, Genève, 25 Aug 1996.
57. IS Medicinsk teknologivurdering og lægemidler. MEDIF's direktørseminarium, Hornbæk, 4 sept 1996.
58. Cochrane-samarbejdet. Staff-meeting, Hvidovre Hospital, 17 sept 1996.
59. IS Meta-analyser. Det Medicinske Selskab i København, Domus Medica, 24 sept 1996.
60. IS Debate: Within ten years, all health decisions will be evidence-based. 4th Annual Cochrane Colloquium, Adelaide, 24 Oct 1996.
61. IS Hvad skal diagnosen bruges til? Dansk Selskab for Klinisk Mikrobiologi, Kolding, 8 nov 1996.
62. Omsorg som effektiv behandling? Næstekærlighed, placebo og alternativ medicin. Dansk Selskab for Medicinsk Filosofi, Etik og Metode, Domus Medica, 14 nov 1996.
63. IS MTV - en nødvendighed i sundhedsvæsenet. Dansk Selskab for Sygehusledelse, Kolding, 28 nov 1996.
64. IS Is the Norwegian Minister of Health correct in saying that the Cochrane Collaboration has made a fetish of the randomised controlled trial? Annual Meeting for The Nordic Cochrane Centre and Network, Oslo, 17 Jan 1997.
65. IS Det Nordiske Cochrane Center. H:S Bestyrelse, København, 29 jan 1997.
66. IS Cochrane centeret. Sundhedsministeriet, København, 30 jan 1997.
67. IS Evidensbaseret medicin. Foreningen af Læger i Erhvervslivet, København, 19 mar 1997.
68. IS The Cochrane Collaboration. Svensk Internmedicinsk förenings vårmöte, Umeå, 20 mar 1997.
69. IS Hvilkens sundhedsforskning har vi brug for? (paneloplæg). Forskningsudvalgets og Sundhedsudvalgets høring om sundhedsforskning, Folketinget, 2 apr 1997.
70. IS Nordiska Cochrane-centrat i Köpenhamn. Karolinska Institutet och Stockholm läns landsting, 3 apr 1997.
71. IS Beware of surrogate outcome measures. Dansk hypertensionsselskabs årsmøde, Svendborg, 11 Apr 1997.
72. IS The Cochrane Collaboration. 3rd Cochrane Hepato-Biliary Group meeting, 32nd annual EASL meeting, London, 12 Apr 1997.
73. IS Systematic review: somatostatin and octreotide in bleeding oesophageal varices. 3rd Cochrane Hepato-Biliary Group meeting, 32nd annual EASL meeting, London, 12 Apr 1997.
74. IS Quality and relevance of clinical trials. European Headache Federation 5th Summer School. Rungsted, 25 Apr 1997.
75. IS Sammenfattende vurderinger af behandlingsmetoders værdi - metaanalyser. Møde mellem medlemmerne af de regionale videnskabsetiske komiteer og Den Centrale Videnskabsetiske Komité. Kolding, 21 aug 1997.
76. IS "Evidence Based Medicine". Overlægeforeningens Årsmøde. Nyborg Strand, 29 Aug 1997.
77. The Cochrane Collaboration. WHO's European Office, Programme Manager's Meeting. København, 3 Sept 1997.
78. Cochrane-samarbejdet. Lægemiddelstyrelsen. København, 16 sept 1997.
79. IS Rigshospitalets forskningsproduktion i 1994-96. Temadag om budgettering af forsknings- og udviklingsmidler, Rigshospitalet, 23 sept 1997.
80. IS Scopes and topic lists of Review Groups. 5th Annual Cochrane Colloquium, Amsterdam, 9 Oct 1997.

81. IS Hjælp til selvhjælp: Hvad kan Cochrane-samarbejdet tilbyde sundhedsvæsenet, og hvad kan sundhedsvæsenet tilbyde Cochrane-samarbejdet? Institut for Sundhedsvæsen, Symposium, Køge, 24 okt 1997.
82. IS Evidence based medicine - oplæg og diskussion. H:S Sundhedsfaglige råd, Rigshospitalet, 28 okt 1997.
83. IS Vad är - och hur arbetar - Cochrane Collaboration? Regiondag om Evidence Based Medicine, Södra sjukvårdsregionen, Malmö, 21 nov 1997.
84. Cochrane-samarbetet. Läkemedelsverket, Uppsala, 5 dec 1997.
85. IS Evidence-based medicine: the present and the future. Duodecim, 10th Anniversary Seminar of the Physician's Desk Reference and Database, Helsinki, 28 Jan 1998.
86. IS Ethical aspects in the use of systematic reviews in health care. Workshop on systematic reviews, Stakes & FinOHTA, Helsinki, 30 Jan 1998.
87. IS Præsentation af Cochrane-projektet. Nordisk Ministerråd, Hellerup, 25 mar 1998.
88. IS Getting the message across. 7th European Stroke Conference, Edinburgh, 29 May 1998.
89. IS RCT, status og visioner. Dansk Selskab for Medicinsk Filosofi, Etik og Metode. Festmøde, København, 17 sept 1998.
90. IS Evidensbaseret medicin. Farmaciens Dag, Danmarks Farmaceutiske Selskab, København, 2 okt 1998.
91. IS Demonstrating evidence in action: a case study. 6th Annual Cochrane Colloquium, Baltimore, 25 Oct 1998.
92. IS Bias i randomiserade försök och meta-analyser. Svenska Läkarsällskapets Riksstämma, Göteborg, 24 nov 1998.
93. IS Det Nordiske Cochrane Center og dets samarbejde med klinisk praksis. Statens Sundhedsvidenskabelige Forskningsråd og Statens Institut for Medicinsk Teknologivurdering, Middelfart, 11 feb 1999.
94. IS Evidens fra systematiske reviews. Dansk Endokrinologisk Selskab, Domus Medica, 22 feb 1999.
95. IS Overall status of the Cochrane Collaboration. Cochrane Colorectal Cancer Group meeting, København, 19 Mar 1999.
96. Det Nordiske Cochrane Center og evidensbaseret medicin. Folketingets Sundhedsudvalg, 24 mar 1999.
97. IS Evidensbaseret klinisk praksis. Områdeledelsens Stab og Sekretariat, Odense Universitetshospital, 8 apr 1999.
98. IS Hvad kan Cochrane-databasen bruges til? Dansk Kirurgisk Selskabs Forårsmøde, Herlev, 15 apr 1999.
99. Presentation of The Cochrane Collaboration. Exploratory meeting to consider establishing a Russian Branch of The Nordic Cochrane Centre. Hotel Akademicheskaya, Moskva, 7-8 June 1999.
100. IS Mega-trials or meta-analysis? European Society for Paediatric Research, Panum Instituttet, 28 June 1999.
101. IS Hvad er rationel farmakoterapi? Dansk Selskab for Medicinsk Filosofi, Etik og Metode, København, 22 okt 1999.
102. IS The Cochrane Collaboration i Norden. SBU, Evidensbaseret sjukvård. Stockholm, 27 jan 2000.
103. IS Hvad vil det sige, at behandlingen er evidensbaseret? Jydsk Medicinsk Selskab, Århus, 5 apr 2000.
104. IS Meta-analyser, systematiske reviews. Kursus i evidensbaseret klinik. Frederiksberg hospital, 9 juni 2000.
105. IS Systematic review of breast cancer screening. Meeting with local minister of health and specialist societies. Barcelona, 29 June 2000.
106. IS History of The Cochrane Collaboration. 8th Cochrane Colloquium, Cape Town, 25 Oct 2000.
107. IS Er det alvorlige mangler ved det vitenskapelige grunnlaget for mammografi-screeningen? Årsmøde i Norsk Patologforening, Oslo, 10 nov 2000.
108. IS Är mammografiscreening värdefull? Svensk förening för radiologisk bröstdiagnostik, Rigshospitalet, 16 nov 2000.
109. IS Systematic review of mass screening for breast cancer with mammography. Dansk Selskab for Medicinsk Onkologi, Panum, 20 Nov 2000.
110. IS Hvornår er ændret klinisk praksis nødvendig? Dansk Selskab for Medicinsk Filosofi, Etik og Metode, København, 23 nov 2000.
111. IS Evidensbaseret medicin. KAS Herlev, 28 nov 2000.

112. IS Fallstudie Mammographic Screening. Bern's Universität, 6 Dec 2000.
113. IS Cochrane Collaboration. SBU, Stockholm, 7 feb 2001.
114. IS Utility of mammographic screening for detection of breast cancer and the measurement of the placebo effect. São Paulo, 23 Feb 2001.
115. IS Screening for breast cancer with mammography: a systematic review. Breast and Cervical Cancer Screening Conference, Bielefeld, 6 Apr 2001.
116. IS Concept and methods in Cochrane reviews. Dansk Selskab for Psykiatrisk Epidemiologi, 20 apr 2001.
117. IS Putting the evidence into breast cancer care - challenges and controversies for the future. National Breast Cancer Coalition's Annual Meeting, Washington, 6 May 2001.
118. IS Ankelligament-metaanalyse. Dansk Fod- og Ankelkirurgisk Selskab, Gjern, 18 aug 2001.
119. Misleading publications of major mammography screening trials in major medical journals. Fourth International Congress on Peer Review in Biomedical Publication, Barcelona, 14 Sept 2001.
120. IS Cochrane reviews - the clinical application of evidence. Skandinavisk Forening af Oral og Maxillofacial Kirurger, 21 Sept 2001.
121. IS Hvilke problemer ved screeningsmetoder er politikere ikke blevet informeret om? Dansk Selskab for Medicinsk Prioritering og Dansk Selskab for Almen Medicin, København, 30 okt 2001.
122. IS Mammografiscreening - undersøgt i en metaanalyse. Dansk Selskab for Almen Medicins Risikogruppe, Silkeborg, 23 nov 2001.
123. IS Metaanalyse. Foredrag efter modtagelse af Niels A Lassen prisen, Bispebjerg Hospital, 7 dec 2001.
124. IS Metaanalyse, styrke og svaghed, metodologiske betragtninger. Gruppen af Yngre Gastroenterologer På Vej, København, 12 dec 2001.
125. IS Metaanalyser - hvad kan og skal de bruges til? Selskabet for Teoretisk og Anvendt Terapi, København, 7 feb 2002.
126. IS The old vs the new review. Second Asian-Pacific Conference on Evidence Based Medicine, Chengdu, China, 9 Apr 2002.
127. IS The importance of the published, peer reviewed protocol. Second Asian-Pacific Conference on Evidence Based Medicine, Chengdu, China, 9 Apr 2002.
128. IS Problemer ved vurderingen af lægemiddelundersøgelser. Dansk Reumatologisk Selskab, Horsens, 19 apr 2002.
129. IS Conflict of interest. Cochrane Colorectal Cancer Group's Status Meeting, København, 19 Apr 2002.
130. IS Lægers videnskabelige ytringsfrihed, interkollegiale problemer. Dansk Selskab til Sikring af Lægers Ytringsfrihed, København, 3 juni 2002.
131. IS Things to be cautious about when making policy recommendations based on systematic reviews, randomised trials, cohort studies, and expert opinion. Delegates from The Ministry of Health, China, Rigshospitalet, 20 Aug 2002.
132. IS Forskning er ikke fuldstændig objektiv - den kan drejes og vendes, så den passer politisk. Kursus for journalister, København, okt 2002.
- 133 IS Mammascrining: a critical analysis. Wenckebach Symposium, Groningen, 5 Nov 2002.
134. IS Dissemination experiences in the Cochrane Collaboration. Nordic Campbell Center inauguration seminar, Helsingør, 13 Nov 2002.
135. IS Hva kan epidemiologer bidra med i deatten om mammografiscreening? Den tiende norske epidemiologikonferansen, Trondheim, 14 nov 2002.
136. IS Unambiguous and comparable results as quality measures in health related research. Is randomisation a necessity to obtain reliable knowledge? How are self-selection and self-conscious efforts handled? Konference arrangeret af Videns- og Forskningscenter for Alternativ Behandling, Århus, 27 Nov 2002.
137. IS Ten years of the Cochrane Collaboration. Seminar for Finnish doctors, Biomedicum, Helsinki, 23 Jan 2003.
138. IS Dronning Ingrid's Festforelæsning. Hvad er vore behandlinger værd? Åbenrå Sygehus, 8 maj 2003.
139. IS Temaeftermiddag. Evidensbaseret forebyggelse og behandling. Ålborg Sygehus, 9 sept 2003.
140. IS Plenary lecture. Pitfalls in evidence based medicine. 4th Congress, European Federation of Internal Medicine, Berlin, 11 Sept 2003.
141. IS Debate. Population based breast cancer screening. ECCO 12, Federation of European Cancer Societies, København, 25 Sept 2003.

141. Evidensbaseret forbrugeroplysning. Konference arrangeret af Forbrugerrådet og Det Nordiske Cochrane Center, Christiansborg, København, 22 okt 2003.
142. IS Plenary lecture. Conflicts of interest. XIth Cochrane Colloquium, Barcelona, 27 Oct 2003.
143. IS Evidensbaseret medicin: eksempler og betydning. Møde om medicinforsøg, arrangeret af Institut for Rationel Farmakoterapi, København, 19 nov 2003.
144. Discrepancies between protocols and publications: Evidence of outcome reporting bias in randomised trials. De Videnskabsetiske komitéer for Københavns og Frederiksbergs kommuner, 11 dec 2003.
145. IS Experiences within the Cochrane Collaboration. WHO workshop on grading of evidence, København, 16 Dec 2003.
146. IS Evidensbaseret medicin. Sosial- og helsedirektoratet, Oslo, 15 jan 2004.
147. IS Why is the practice of evidence-based medicine more difficult than it seems? Læknadager 2004, Reykjavik, 23 Jan 2004.
148. IS Doctor, should I have a mammography? (debate). Læknadager 2004, Reykjavik, 23 Jan 2004.
149. IS The management of hypertension, should we rely on the good old drugs? (debate). Læknadager 2004, Reykjavik, 23 Jan 2004.
150. IS Evidence-based microbiology. Dansk Selskab for Klinisk Mikrobiologi, uddeling af Wyeth-prisen for 2003, København, 27 jan 2004.
151. IS Mammografi-screening, contra. Foreningen af Yngre Gynækologer og Obstetrikeres Forårsmøde, Odense, 18 marts 2004.
152. IS Evidensgrundlag. Institut for Rationel Farmakoterapi, møde om kriterier for rationelt valg af lægemidler, Kolding, 30 april 2004.
153. IS Hvad er vore behandlinger værd? Gentofte-Vangede Rotary Klub, 26 aug 2004.
154. IS Empirical evidence for selective reporting of outcomes in randomised trials. Den Centrale Videnskabsetiske Komité, København, 27 aug 2004.
155. IS Risikovurdering og formidling omkring screening, og industrisponsoreret forskning. Det Etiske Råd, København, 16 sept 2004.
156. IS Fortsat udbredelse af mammografiscreening. Nordjyllands amtsråd, Ålborg, 19 nov 2004.
157. IS Harry Boström föreläsningen: Cochrane-samarbetet och evidensbaserad medicin. Riksstämma, Svensk Internmedicinsk Förening, Göteborg 25 nov 2004.
158. IS Nutidens og fremtidens krav om evidens for det lægelige arbejde. Nordjyllands Lægekredsforenings 150 års jubilæum, Ålborg, 26 nov 2004.
159. IS Blinding. Expert Discussion Workshop. Institute of Public Health, Cambridge, 17 maj 2005.
160. Sponsorship, bias and methodology: Cochrane Reviews compared with industry-sponsored meta-analyses of the same drugs. 5th International congress on peer review and biomedical publication, Chicago, 17 Sept 2005.
161. Are relative risks and odds ratios in abstracts believable? 5th International congress on peer review and biomedical publication, Chicago, 18 Sept 2005.
162. IS Medical statistics in practice: Dr Jekyll and Mr Hyde. 10 year celebration, Centre for Statistics in Medicine, Oxford, 20 Sept 2005.
163. IS Introduction to key concepts and principles of evidence-based medicine. Moscow Medical Academy, 13 Oct 2005.
164. Constraints on academic freedom in industry-initiated clinical trials. XIII Cochrane Colloquium, Melbourne, 22-26 Oct 2005.
165. IS Should we believe in epidemiology? Scientific seminar, Royal Veterinary and Agricultural University, Copenhagen, 14 Nov 2005.
166. IS Evidence in health care. Health Administration, Copenhagen County, 28 April 2006.
167. IS Commercial interests versus common goods. Nordic Committee on Bioethics, Malmö, 16 Oct 2006.
168. Far too many excluded studies listed in Cochrane Reviews. XIV Cochrane Colloquium, Dublin, 23-26 Oct 2006.
169. IS Cochrane Library. Ministry of Health, Warszawa, 18 Dec 2006.
170. IS Editorial misconduct. Finnish Medical Association, Helsinki, 25 Jan 2007.
171. IS Evidence-based health care. Institute for Competence Development, Copenhagen, 27 Feb 2007.

172. IS Commercial interests. Institute of Technology, Copenhagen, 14 Mar 2007.
173. IS Screening. Danish Society for Pathology, Copenhagen, 23 Mar 2007.
174. IS Selective reporting. Dutch Cochrane Centre's 12.5-year anniversary. Amsterdam, 18 April 2007.
175. IS Evidence-based health care. Aalborg University Hospital, 26 Sept 2007.
176. IS Bias in drug trials. Eur Assoc Clin Pharmacol, Amsterdam, 29 Aug 2007.
177. IS Commercial influence on clinical research. University of Southern Denmark, 15 Nov 2007.
178. IS Evidence-based medicine. Clinical microbiologists, Copenhagen, 21 Nov 2007.
179. IS Evidence for prevention. National Board of Health, Nyborg, 26 Nov 2007.
180. IS Can we trust clinical research results? Medical Society of Copenhagen, 27 Nov 2007.
181. IS Tainted evidence: drug companies and the power of marketing. 2nd South Asian Regional Symposium on Evidence Informed Health Care. Vellore, India, 9 April 2008.
182. IS Research collaboration. Danish Society for Theory in Medicine, Panum, 21 Apr 2008.
183. IS Mammography screening. Dept of Obstetrics, Rigshospitalet, 15 May 2008.
184. IS The corruption of drug research. Swiss Soc Intern Med, Lausanne, 21 May 2008.
185. IS Credibility of clinical research. Central Ethics Committee, Copenhagen, 13 June 2008.
186. IS The burdens of screening. Euroscience Open Forum, Barcelona, 21 July 2008.
187. IS Unhealthy health care. Distinguished scholar lecture, University of Minneapolis, 9 Sept 2008.
188. IS Unhealthy health care. Visiting scientist, University of Dartmouth, 11 Sept 2008.
189. IS Off-label use of drugs. Danish Pharmaceutical Society, Copenhagen, 29 Oct 2008.
190. IS Bias in drug trials. Danish Society for Psychiatric Epidemiology, Copenhagen, 6 Nov 2008.
191. IS Screening for lung cancer. Symposium, Focus on Lung Cancer, Copenhagen, 17 Nov 2008.
192. IS Screening for lung cancer. Danish Society for Pulmonary Medicine, Kolding, 28 Nov 2008.
193. IS Commercial interests. Institute of Technology, Copenhagen, 17 Dec 2008.
194. IS Screening and ethics. Clinical Ethics Committee, Frederiksberg Hospital, 2 Apr 2009.
195. IS Reflexions on screening. Region Middle Jutland, 15 Apr 2009.
196. IS Is the university trustworthy? LIFE, The Bioscientific Faculty, 6 May 2009.
196. IS Mammography screening. Nordic Congress in General Medicine, Copenhagen, 15 May 2009.
197. IS Opening lecture, Evidence-Based Medicine. 8th Congress of European Federation of Internal Medicine, Istanbul, 27 May 2009.
198. IS Cancer screening. Heinrich-Heine University, Düsseldorf, 17 June 2009.
199. IS Overdiagnosis of breast cancer. Cancer Intervention and Surveillance Modelling Network (CISNET), Rotterdam, 24 June 2009.
200. IS Good quality of drug trials. GCP meeting, Gentofte Hospital, 21 Sept 2009.
201. IS Forskningspolitiske debat, cancer screening. Forskningens dag, Herlev Hospital, 28 Okt 2009.
202. IS Breast screening. Norwegian-Danish Seminar, Oslobåden, 2 Nov 2009.
203. IS Breast screening - the facts. Royal College of Obstetricians, London, 9 Nov 2009.
204. IS Er det dyreste det bedste? Region Sjælland, Sørup Heregård, 1 Dec 2009.
205. IS Randomisering i praksis. Trygfondens Forebyggelsescenter, 14 Jan 2010.
206. IS Mammographie-Screening. Berlin, German Cancer Society, 25 Feb 2010.
207. IS Klinisk relevans, hvad er det? Danish Society for Clinical Pharmacology, 2 Mar 2010.
208. IS Evidence: conflict of interest. Auckland, 22 Mar 2010.
209. IS Lægers interaktioner med medicinalindustrien. Region Nordjylland, 4 May 2010.
210. IS Fungal infections. Rigshospitalet, 12 May 2010.
211. IS Arguments for RCTs. Nordic Gastroenterology Congress, Copenhagen, 11 June 2010.
212. IS Ghostwriting is scientific misconduct. Polish Academy of Sciences, 8 Oct 2010.
213. IS Conflicts of interest. Danish University Antidepressant Group, Nyborg, 5 Nov 2010.
214. IS Bioethics: access to data and mammography screening. EU Parliament, Strasbourg, 24 Nov 2010.
215. IS Hvem har mest gavn af lægens medicinudskrivning? Patientforeningen Danmark, 18 Jan 2011.
216. IS Ethical aspects of public vs private research. Nordic Committee on Bioethics, Helsinki, 1 Nov 2011.

217. IS Strengthening and opening up EU's health research. EU Parliament, Brussels, 30 Nov 2011.
218. IS Medicinalindustrien. EU Parliament, Brussels, Social democrats, 1 Feb 2012.
219. IS Access to data from regulatory authorities. Paris, 19 April 2012.
220. IS European Drug Regulators' meeting. Why we need easy access to all data from all clinical trials and how to accomplish it. Copenhagen, 26 April 2012.
221. IS Why we need to open up health research by sharing our raw data. EU Parliament, Brussels, 6 June 2012.
222. IS Access to medical research data in the EU. HAI Europe, Amsterdam, 12 Oct 2012.
223. IS Rethinking clinical practice. Danish University Antidepressant Group, Nyborg, 9 Nov 2012.
224. IS Open access to all data is a moral obligation towards the patients. EU Parliament, Brussels, 13 Nov 2012.
225. IS Introductory statement. European Medicines Agency, London, 22 Nov 2012.
226. IS Time to stop mammography screening. Selling sickness, Washington DC, 21 Feb 2013.
227. IS Transparency saves lives. EU Parliament, Brussels, 10 Apr 2013.
228. IS Medical data transparency. Ombudsman meeting, EU Parliament, Brussels, 23 Apr 2013.
229. IS Overblik over børn med psykisk sygdom/diagnoser. Sundhedsudvalget, Folketinget, 27 May 2013.
230. IS Gavnlige og skadelige virkninger ved medicinering af børn med psykisk sygdom. Sundhedsudvalget, Folketinget, 27 May 2013.
231. IS Mammografiscreening er skadelig og bør stoppes. Dagens Medicin, Folketinget, 31 May 2013.
232. IS What will we do about overdiagnosis? Dartmouth Institute for Health Policy & Clinical Practice, 12 Sept 2013.
233. IS Deadly medicines and organised crime. Johns Hopkins School of Public Health, Baltimore, 13 Sept 2013.
234. IS Deadly medicines and organised crime. Georgetown University, Washington DC, 16 Sept 2013.
235. IS Why drugs are the third leading cause of death. University College, London, 2 Oct 2013.
236. IS Early diagnosis. University College, London, 2 Oct 2013.
237. IS Psykiatri: medicinalindustriens paradis. Dispuk, Helsingør, 3 Oct 2013.
238. IS Working with evidence. Dansk Selskab for Obstetrik og Gynækologi, Roskilde, 7 Oct 2013.
239. IS 12 usandheder om depression til skade for patienterne. Psykovision, København, 7 Nov 2013.
240. IS Deadly medicines and organised crime. Harvard University, Safra Center for Ethics, 5 Dec 2013.
241. IS Deadly medicines and organised crime. McGill University, Montreal, 6 Dec 2013.
242. IS Deadly medicines and organised crime. Quebec University, Quebec, 9 Dec 2013.
241. IS Deadly medicines and organised crime. Ottawa Hospital, 10 Dec 2013.
243. IS Deadly medicines and organised crime. Women's College Hospital, Toronto, 11 Dec 2013.
244. IS Deadly medicines and organised crime. Toronto University, 12 Dec 2013.
- 245 IS Dødelig medicin og organiseret kriminalitet. Patientforeningen Danmark, Rigshospitalet, 14 Jan 2014.
- 246 IS Myter og facts om antidepressiva. Plastikkirurgisk afd, , 16 Jan 2014.
- 247 IS Lægers samarbejde med industrien, Overlægeforeningen, Hvidovre Hospital, 23 Jan 2014.
- 248 IS Receptpligtig medicin – den tredje hyppigste dødsårsag. FoF København, 25 Feb 2014.
- 249 IS Dødelig medicin og organiseret kriminalitet. Ølstykke Bibliotek, 27 Feb 2014.
- 250 IS Dødelig medicin og organiseret kriminalitet. JP Læserarrangement, 4 Mar 2014.
- 251 IS Psykofarmaka. Psykologisk Studenterforum, Århus Universitet, 4 Mar 2014.
- 252 IS Dødelig medicin og organiseret kriminalitet. Enhedslisten, Region Hovedstaden, 6 Mar 2014.
- 253 IS Psykofarmaka og andre lægemidler. Plan & Handling, Socialt-Lægeligt Seminar, Valby, 10 Mar 2014.
- 254 IS General health checks in adults. Deutsche EBM Netzwerk, Halle, 14 Mar 2014.
- 255 IS Why mammography screening should be stopped. Deutsche EBM Netzwerk, Halle, 14 Mar 2014.
- 256 IS Dødelig medicin og organiseret kriminalitet. Gentofte Bibliotek, 18 Mar 2014.
- 257 IS Why are prescription drugs the third leading cause of death? Panama City, 2 Apr 2014.
- 258 IS Health checks, what were the reactions? Nordic Cochrane Centre, 8 Apr 2014.

- 259 IS Set all data free. Young Investigators Network, Faculty Club, Panum, 10 Apr 2014.
- 260 IS Receptpligtig medicin – den tredjehyppigste dødsårsag. FoF København, 22 Apr 2014.
- 261 IS Why the use of psychiatric drugs may be doing more harm than good. House of Lords, UK, 30 Apr 2014.
- 262 IS This is not a symptom. South London Gallery, 30 Apr 2014.
- 263 IS Hvorfor er lægemidler den 3. hyppigste dødsårsag? Studenterforeningen, København, 2 May 2014.
- 264 IS Good scientific practice. Institute for Public Health, Copenhagen, 7 May 2014.
- 265 IS Dodelig medicin og organiseret kriminalitet. Praktiserende læger, Hotel Hesselet, 9 May 2014.
- 266 IS Psykiatri. Sundhedspolitisk Netværk, Ingenørforeningen, 12 May 2014.
- 267 IS Psykiatri på afveje. Psykovision, Bethesda, København, 14 May 2014.
- 268 IS Interessekonflikter i lægeverdenen. Panum Instituttet, 19 May 2014.
- 269 IS Lægers relation til medicinalindustrien. Roskilde Sygehus, 21 May 2014.
- 270 IS Psychiatric drugs: does the way we use them cause more harm than good? Distinguished seminars in neuroscience and pharmacology. Panum Institute, 28 May 2014.
- 271 IS Håndtering af kommersielle interesser. Københavns Universitet, 10 June 2014.
- 272 IS Psychiatric drugs: does the way we use them cause more harm than good? Amsterdam, 13 June 2014.
- 273 IS Psykiatri på afveje. Stemmegørernetværket, Christiansborg, 17 June 2014.
- 274 IS Academia and industry. Annual Nobel Laureate meeting, Lindau, 3 July 2014.
- 275 IS Overdiagnosis and overtreatment in psychiatry. Finnish Psychological Association, Helsinki, 1 Sept 2014.
- 276 IS Deadly medicines and organised crime. Helsinki University, 2 Sept 2014.
- 277 IS Medicamentos que matan y crimen organizado. Barcelona, Institut d'Estudis Catalans, 8 Sept 2014.
- 278 IS Medicamentos que matan y crimen organizado. Madrid, Organización de Consumidores y Usuarios (OCU), 9 Sept 2014.
- 279 IS Psykofarmaka-debat. Århus Universitet, 11 Sept 2014.
- 280 IS What are the true benefits and harms of our drugs? Jagiellonian University, Krakow, 7 Oct 2014.
- 281 IS Cochrane reviews and their importance for evidence-based medicine. Jagiellonian University, Krakow, 7 Oct 2014.
- 282 IS Deadly medicines and organised crime. Maynooth University, Dublin, 8 Oct 2014.
- 283 IS Deadly medicines and organised crime. Stillorgan Park Hotel, Dublin, 8 Oct 2014.
- 284 IS Danmark på lykkepiller. Herstedøster Forsamlingshus, 21 Oct 2014.
- 285 IS Kan kræft forsvinde af sig selv? Mølholm Forsikring, Carlsberg, 23 Oct 2014.
- 286 IS Dansernes mentale sundhed. Folkeuniversitetet, Panum, 3 Nov 2014.
- 287 IS Kliniske forsøg. Pharmaschool, Copenhagen, 5 Nov 2014.
- 288 IS Dodelig medicin og organiseret kriminalitet. Lægeforeningen Syddanmark, Kolding, 5 Nov 2014.
- 289 IS Kan kræft forsvinde af sig selv? Mølholm Forsikring, Århus, 5 Nov 2014.
- 290 IS Mammography screening: why it hasn't lived up to expectations. Santa Rosa, California, 8 Nov 2014.
- 291 IS Why very few patients benefit from the drugs they take and why many are killed by them. Santa Rosa, California, 9 Nov 2014.
- 292 IS Why very few patients benefit from the drugs they take and why many are killed by them. Stanford Medical School, 11 Nov 2014.
- 293 IS Why very few patients benefit from the drugs they take and why many are killed by them. University of British Columbia, Vancouver, 11 Nov 2014.
- 294 IS Mammography screening: why it hasn't lived up to expectations. University of British Columbia, Vancouver, 12 Nov 2014.
- 295 IS How to reduce big pharma's influence on guidelines. Kaiser Permanente, Los Angeles, 13 Nov 2014.
- 296 IS Transforming mad science, reimagining mental health care. International Society of Ethical Psychology and Psychiatry, Los Angeles, 15 Nov 2014.
- 297 IS Medisinering av psyken – mer skade enn gagn? Cinemateket, Oslo, 25 Nov 2014.
- 298 IS Global Health. Univ. of Copenhagen, 6 Jan 2015.

- 299 IS Depression. Young Psychiatrists, Rigshospitalet, 19 Jan 2015.
- 300 IS Psychiatry. Nurses, Silkeborg 20 Jan 2015.
- 301 IS Selective publication. Joanna Briggs Institute, Adelaide, 9 Feb 2015.
- 302 IS Drugs. Grand round. Royal Adelaide Hospital, Adelaide, 10 Feb 2015.
- 303 IS Psychiatry. Univ. of Adelaide, Adelaide, 10 Feb 2015.
- 304 IS Drug crimes. Alfred Hospital, Melbourne, 11 Feb 2015.
- 305 IS Psychiatry. State Library of Victoria, Melbourne, 11 Feb 2015.
- 306 IS Mammography screening. Alfred Hospital, Melbourne, 12 Feb 2015.
- 307 IS Drug crimes. Grand round. Royal Melbourne Hospital, Melbourne, 12 Feb 2015.
- 308 IS Antidepressants. Garvan Institute, Sydney, 12 Feb 2015.
- 309 IS Drug crimes. Concord Hospital Clinical School, Sydney, 13 Feb 2015.
- 310 IS Mammography screening. Dougherty Community Centre, Sydney, 13 Feb 2015.
- 311 IS Psychiatric drugs. University of Sydney Law School, Sydney, 14 Feb 2015.
- 312 IS Drug crimes. Grand round. Princess Alexandra Hospital, Brisbane, 16 Feb 2015.
- 313 IS Drug crimes. RACGP College House, Brisbane, 16 Feb 2015.
- 314 IS Drug crimes. Univ. of Queensland Medical School, Brisbane, 17 Feb 2015.
- 315 IS Psychiatry. Lady Cilento Children's Hospital, Brisbane, 18 Feb 2015.
- 316 IS Psychiatry. Adina Apartment Hotel, Brisbane, 18 Feb 2015.
- 317 IS Drug crimes. Grand round. Gold Coast University Hospital, 19 Feb 2015.
- 318 IS Lægemidler. Medicinsk Studenterforskning, Nyborg, 12 Mar 2015.
- 319 IS Depression. Rigshospitalet, 16 Apr 2015.
- 320 IS Psychiatric drugs. Lansing, Michigan, 17 Apr 2015.
- 321 IS Antidepressiva. Ålborg Sygehus, 21 Apr 2015.
- 322 IS Drugs. Danish National Board of Health, 27 Apr 2015.
- 323 IS The Maudsley Debate. London, 13 May 2015.
- 324 IS Drugs. Robert-Bosch-Stiftung, Berlin 22 May 2015.
- 325 IS Psychiatry. General Practitioners Annual Meeting, Bergen 27 May 2015.
- 326 IS Lægemidler. Læger fra Lolland, 29 May 2015.
- 327 IS Regulatory data. Int Soc Drug Bull, Pamplona, 29 June 2015.
- 328 IS Overdiagnosis and overtreatment. Int Soc Drug Bull, Pamplona, 30 June 2015.
- 329 IS Psykofarmaka. Dansk Psykologforening, København, 12 Sep 2015.
- 330 IS Antidepressants. Int Meeting, Copenhagen, 16 Sep 2015.
- 331 IS Forced treatment. Int Meeting, Copenhagen, 16 Sep 2015.
- 332 IS Antidepressants. Univ. of Roehampton, London, 18 Sept 2015.
- 333 IS Drugs. Katowice, 19 Sept 2015.
- 334 IS Mammography screening. Cochrane Colloquium, Wien, 3 Oct 2015.
- 335 IS Drugs. Oslo 20 years Anniversary Seminar, 19 Oct 2015.
- 336 IS Tvangsmedicinering. Litteraturhuset, Oslo, 19 Oct 2015.
- 337 IS Lægemidler. Guldborgsund Bibliotekerne, Nykøbing F, 21 Oct 2015.
- 338 IS Psykofarmaka. Benzorådgivningen, Middelfart, 23 Oct 2015.
- 339 IS Psykofarmaka. Enhedslisten, København, 23 Oct 2015.
- 340 IS Lægemidler. Norsk Studenterforening, Tromsø, 30 Oct 2015.
- 341 IS Psykofarmaka. Dansk Psykologforening, København, 7 Nov 2015.
- 342 IS Drugs. Medical Centre in Leiden, 11 Nov 2015.
- 342 IS Drugs. Arminius, Rotterdam, 12 Nov 2015.
- 343 IS Lægemidler. FOF Hvalsø, 23 Nov 2015.
- 344 IS Cancer screening. Gemeinschaftskrankenhaus Havehöhe, Berlin, 25 Nov 2015.
- 345 IS Psykofarmaka. Dansk Socialrådgiverforening, Fredericia, 30 Nov 2015.

- 346 IS Deadly medicines. Roma, Italy, 1 Dec 2015.
 347 IS Deadly medicines. Univ. of Verona, 2 Dec 2015.
 348 IS Deadly medicines. Gruppo Abele, Torino, 3 Dec 2015.
 349 IS Deadly medicines. Alba, 3 Dec 2015.
 350 IS Psykofarmaka. LAP, København, 18 Dec 2015.
 351 IS Global Health. Univ. of Copenhagen, 6 Jan 2016.
 352 IS Psykofarmaka. Hvidovre og Glostrup Psykiatri, 7 Jan 2016.
 353 IS Psykofarmaka. Bedre Psykiatri, Odense, 14 Jan 2016.
 354 IS Läkemedel. Stockholm läns landstings läkemedelskomité, 20 Jan 2016.
 355 IS Psykofarmaka. Socialmedicinsk Enhed, Frederiksberg Hospital, 22 Jan 2016.
 356 IS Vore overmedicinerede ældre. Assens Ældreråd, 26 Jan 2016.

Research mentorships

PhD and other degrees

- 1992 - 1994 Pia Therkildsen. Clinical research behaviour in Denmark. Main tutor. PhD not finished.
 1993 - 1994 Flemming Ørnskov. Drug treatment. Main tutor. PhD not finished (emigration).
 1996 - 2001 Asbjørn Hróbjartsson. The placebo concept. Main tutor. PhD defended 8 June 2001 at the University of Copenhagen.
 2001 - 2004 Jan Peter Kösters (German doctor). Breast cancer screening. Main tutor. Doktors der Medizin defended 17 Sept 2004 at the University of Hamburg.
 2000 - 2004 Lise Lotte Kjærgaard. The randomised clinical trial. PhD, changed to DrMedSci, defended 19 Aug 2005 at the University of Copenhagen.
 2001 - 2005 Bodil Als-Nielsen. Hepatic encephalopathy. PhD defended 13 May 2005 at the University of Copenhagen.
 2001 - 2005 Julie Pildal. Bias in systematic reviews. Main tutor. PhD defended 6 Sept 2005 at the University of Copenhagen.
 2004 - 2013 Karsten Juhl Jørgensen. Screening for breast cancer. Main tutor. PhD changed to DrMedSci, defended 11 Jan 2013 at the University of Copenhagen.
 2008 - 2009 Marija Barbateskovic. Impact factors and sponsorship. Main tutor. Candidate in science. Marks 12 (top on new scale)
 2007 - 2010 Britta Tendal. Standardised mean difference in meta-analysis. Main tutor. PhD defended 26 Aug 2010 at the University of Copenhagen.
 2007 - 2011 Anders W. Jørgensen. Robustness of results and conclusions in systematic reviews, trials and abstracts. Main tutor. PhD defended 16 Nov 2011 at the University of Copenhagen.
 2007 - 2013 Margrethe Nielsen. Selective serotonin reuptake inhibitors. Main tutor. PhD defended 19 April 2013 at the University of Copenhagen.
 2008 - 2013 Andreas Lundh. Conflicts of interest in biomedical publishing. Main tutor. PhD defended 25 April 2013 at the University of Copenhagen.
 2010 - 2015 Lasse Teis Krogsbøll. Health checks. Main tutor.
 2011 - 2015 Jeppe Schroll. Coding of harms in randomised trials. Main tutor.
 2011 - Emma Maund. Harms of Selective serotonin reuptake inhibitors. Main tutor.
 2012 - Tarang Sharma. Suicidality and violence on SSRIs. Main tutor.
 2012 - Michelle Ogden. Are randomised trials ethical? Main tutor.
 2014 - Pia Danborg.

Training students in research

- 2003 Troels Wienecke. OSVAL II, marks 9, ref. 153 in reference list above.
 2003 Karsten Juhl Jørgensen. OSVAL II, marks 10, ref. 154 in reference list above.
 2003 Mette Haahr, scholar student, ref. 157 in reference list above.
 2003 Lasse Schmidt. OSVAL II, marks 10, ref. 169 in reference list above.
 2003 Katrine Karmisholt, scholar student, ref. 172 og 173 in reference list above.
 2004 Anne Due, OSVAL II, marks 10, ref. 189 in reference list above.
 2004 Anders Jørgensen, OSVAL II, marks 10, ref. 190 in reference list above.

- 2005 Anders Klahn, OSVAL II, marks 10, ref. 198 in reference list above.
 2006 Britta Tendal, scholar student, ref. 196 in reference list above.
 2006 Katja Marie, scholar student, ref. 196 in reference list above.
 2007 Matias Vested Madsen, OSVAL II, marks 9, ref. 215 in reference list above.
 2007 Lasse Krogsbøll, OSVAL II, marks 10, ref. 221 in reference list above.
 2007 Jørgen Jacob Eschen, OSVAL II, marks 11. No journal manuscript.
 2009 Marija Barbateskovic, manuscript under preparation.
 2009 Jeppe Lerche Hansen, manuscript under revision.
 2009 Jeppe Schroll, manuscript under revision.
 2010 Ann-Sofia Skou Thomsen, OSVAL II, marks 12
 2010 Frida Samuelsson, OSVAL II, marks 12
 2010 Christian Grønhøj Larsen, OSVAL II, marks 12
 2010 Nino Ortner, OSVAL II, marks 12 (Hróbjartsson tutor)
 2011 Kristine Rasmussen, special subject, marks 12
 2011 Anine Skibsted, special subject, marks 12
 2011 Jon Egelund Jensen, special subject, marks 10
 2012 Julie Bindlev, special subject, marks 12
 2012 Marie Damkjær Hansen, special subject, marks 10 (Hróbjartsson tutor)
 2014 Mikkel Marquardsen, special subject, marks 12
 2014 Andreas Bielefeldt, special subject, marks 12
 2014 Jakob Jensen, special subject, marks 7
 2014 Louise Jensen
 2014 Nana Freund, no special subject
 2014 Asmus Mortensen, special subject, marks 10
 2015 Asger Paludan-Müller, bachelor subject, marks 12
 2015 Kim Boesen, special subject, marks 12
 2015 Anders Simonsen, special subject, marks 12

Expert, Medical Research Council's Statistical Aid Service

- 1991 Nick Rasmussen. Randomised trial, steroids in periarthritis.
 1991 Holger Sørensen. Randomised trial, haloperidol vs. oxazepam.
 1991 Arne Gam. Meta-analysis, soft laser treatment.
 1992 Søren Eiskjær. Meta-analysis, osteosynthesis methods in collum fracture.
 1993 Arne Gam. Meta-analysis, ultrasound in musculoskeletal disorders.
 1993 Hanne Olesen. Meta-analysis, oxygen deficit by anaerobic training.
 1993 Kim Brøsen. Meta-analysis, genetic polymorphism and disease risk.
 1993 Anita Rønn. Randomised trial, Maloprim vs. placebo in malaria.
 1993 Mette Bitsch-Christensen. Immune therapy of children with allergy.
 1993 Anne-Lise Christensen. Comparison of methods to diagnose pneumonia.
 1993 Anne-Cathrine Halvorsen. Diagnostic methods in bleeding disorders.
 1993 Michael Hansen. Biochemical markers for bone formation and resorption.
 1994 Robin Bohr. Treatment of fibromyalgia based on psychomotoric theory.
 1994 Helle Rask. Randomised trial, volume expansion in surgery.
 1995 Allan Ibsen Sørensen. Meta-analysis of endoscopic carpal tunnel dissection.
 1996 Hanne Sørensen. Randomised trial, physioterapy in back pain.
 1997 Judith Kongsted. Healing in breast cancer.
 1998 Poul Sindberg Eriksen. Risks after laser conisation of cervix uteri.
 1998 Niels Petri. Orthodontic treatment of sleep apnoea.
 2000 Hanne Sørensen. Training for back pain.
 2002 Lars Høgaard-Rasmussen. Asthma and osteopathy.
 2002 Mette Pedersen. Vocal cord nodules: non-surgery vs. surgery.
 2004 Thorkil Christensen. Randomised trial, herbal cream for pain.

Scientific assignments

General

Previously

| | |
|-------------|---|
| 1988 - 1990 | Secretary, Danish Society for Theory in Medicine. |
| 1990 | Examiner, prize report in medicine, University of Copenhagen. |
| 1990 | Member of WHO's expert group in Bukarest, evaluation of AIDS trial in children. |
| 1991 | Member of drug committee's quality group, Rigshospitalet. |
| 1992 | Member of Ministry of Education's group in Latvia, research evaluation. |
| 1991 - 1998 | Expert, Medical Research Council's Statistical Aid Service. |
| 1992 - 1996 | Chairman, Danish Society for Theory in Medicine. |
| 1993 - 2005 | Examiner, PhD applications, Rigshospitalet. |
| 1993 - 2005 | Member of Research Council, Rigshospitalet. |
| 1993 - 2010 | Member of Drug Committee, Rigshospitalet. |
| 1995 | Member of HS's working group on clinical databases. |
| 1998 | Examiner, PhD thesis (Rasmus Licht). |
| 1998 | Chairman and examiner, PhD thesis (Palle Valentiner-Brandt). |
| 1998 | Member of ad hoc committee, Office for Scientific Integrity. |
| 1998 - 2005 | Expert, Medical Research Council's Statistical Aid Service for East Denmark. |
| 1999 | Member of ad hoc committee, Office for Scientific Integrity. |
| 2001 | Member of ad hoc committee, Office for Scientific Integrity. |
| 2008 | Examiner of case of suspected scientific misconduct in Iran for The Oxford Health Alliance. |
| 2008 | Examiner of case of suspected scientific misconduct in Norway. |
| 2011 | Examiner, PhD thesis (Bendt Johansen), University of Southern Denmark |
| 2013 | Chairman, assessment of candidates for a professorship, University of Copenhagen |
| 2014 | Chairman and examiner, PhD thesis (Robert Eriksson), University of Copenhagen |
| 2015 | Chairman and examiner, PhD thesis (Bruno Heleno), University of Copenhagen |

Currently

| | |
|--------|--|
| 1993 - | Member CONSORT (Consolidated Standards of Reporting Trials), see www.consort-statement.org . |
| 2004 - | Member of STROBE (Developing Standards of Reporting for Observational Studies in Epidemiology), see www.strobe-statement.org . |
| 2005 - | Member of PRISMA (Quality of reporting of meta-analyses), see http://www.prisma-statement.org/ . |
| 2005 - | Member of SPIRIT (Standard Protocol Items for Randomised Trials), see www.spirit-statement.org/ . |

Editorial work

| | |
|-------------|---|
| 1992 - 1998 | Editor, Bibliotek for Læger. |
| 1995 - 2002 | Member of Editorial Board, British Medical Journal. |
| 1995 - | Member of Editorial Advisory Board, Scandinavian Journal of Rheumatology. |
| 1995 - | Member of Editorial Advisory Board, The Cochrane Collaboration. |
| 1997 - 2014 | Editor, Cochrane Methodology Review Group |
| 1997 - | Member of Advisory Board, Clinical Evidence, BMJ Publishing. |
| 2000 - | Editorial advisor, BioMedCentral (supports PubMedCentral, USA). |
| 2000 - 2010 | Member of Scientific Board, Ugeskrift for Læger |
| 2004 - | Member of Editorial Board, BioMedCentral Medical Research Methodology |
| 2004 - | Member of BMJ Knowledge Advisory Board |
| 2007 - | Academic editor, PLoS Medicine |

Performed peer reviews for:

Annals of Internal Medicine
BioMed Central Medical Research Methodology
BioMed Central Family Practice
BioMed Central Infectious Diseases
Bibliotek for Læger
BMJ

BMJ Open
Breast Cancer Research and Treatment
Canadian Medical Association Journal
Cancers
Clinical Evidence
Clinical Trials
Clinical Trials and Meta-analysis
Cochrane Airways Group
Cochrane Anaesthesia Group
Cochrane Gynaecological Cancer Group
Cochrane Hepato-Biliary Group
Cochrane Infectious Diseases Group
Cochrane Musculoskeletal Group
Cochrane Musculoskeletal Injuries Group
Cochrane Oral Health Group
Controlled Clinical Trials
Danish Medical Bulletin
European Journal of Neurology
Hong Kong Government Research Council
International Journal of Cancer
International Journal of Epidemiology
International Journal of Technology Assessment in Health Care
JAMA
Journal of Clinical Epidemiology
Journal of Medical Ethics
Lancet
La revue Préscrire
Medical Journal of Australia
Medical Research Council, UK
Medicine, Philosophy and Health Care
Nature Reviews Nephrology
New England Journal of Medicine
PLoS Medicine
Politik
Pharmacogenetics
PharmacoEconomics
Radiotherapy and Oncology
Scandinavian Journal of Gastroenterology
Scandinavian Journal of Medicine and Science in Sports
Scandinavian Journal of Rheumatology
Scandinavian Journal of Social Medicine
Science
Statens beredning för medicinsk utvärdering
Statistics in Medicine
Tobacco Control
Ugeskrift for Læger
Vetenskapsrådet, Sverige
Women's Health

Chairman at congresses and meetings

1. Seminar on Bias and Controversies in Clinical Research. Rigshospitalet, 28 Feb 1992.
2. Pharmacotherapy I - methodological aspects. 25th Scand Congr Rheumatol, Lillehammer, 2 June 1994.
3. Reviews of data on continuous scales. Workshop, 2nd Cochrane Colloq, Hamilton, Canada, 1 Oct 1994.
4. Reviews and Syntheses. 11th Meeting, International Society of Technology Assessment in Health Care, Stockholm, 6 June 1995.
5. Cochrane Hepato-biliary Review Group Meeting. European Association for the Study of the Liver, København, 19 Aug 1995.

6. Cochrane Tuberculosis Review Group Meeting. International Union against Tuberculosis and Lung Disease, Paris, 9 Sept 1995.
7. Scientific presentations. 3rd Annual Cochrane Colloquium, Oslo, 4-8 Oct 1995.
8. Cochrane Depression/Neurosis Review Group Meeting. 3rd Annual Cochrane Colloq, Oslo, 8 Oct 1995.
9. Cochrane Placebo Methods Working Group Meeting. 4th Annual Cochrane Colloq, Adelaide, 21 Oct 1996.
10. Cochrane Colorectal Cancer Group Pre-exploratory Meeting. Cochrane Cancer Network Meeting, Bruxelles, 1 Feb 1997.
11. Cochrane Colorectal Cancer Group Exploratory Meeting. København, 12-13 Sept 1997.
12. 50 years of clinical trials: past, present and future. BMA/BMJ, London, 29-30 Oct 1998. Conference chair and chair of session: Quality and relevance of randomised controlled trials.
13. Evidence based medicine: How do we implement research results effectively? Annual meeting for the Nordic Cochrane Centre and Network, Rigshospitalet, 28 Jan 1999.
14. Exploratory meeting for the Cochrane Anaesthesia Group. 7th Annual Meeting of the European Society of Anaesthesiologists, Amsterdam, 29-30 May 1999.
15. Medical Editors. Second Asian-Pacific Conference on Evidence Based Medicine, Chengdu, China, 8-10 Apr 2002.
16. Scientific presentations. 15th Annual Cochrane Colloquium, São Paulo, 23-27 Oct 2007.
17. Influenza symposium. Rigshospitalet, 23 Sept 2008.
18. Scientific presentations. 16th Annual Cochrane Colloquium, Freiburg, 3-7 Oct 2008.
19. International Cochrane Symposium: EBM and Cochrane reviews. Rigshospitalet, 22 April 2009.
20. Investigating bias. 19th Cochrane Colloquium, Madrid, 21 Oct 2011.

Advisory Board member at international congresses

- 2nd Cochrane Colloquium, Hamilton, Ontario, 1-4 Oct 1994.
 3rd Cochrane Colloquium, Oslo, 4-8 Oct 1995.
 4th Cochrane Colloquium, Adelaide, Australia, 20-24 Oct 1996.
 7th Cochrane Colloquium, Rome, Italien, 5-9 Oct 1999.
 8th Cochrane Colloquium, Cape Town, Sydafrika, 25-29 Oct 2000.
 9th Cochrane Colloquium, Lyon, 9-13 Oct 2001.
 11th Cochrane Colloquium, Barcelona, 26-31 Oct 2003.
 12th Cochrane Colloquium, Ottawa, 2-6 Oct 2004.
 5th Congress on Peer Review and Biomedical Publication, Chicago, 15-17 Sept 2005.
 15th Cochrane Colloquium, São Paulo, 23-27 Oct, 2007, Scientific Program Committee.
 6th Congress on Peer Review and Biomedical Publication, Vancouver, 10-12 Sept 2009.
 7th Congress on Peer Review and Biomedical Publication, Chicago, 8-10 Sept 2013.
 Psychiatric drugs do more harm than good. Copenhagen, 16 Sept 2015.

Expert witness in court cases

- 2014 Danish High Court, double homicide attempt on methylphenidate
 2014 Norwegian High Court, forced treatment with olanzapine
 2015 Norwegian High Court, Patient Damage Council, oseltamivir for influenza
 2016 Dutch High Court, double homicide case on paroxetine

Management experience

- 1977 - 1983 Founder and head, medical department, Astra-Syntex.
 1987 - 1995 Founder and head, Nordic coordination office for AIDS trials, Rigshospitalet.
 1993 Co-founder of the Cochrane Collaboration
 1993 - Founder and head, The Nordic Cochrane Centre (39 people employed in 2014, incl. those in Copenhagen Trial Unit).
 1993 - 1996 Member of the Steering Group, the Cochrane Collaboration.

1996 - 2001 Founder and head, Cochrane Placebo Methods Group.
2002 SHL leadership course.



THE STATE
of **ALASKA**
GOVERNOR BILL WALKER

Department of Law

CIVIL DIVISION

1031 West 4th Avenue, Suite 200
Anchorage, Alaska 99501
Main: 907-269-5100
Fax: 907-276-3697

June 30, 2016

Presiding Judge Morse
Nesbett Courthouse
825 W 4th Ave., Rm 601
Anchorage, Alaska 99501



Re: Response to Alaska Administrative Rule 37.7 Research Request

Dear Presiding Judge Morse:

The court should deny James B. Gottstein's request for access to 30 consecutive non-public court files, beginning January 1, 2016, in which a petition for court approval of administration of psychotropic medication was filed. Mr. Gottstein requests these files so that he can hand them over to Dr. Peter C. Gøtzsche, who wishes to independently assess the court's findings in the 30 case files requested and compare and contrast those findings with analogous cases on court ordered medication in Denmark. The court should deny Mr. Gottstein's request because his interest in disclosure does not outweigh the potential harm to the persons or interests protected by keeping the files undisclosed.

First, the court should deny Mr. Gottstein's request for access because allowing him access to 30 consecutive court files is not in Mr. Gottstein's own interest. Second, the court should deny Mr. Gottstein's request because Mr. Gottstein has a propensity to illegally disseminate confidential information. Allowing Mr. Gottstein access to the files would potentially harm 30 people by violating their right to privacy. Third, the court should deny Mr. Gottstein's request because his interest in disclosure does not outweigh the State of Alaska's interest in avoiding excessive administrative burden on its court system. Fourth, the court should deny Mr. Gottstein's request because Dr. Gøtzsche does not need the files to answer his research questions. Fifth, the court should deny his request because he did not serve his request on all the parties who must be served under Alaska Administrative Rule 37.7(b).

Discussion

By order, the court may allow access to non-public information in a case or administrative record if it finds that the requestor's interest in disclosure outweighs the potential harm to the person or interests being protected, including but not limited to:

- (1) risk of injury to individuals;
- (2) individual privacy rights and interests;
- (3) proprietary business information;
- (4) the deliberative process; or
- (5) public safety.¹

Non-public information includes information designated as confidential or sealed by statute or court rule and public information to which Administrative Rule 37.6 limits access.² Any person may make a request to allow access or the court may move itself to allow access.³

Procedurally, any request to allow access must be made in writing to the court and served on all parties to the case unless otherwise ordered.⁴ The court also requires service on other individuals or entities that could be affected by disclosure of the information.⁵

The court files that Mr. Gottstein requests contain confidential records. Information and records obtained in the course of a screening investigation, evaluation, examination, or treatment are confidential and are not public records, except as the requirements of a hearing under AS 47.30.660 – 47.30.915 may necessitate a different procedure.⁶ Court files for medication hearings contain information and records obtained in the course of screening, evaluation, examination and treatment, such as patients' names and addresses, their medical and psychiatric diagnoses, and their treatment histories. Psychiatrist testimony regularly concerns the medicines that respondents have taken and the treatments they have received. Moreover, the court files usually describe any relevant diseases and symptoms from which respondents suffer. Some of this

¹ Alaska R. of Admin. 37.7(a).

² *Id.*

³ *Id.*

⁴ Alaska R. of Admin. 37.7(b).

⁵ *Id.*

⁶ Alaska Statute 47.30.845

information originates in the petitions for the administration of medication, but much of it derives from confidential, non-public medical records. Thus, the information and records to which Mr. Gottstein requests access are confidential. The court will not disclose that information to Mr. Gottstein if it finds that his interest in the information's disclosure does not outweigh the potential harm to a person or interests protected by keeping the information undisclosed.⁷

1. Mr. Gottstein's interest in disclosure of the information does not outweigh the persons or interests being protected because he has no interest in disclosure of the information.

Alaska Administrative Rule 37.7(a) requires the court to balance the interest in disclosure against the potential harm to a protected person or interests. The relevant interest in disclosure is the interest of the requestor. In this case, the requestor is Mr. Gottstein and the protected persons are the respondents in the hearings for the court ordered administration of psychotropic medication.

Mr. Gottstein's interest in disclosure of the information cannot possibly outweigh the potential harm to the persons and interests being protected because Mr. Gottstein has no interest in disclosure of the information. Although Mr. Gottstein states that "the requestor's interest" in disclosure of the records "is quite compelling," he never explains what his own interest in disclosure is or how disclosure could advance his interests.⁸ Despite stating that "[t]he opportunity to have such an internationally recognized researcher [as Dr. Gøtzsche] analyze the extent to which petitions under AS 47.30.839 comply with the requirements set forth in *Myers* and *Bigley*, and compare them with Danish analogues will be extremely valuable," Mr. Gottstein never explains how his interests could be served by this extremely valuable research. In fact, Mr. Gottstein has no individual interest in the research and his request for access to non-public information should be denied.

///

///

///

⁷ Alaska R. of Admin 37.7(a).

⁸ Gottstein, Alaska Administrative Rule 37.7 Research Request, June 20, page 2.

2. The Court should deny Mr. Gottstein's request because his interest in disclosure of the information does not outweigh the potential harm to persons protected.

The court should deny Mr. Gottstein's request because his interest in disclosure does not outweigh the potential harm to the persons protected. In 2006, Mr. Gottstein carried out a scheme for obtaining and disseminating confidential documents sealed by a protective order in a case in the United States Court for the Eastern District of New York.⁹ The documents originated with Elly Lilly & Co. and concerned the psychotropic medicine Zyprexa, which the company manufactures. Mr. Gottstein learned about the documents from a plaintiff's witness and conspired with the witness to subpoena them from the witness and disseminate them widely.¹⁰ The United States District Court found that Mr. Gottstein knew the documents were confidential and under protective order, and that they had no relevance to Mr. Gottstein's Alaska case.¹¹ The United States District Court found that Mr. Gottstein had deliberately kept the defendant in the dark about the subpoena (to prevent a reply to it) and had immediately sent the confidential documents to a *New York Times*' reporter and to contacts who immediately published the documents to the internet.¹² In light of these findings, the United States District Court permanently enjoined Mr. Gottstein from disseminating the documents and demanded their return.¹³ On appeal, the Second Circuit affirmed the permanent injunction and held that Mr. Gottstein's acquiring and disseminating the documents involved his aiding and abetting a violation of the court's protective order through the use of sham subpoenas.¹⁴

The court should deny Mr. Gottstein's request because Mr. Gottstein may make confidential information from non-public court files for court ordered administration of psychotropic medicine known to the public. In his appeal, Mr. Gottstein asserted that one of his purposes in disseminating the confidential documents was to "make evidence of suppressed hazards or illegal marketing or other evidence of Zyprexa hazards and Lilly [sic] misconduct known to the public."¹⁵ This assertion displays Mr. Gottstein's propensity to make confidential information known to the public.

⁹ *Zyprexa Litig.*, 474 F. Supp. 2d 385, 392 (E.D.N.Y. 2007)

¹⁰ *Id.*

¹¹ *Id.*

¹² *Zyprexa Litig.*, 474 Supp. 2d 385 at 392-93.

¹³ *Zyprexa Litig.*, 474 Supp. 2d 385 at 428.

¹⁴ *Eli Lilly & Co. v. Gottstein.*, 617 F.3d 186, 191 (2d Cir. 2010)

¹⁵ *Eli Lilly & Co. v. Gottstein.*, 617 F.3d at 193.

Mr. Gottstein has said he will redact identifying information from any court files he receives, or that he will instruct Dr. Gøtzsche to do so,¹⁶ but his past behavior shows his predisposition to reveal confidential information. Thus, he is not to be trusted to keep the respondents' personal medical information from reaching third parties. The court should deny his request and protect the privacy rights of the 30 respondents in hearings for the court ordered administration of psychotropic medications.

3. The Court should deny Mr. Gottstein's request because his interest in disclosure does not outweigh the Alaska court system's interest in the efficient administration of its records.

If the court granted Mr. Gottstein's request, it would have to redact the documents before it allowed Mr. Gottstein access to them. Mr. Gottstein cannot be trusted with confidential documents containing the identifying and medical information of respondents. Removing names, addresses, and other identifying information from 30 court files would place a substantial administrative burden on the Alaska court system. Given the court system's recent reduction in court hours and its conscientious use of limited resources, the court should not devote its energies to redacting documents for a research program that can neither benefit it, the State of Alaska, the parties to the cases, nor the requestor of the documents in any way.

4. Mr. Gottstein's interest in disclosure of the information does not outweigh the potential harm to persons or interests protected because Dr. Gøtzsche does not need the 30 court files to answer his research questions.

Dr. Gøtzsche does not need the court files to come to conclusions about the courts' compliance with *Myers* and *Bigley*. In *Myers*, the Supreme Court held that the court can order psychotropic medication only if it finds, by clear and convincing evidence, that the medications are in the respondent's best interest and that no less intrusive treatment is available.¹⁷ In a sworn affidavit, Dr. Gøtzsche states that "administering a psychotropic medication or medications to a patient against his or her will is not in his or her best interest," that this conclusion is "solidly based on scientific facts," and that "there are feasible less intrusive alternatives to administering a psychotropic medication or medications against a patient's will."¹⁸ These statements can be true only if court ordered administration of psychotropic medication is never in a person's best interest and a less

¹⁶ Gottstein, Alaska Administrative Rule 37.7 Research Request, June 20.

¹⁷ *Myers v. Alaska Psychiatric Inst.*, 138 P.3d 238, 239 (Alaska 2006).

¹⁸ Gøtzsche, Affidavit, page 9.

intrusive alternative to court ordered psychotropic medication is always available. Thus, Dr. Gøtzsche has already concluded, with respect to *any* case of court ordered psychotropic medication, that the medications are not in the respondent's best interests and that a less intrusive alternative is available. He has no need for the 30 court files because he has already made up his mind without them.

Dr. Gøtzsche's swprn statements show he already has his answers to the questions posed in his Research Protocol. He has no need of the court files to answer his questions. Mr. Gottstein's interest in the information's disclosure cannot outweigh the potential harm to persons or interests protected by not disclosing the information because Dr. Gøtzsche has no need of the files to answer his questions.

5. The Court should deny Mr. Gottstein's request because he has not served all individuals that could be affected by disclosure of the information with his request for the non-public records.

The court should deny Mr. Gottstein's request for access to non-public information because he has not served his request on all the individuals that could be affected by disclosure of the information. Under Alaska Administrative Rule 37.7(b), the court shall require service on individuals or entities that could be affected by disclosure of the information.¹⁹ In this case, the respondents could be affected by disclosure of this information because the court files Mr. Gottstein requests contain confidential medical information about the respondents that Mr. Gottstein could reveal to third parties. Thus, because he has not served the respondents in the medication hearings, the court should deny his request.

Conclusion

The court should deny Mr. Gottstein's request for access to the 30 consecutive non-public court files because his interest in disclosure does not outweigh the potential harm to the persons or interests being protected. His interest in disclosure does not outweigh the potential harm to the persons or interests being protected because (1) Mr. Gottstein has no interest in disclosure of the documents, (2) Mr. Gottstein's propensity to reveal confidential documents to third parties makes him likely to violate the privacy rights of the respondents in the 30 cases he requests, (3) Mr. Gottstein's interest in the disclosure of the information does not outweigh the Alaska court system's interest in the efficient administration of its records, and (4) Dr. Gøtzsche does not need

¹⁹ Alaska R. of Admin. 37.7(b)

the files to answer his research questions. Finally, (5) Mr. Gottstein's request violates Alaska Administrative Rule 37.7(b) because individuals that could be affected by disclosure of the court files have not been served with Mr. Gottstein's request.

Sincerely,


Douglas Ryan
Legal Intern


Steven Bookman
Assistant Attorney General

cc: James B. Gottstein
Linda Beecher

Enclosures: *Zyprexa Litig.*, 474 F. Supp. 2d 385 (E.D.N.Y. 2007)
 Eli Lilly & Co. v. Gottstein., 617 F.3d 186, 191 (2d Cir. 2010)
 Affidavit of Peter C. Gøtzsche



July 6, 2016

Presiding Judge William Morse
Nesbett Courthouse
825 W 4th Ave, Rm 601
Anchorage, Alaska

Hand Delivered

Re: Administration Rule 37.7 Research Request

Dear Presiding Judge Morse:

This is in response to the objection by the Alaska Psychiatric Institute (API) to Dr. Gøtzsche's research request for copies of 30 consecutive case files where a Petition for Court Approval of Administration of Psychotropic Medication, under AS 47.30.839 was filed, starting on January 1, 2016 (Request).

(1) The Request is From Dr. Gøtzsche

The first thing I should clear up is that the Request is being made by Dr. Gøtzsche for his research project (Research Protocol), not me. I am just assisting him in attempting to obtain the records. Thus, API's objection based on my so-called interests are not relevant. They are also wrong, but I won't address them because they are irrelevant.

(2) Confidentiality Will Be Preserved

The main complaint that API made is that respondent names and other identifying information will not be kept confidential.¹ To address this issue, the request set forth three options. One is for court staff to redact the documents. The second, recognizing the burden on court staff, particularly in light of the current fiscal pressure, is for me to redact them. The third alternative was that Dr. Gøtzsche will simply not report the results in a way that allows identification of any of the respondents. Another possibility is for API to redact them. Or a third party could be paid to redact them. I imagine Dr. Gøtzsche would be able to pay up to \$1,000 to accomplish this. It is respectfully suggested, that preserving confidentiality is not API's real objection.

¹ API cites to the Zyprexa Papers case to suggest I will turn around and release the documents to the public in spite of their confidentiality restrictions. This is not the place to re-litigate that case, but will certainly not release any confidential information that is provided pursuant to the Request.

(3) There Is No Potential Harm to Respondents

There is no potential harm to the respondents because their confidentiality will be preserved.

(4) Dr. Gøtzsche Has A Strong Interest In the Information

API also objects to the Request because Dr. Gøtzsche believes the forced drugging of respondents is not in their best interests and there are feasible less intrusive alternatives, and therefore he doesn't need to conduct the research. However, this is not what the Research Protocol addresses. The Research Protocol includes whether:

1. The petitions comply with the requirements of *Bigley* in Alaska and Danish requirements in Denmark.
2. Information is provided that documents that the patient cannot provide informed consent.
3. Information about the psychiatric drugs the patient takes or will be forced to take is accurate.
4. A less intrusive alternative is available.
5. The combination of drugs the patient takes is safe.
6. The arguments for using force are reasonable and documented.
7. The patients' rights have been respected.

Based on Dr. Gøtzsche's experience in reviewing petitions in advance of his testimony, the Research Protocol also comments that "there are striking similarities from case to case considering that patients are different." The Research Protocol then states that the judge's ruling will be noted. As is apparent, the Research Protocol is focused on the contents of the petitions, not the ultimate decision, although that will be noted. The Research Protocol is focused on the process, not the results.

(5) Dr. Gøtzsche Has No Objection to Serving All Individuals or Entities That Could be Affected by the Request

API makes the argument that the Request should be denied because not all individuals that could be affected by the Request have been served. Administration Rule 37.7(b) provides in pertinent part:

(b) Procedure. Any request to allow access must be made in writing to the court and served on all parties to the case unless otherwise ordered. The court shall also require service on other individuals or entities that could be affected by disclosure of the information.

The first sentence requiring service on all parties has been satisfied by service on the Public Defender Agency, which presumably represented all of the respondents involved.

If someone else represented any other respondent, Dr. Gøtzsche will be pleased to serve them with the Request. With respect to the second sentence, Dr. Gøtzsche will certainly also serve any other individuals or entities that could be affected by disclosure that the court shall require.

(6) United States Constitutional and Common Law

There is also a constitutional dimension to the Request. In *Nixon v. Warner Communications*, 435 U.S. 589, 597, 98 S.Ct. 1306, 1312 (1978), citing to *Sloan Filter Co. v. El Paso Reduction Co.*, 117 F. 504 (CC Colo.1902); *In re Sackett*, 30 C.C.P.A. 1214 (Pat.), 136 F.2d 248 (1943); *C. v. C.*, 320 A.2d 717, 724-727 (Del.1974); *State ex rel. Williston Herald, Inc. v. O'Connell*, 151 N.W.2d 758, 762-763 (N.D.1967); *Ex parte Uppercu*, 239 U.S. 435, 36 S.Ct. 140, 60 L.Ed. 368 (1915); *Ex parte Drawbaugh*, 2 App.D.C. 404 (1894); and *United States v. Burka*, 289 A.2d 376 (D.C.App.1972), the United States Supreme Court stated.

It is clear that the courts of this country recognize a general right to inspect and copy public records and documents, including judicial records and documents.

This right is not absolute, however, and at that time, the United States Supreme Court said:

It is difficult to distill from the relatively few judicial decisions a comprehensive definition of what is referred to as the common-law right of access or to identify all the factors to be weighed in determining whether access is appropriate.²

One of the cases cited with approval by the United States Supreme Court in *Nixon*, as cited above, is *State ex rel Williston Herald*, in which the court made clear that the right to have the "hearing" open to the public necessarily includes access to the court file, subject to reasonable regulation. In rejecting the contention that any information the seeker of the information wanted could be obtained by going to the public hearing, the court held:

We have carefully considered this entire question. We believe that it is the right of the public to inspect the records of judicial proceedings after such proceedings are completed and entered in the docket of the court.³

In *Baby Doe v. Methacton School District*, 878 F.Supp.40 (E.D.Pa. 1995), the question was whether documents filed in connection with a child sexual molestation case should be open for public inspection. The court there first discussed the general principles involved, including recognizing there is a constitutional right of public access:

² 435 U.S. at 598-9, 98 S.Ct. at 1312

³ 151 N.W. 2d at 763.

In the United States, there is a strong tradition of public access to both criminal and civil trials and the resulting judicial records. This tradition is based on both the common law right to access doctrine as well as the First Amendment. *Pansy*, 23 F.3d at 780-81; *Publicker Indus., Inc. v. Cohen*, 733 F.2d 1059, 1066, 1070 (3d Cir.1984). . . .

Courts should take the least restrictive course when ruling on these matters.

In ordering the file open to the public, the court weighed Baby Doe and her family's interest in keeping the records secret, against the public's right to access as follows:

We turn now to our decision to seal the entire file in the action. PNI asserts that the public has an interest in this action because defendants are two public school districts and its officials, and because it involves the sexual molestation of a child by her school teacher. It alleges that the public has an interest in learning what knowledge the school districts had when they hired and fired the school teacher, whether any other children were molested by the teacher, whether any decision-makers are still in decision-making positions with the schools, and whether any school employees were disciplined as a result of the events. . . .

Plaintiffs argue that, in contrast to the public interest, the interest of the Plaintiffs, especially Baby Doe, is of overwhelming significance. They assert that Baby Doe is still a student at the school where she was molested and where the facts of the case are well known. They argue that:

[w]here Baby Doe to be identified, or were facts disclosed that might lead to her identification, this minor child could sustain emotional upset, psychological damage, teasing by fellow students, different treatment by her teacher(s), etc. She could become a social outcast among her peers.

* * *

Given the effective arguments on both sides of this issue, we turn now to the balancing of the Plaintiffs' and the public's interests. Plaintiffs undoubtedly have a compelling interest in maintaining the seal. This Court agrees that Baby Doe was the victim of a heinous crime and should not be put at risk of suffering any additional harm. Potential embarrassment to her and her family is certainly an issue in this situation. *Pansy*, 23 F.3d at 787.

. . .

However, the case does involve public entities, and other parents have an interest in learning how their school districts address the issue of sexual

molestation by teachers and whether the threat of abuse is taken seriously enough.⁴

Most recently, in *Delaware Coalition for Open Government, Inc. v. Strine*, 733 F.3d 510, 513-514, (3rd Cir. 2013), the United States Court of Appeals for the Third Circuit noted,

"The First Amendment, in conjunction with the Fourteenth, prohibits governments from 'abridging the freedom of speech, or of the press....'" *Richmond Newspapers, Inc. v. Virginia*, 448 U.S. 555, 575, 100 S.Ct. 2814, 65 L.Ed.2d 973 (1980) (quoting U.S. CONST. amend. I). This protection of speech includes a right of public access to trials . . .


We have found a right of public access to civil trials, as has every other federal court of appeals to consider the issue.

I could not find any Alaska cases on this issue, but presumably Alaska's constitutional protections are as great as, if not greater than, under the United States Constitution.

Here, the respondents' interests in keeping the records from Dr. Gøtzsche for the Research Protocol are non-existent to tenuous at best. In fact, it very well may be that some, most, or all of the as yet unidentified respondents would support disclosure for the purposes of the Research Protocol if asked. In any event, if the records are redacted before I or Dr. Gøtzsche receive them, it is hard to see respondents' having any interest at all. If the records are given to Dr. Gøtzsche without being redacted, no identifying information will be reported. Under these circumstances, the balance in favor of providing the records is far greater than in the *Baby Doe* case.

(7) Conclusion

For the foregoing reasons, it is respectfully suggested the Court grant Dr. Gøtzsche's request for copies of 30 consecutive case files where a Petition for Court Approval of Administration of Psychotropic Medication, under AS 47.30.839 was filed, starting on January 1, 2016

Yours truly,

James B. Gottstein, Esq.

cc: Peter C. Gøtzsche, MD (*via e-mail*)
Steve Bookman (*via e-mail*)
Linda Beecher (*via e-mail*)

⁴ 878 F.Supp at 42-3.

IN THE SUPERIOR COURT FOR THE STATE OF ALASKA
THIRD JUDICIAL DISTRICT AT ANCHORAGE

In the Matter of
a Request for Information,


CASE NO. 3AN-16-00695 DN

NOTICE

On 20 June 2016 Dr. Peter C. Gotzsche requested certain information in pursuit of research. The State of Alaska has opposed the request. The Court is still considering it.

Further pleading shall be under the caption and case number identified above.

DONE this 19th day of October 2016, at Anchorage, Alaska.




William F. Morse
Superior Court Judge

CERTIFICATE OF SERVICE

I certify that on 19 October 2016
a copy of the above was mailed/mailed to each of the
following at their addresses of record:

J. Gottstein
AGO: S. Bookman


Ellen Bozzini
Judicial Assistant

3AN-16-00695 DN
ITMO Request for Information
Notice of Caption

3AN-16-00695DN

Case Type: Probate Non-Case Filing (3AN)
Case Status: Closed
File Date: 10/13/2016 **Case Judge:** Morse, William F

All Information Party Docket Disposition

Party Information

Request, Information

DOB _____ **Alias** _____

Party Attorney

Request for Information

Party

— 10 —

Docket Information

| Date | Description | Docket Text |
|------------|--|--|
| 10/13/2016 | Request to Obtain Access to Non-Public Records (Admin Rule 37.7) | Request to Obtain Access to Non-Public Records (Admin Rule 37.7) |
| 10/19/2016 | Miscellaneous | Notice: Further Pleadings |
| 10/21/2016 | Case Closed | Case Closed |

Case Disposition

| Disposition | Date | Case Judge |
|-----------------------------|------------|--------------------|
| Initial Judicial Assignment | 10/13/2016 | Not Assigned (3AN) |
| Case Closed | 10/21/2016 | Morse, William F |

Attachment E

IN THE SUPERIOR COURT FOR THE STATE OF ALASKA
THIRD JUDICIAL DISTRICT, AT ANCHORAGE

In the Matter of)
A Request for Information)
)

COPY
Original Received
AUG 07 2017

Case No. 3AN-16-00695DN

Clerk of the Trial Courts

MOTION and MEMORANDUM TO AMEND REQUEST

Peter C. Gøtzsche, MD, hereby amends his request for access to 30 consecutive court files where a Petition for Court Approval of Administration of Psychotropic Medication, under AS 47.30.839 was filed, to start from January 1, 2017, rather than January 1, 2016, as originally requested (Research Request). The reason for this motion is that it has been over a year since the request was made and starting at January 1, 2017, will make the research more current.

By way of background, the Research Request was originally made pursuant to Administration Rule 37.7 by letter to the Presiding Judge on June 20, 2016, with counsel for the Alaska Psychiatric Institute (API) and Public Defender Agency served. API opposed by letter dated June 30, 2016, to which Dr. Gøtzsche responded by letter dated July 6, 2016. On October 19, 2016, this Court issued a notice that the Court was still considering the Research Request and ordered that further pleadings be filed under the above caption and case number (Notice). No further communication from the Court has been received, but recently checking CourtView reveals that two days after the Notice was issued the case was closed. This appears to be a mistake, but is perhaps why nothing further has been heard from the Court.

LAW OFFICES OF
JAMES B. GOTTSSTEIN
406 G STREET, SUITE 206
ANCHORAGE, ALASKA
99501


TELEPHONE
(907) 274-7666
FACSIMILE
(907) 274-9493

In any event, because of the passage of time since the Research Request was made it makes sense for the starting date to commence on January 2, 2017, rather than January 1, 2016, and it is respectfully suggested that Dr. Gøtzsche's request to amend the starting date for the files should be granted as well as the Research Request itself. A proposed order so to do is lodged herewith.

DATED August 7, 2017.

Law Project for Psychiatric Rights

By:


James B. Gottstein, ABA # 7811100

LAW OFFICES OF
JAMES B. GOTTSSTEIN
406 G STREET, SUITE 206
ANCHORAGE, ALASKA
99501
TELEPHONE
(907) 274-7666
FACSIMILE
(907) 274-9493

IN THE SUPERIOR COURT FOR THE STATE OF ALASKA
THIRD JUDICIAL DISTRICT, AT ANCHORAGE

In the Matter of)
A Request for Information)
Case No. 3AN-16-00695DN)

COPY
Original Received

ORDER AUG 07 2017

Clerk of the Trial Courts

The motion by Peter C. Gøtzsche, MD, to amend his request for access to 30 consecutive court files where a Petition for Court Approval of Administration of Psychotropic Medication, under AS 47.30.839 was filed, to start on January 1, 2017, rather than January 1, 2016, is hereby GRANTED.

FURTHER, Dr. Gøtzsche's request, as amended, under Administration Rule 37.7 for access to 30 consecutive court files, where a Petition for Court Approval of Administration of Psychotropic Medication, under AS 47.30.839 was filed, starting on January 1, 2017, in order to conduct the research set forth in his Research Protocol: "Forced admission and forced treatment in psychiatry: are patients' rights being respected?" is GRANTED, subject to Dr. Gøtzsche and any co-researchers and staff maintaining the confidentiality of the Respondents and only reporting the results in a way that does not allow identification of any of the Respondents. Upon request by Dr. Gøtzsche, copies of the audio recordings shall also be provided upon payment of the applicable fee and subject to the same confidentiality requirements.

LAW OFFICES OF
JAMES B. GOTTSSTEIN
406 G STREET, SUITE 206
ANCHORAGE, ALASKA
99501

TELEPHONE
(907) 274-7686
FACSIMILE
(907) 274-9493

DATED, _____, 2017.

William F. Morse
Superior Court Judge